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AN EVALUATION OF THE USE OF A CLINICAL RESEARCH DATA WAREHOUSE 
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Bret J. Gardner, PhD 
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Supervisor: James C. McClay, MD, MS 
Replication of clinical research is requisite for forming effective clinical decisions 
and guidelines. While rerunning a clinical trial may be unethical and prohibitively 
expensive, the adoption of EHRs and the infrastructure for distributed research networks 
provide access to clinical data for observational and retrospective studies. Herein I 
deomonstrate a means of using these tools to validate existing results and extend the 
findings to novel populations. I describe the process of evaluating published risk models 
as well as local data and infrastructure to assess the replicability of the study. I use an 
example of a risk model unable to be replicated as well as a study of in-hospital mortality 
risk I replicated using UNMC’s clinical research data warehouse. 
  In these examples and other studies we have participated in, some elements are 
commonly missing or under-developed. One such missing element is a consistent and 
computable phenotype for pregnancy status based on data recorded in the EHR. I 
survey local clinical data and identify a number of variables correlated with pregnancy as 
well as demonstrate the data required to identify the temporal bounds of a pregnancy 
episode. Next, another common obstacle to replicating risk models is the necessity of 
linking to alternative data sources while maintaining data in a de-identified database. I 
demonstrate a pipeline for linking clinical data to socioeconomic variables and indices 
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obtained from the American Community Survey (ACS). While these data are location-
based, I provide a method for storing them in a HIPAA compliant fashion so as not to 
identify a patient’s location. 
 While full and efficient replication of all clinical studies is still a future goal, the 
demonstration of replication as well as beginning the development of a computable 
phenotype for pregnancy and the incorporation of location based data in a de-identified 
data warehouse demonstrate how the EHR data and a research infrastructure may be 
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 Consistently improving clinical care relies on validated evidence applicable to the 
current patient. While any number of experimental designs or anecdotal evidence may 
purport to resolve the mystery, scientifically, the randomized controlled clinical trial is 
considered the gold standard for answering clinical questions 1 . Despite the need for 
high-quality evidence to shape clinical practice, Francis Collins (the director of the 
National Institutes of Health (NIH)) et al. note only 11% of practice recommendations 
issued by cardiologist specialty societies “were based on ‘level A’ evidence, that is, 
evidence based on multiple well-done randomized trials” 2 . Due to challenges of 
conducting clinical trials, insufficient data may be published. In addition, published data 
is not always well-validated. Finally, the results of replicated studies may not be 
extendable to a novel population. For these reasons, demonstrating an efficient method 
for reliably replicating and extending research remains paramount. 
 While these challenges exist, recent advances in technology and policy may 
facilitate the accrual and application of actionable data in the clinical setting. First, 
increased adoption of electronic health records (EHRs) provides an alternative source of 
clinical data for research. Next, the growing number and established infrastructure of 
distributed research networks (DRNs) have the potential to enable pragmatic trials and 
observational studies for comparative effectiveness research (CER) at a greater rate 
than was previously possible. Finally, these tools may be harnessed to allow not only 
novel research, but, replication and extension of previously published results. While 
exhibiting great potential, each of these tools also has inherent weaknesses. One 
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significant obstacle is heterogeneity between datasets being combined within distributed 
networks 3 . A second obstacle is consistent identification of a study population across 
institutions. These concerns must be accounted for and addressed in any effort to 
produce clinical data. 
 In this introduction, I review various factors contributing to the insufficiency and 
lack of applicability of reliable clinical data. I also explore the benefits and challenges of 
the use of EHRs and DRNs for clinical research. Finally, I address how these tools may 
be harnessed to facilitate replication research to validate previously published results 
and enhance the applicability of clinical data. 
Data Challenges Impacting Improving Clinical Decisions 
Challenges to Conducting Clinical Trials 
 As noted above, there is a dearth of high-quality and applicable evidence for 
creating and updating clinical guidelines. This may in part be due to the barriers to 
conducting clinical research. These challenges exist at all elements of the research 
process, from planning a study to implementing changes based on results. Challenges 
may be grouped into categories of trial administration and cost, recruitment, and 
publication. All of these categories must be fully addressed for a trial to succeed.  
Resource and Time Requirements for Trial Administration 
 Trial administration requires investment of a great deal of resources in terms of 
time, personnel, and money. Eligibility screening usually occurs before consent and 
entails reviewing medical records, often necessitating obtaining additional information 
from other institutions and providers 4 . Penberthy et al. reviewed cancer trials over an 
18-month period and discovered that three to thirteen patients were screened for each 
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patient actually enrolled at a cost of $129 to $336 per enrolled patient 4 . Additionally, 
they noted that more than 50% of the screening took 30 or more minutes per patient 4 . 
While resource intensive, eligibility screening represents only one small element of a 
clinical trial. 
 Many additional costs exist in conducting clinical trials. In 2010, of the $46.4 
billion spent by Pharmaceutical Research and Manufacturers of America (PhRMA) 
member companies on R&D, $32.5 billion went toward clinical trials 5 . Xu et al. estimate 
that it costs over $800 million to develop a new drug 6 . Costs for reimbursing patients, 
paying for time to navigate the complex web of the Institutional Review Board (IRB) 
approval process, and translating questionnaires or other documents are just a few of 
the many expenses likely to be incurred when conducting a clinical trial. Emanuel et al. 
concluded that on average, 200 hours were required per patient for pharmaceutical 
industry-sponsored trials. 32% of these hours were for non-clinical activities such as 
those noted above. They concluded that, “on average, excluding overhead expenses, it 
cost slightly more than $6,094 [. . .] per enrolled subject for an industry-sponsored trial, 
including $1,999 devoted to nonclinical costs” 7 . Berndt and Cockburn explain that, “the 
growing complexity of clinical trials and of the underlying science suggests that more 
time, more highly trained personnel, and more sophisticated equipment may be required 
to conduct a typical study 5 . The U.S. Bureau of Labor Statistics estimated that the input 
costs for conducting clinical trials rose 8% per year between 1989 and 2011, nearly 
double the inflation rate in the NIH Biomedical R&D Price Index during the same period 5 
. With today’s extremely competitive funding environment, such costs may be 




 The next set of challenges in conducting effective trials deals with recruitment. 
The population recruited must be large enough for statistical analysis, representative of 
the population results will be applied to, and reachable by the researchers conducting 
the trial. Califf et al. note that 62% of interventional trials registered on ClinicalTrials.gov 
between 2007 and 2010 had fewer than 100 participants 8 . Additionally, they described 
that the majority (66%) of registered trials were single-center 8 . Bernardez-Pereira et al. 
studied over 7,000 cardiovascular clinical trials from 2000 through 2013 and concluded 
low recruitment represented the primary cause of early termination 9 .  
 Connected to low recruitment numbers is the difficulty of generalizing the results 
of clinical trials. Researchers estimate that only 2% to 3% of adult cancer patients are 
enrolled in clinical trials in the United States 10 . Furthermore, minorities are often 
underrepresented relative to the portion of cancer patients composed of any given 
minority 11 . For instance, Blacks have a higher incidence and mortality rate for most 
cancers compared to Whites, nearly double for Black males relative to White males for 
prostate cancer 11 . However, from 1998 to 2001 the total number of Black patients 
enrolled in National Cancer Institute sponsored clinical trials increased by only 38 while 
the total number of participants increased by more than 6,500 11 . Such 
underrepresentation makes it difficult if not impossible to extend results of carefully 
constructed clinical trials to all cancer patients. Additionally, potential population specific 
polymorphisms effecting pharmacokinetics or pharmacodynamics may not be 
recognized 11 . With such a small percentage of patients being enrolled in trials, and this 
small cohort not always being an accurate representation of the entire patient 
population, it is difficult for generalize results from these studies.  
 With the cost and resource requirements to conduct clinical trials compounded by 
the challenge to recruit a patient population representative of the target population, 
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alternate strategies must be employed to effectively acquire and validate high-quality 
clinical data.  
Extant Data Not Validated 
Overview 
 Despite these challenges, researchers persist and clinical data continues to be 
published. ClinicalTrials.gov reports in 2000, fewer than 4,000 trials were registered. By 
2015 this number has exceeded 180,000 (http://ClinicalTrials.gov). This rise in the 
number of registered trials likely represents both a total increase in the number of trials 
being conducted as well as an increased proportion of trials registering. Policy changes 
may influence the proportion registering. In September 2005 the International Committee 
of Medical Journal Editors (ICMJE) required registration as a condition of publication. In 
December 2007 the Food and Drug Administration Amendments Act of 2007 (FDAAA) 
was passed by congress, expanding the types of trials to be registered, increasing trial 
registration information to include summary results and adverse events, and imposed 
potential penalties for non-compliance including civil monetary penalties or withholding 
of NIH grant funding 12 . 
 Despite this increase in clinical trials, data concerns remain. Recent emphasis 
has been given to encouraging improved data management for accessibility and reuse 13 
. However, many studies go unpublished or are published after a great delay (median of 
21 months between completion of trial and publication in a journal) 14 . Few studies are 
replicated or independently validated. This is due in part to publication bias, increased 
emphasis on patient privacy, the aforementioned challenges to conducting clinical 
research, and a culture favoring rapid output of novel results. 
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While clinical data has been accumulating for millennia, with the challenges to 
conducting original research, much of these data have not been validated 15, 16 . This 
trend continues for studies relying on data extracted from the EHR 17 . In a systematic 
review of risk prediction models based on EHR data, only 26 of 107 studies performed 
validation across sites 18 . In addition to some studies without evidence of attempting to 
be validated, examples abound of observational studies contradicting previous studies or 
of being rejected by randomized trials performed later 19 . Some instances of such 
contradictory results include studies of the relation between hormone replacement 
therapy (HRT) and cardiovascular risk 20, 21 , bisphosphanate use and cancer risk 22, 23 , 
and fracture risk accompanying use of statins 24-26 . Wagenmakers et al put the situation 
in perspective stating “findings that do not replicate are worse than fairy tales” 27 . In light 
of these many contradictory findings, accepting any single study becomes questionable. 
With the potential for contradictory results, working toward replication is 
paramount. In this section, I explain the importance of reproducibility in science, review 
disparate definitions of reproducible research, explore the impact of the paucity of 
reproducible results, examine obstacles to replication studies stemming from publication 
practices as well as local infrastructure challenges, and describe some of the existing 
guidelines in various fields for moving toward reproducible research. While efforts are 
underway in many fields to enable and encourage reproducibility, this paradigm shift will 
take time. 
Importance of Reproducibility in Science 
 Reproducibility has been referred to as the cornerstone and Supreme Court of 
science, and as the best and possibly the only believable evidence for reliability of an 
effect 28 . Wagenmakers et al state “findings that do not replicate are worse than fairy 
tales” 27 . Cacioppo continues, “Reproducibility is a minimum necessary condition for a 
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finding to be believable and informative” 29 . Despite the essential nature of replication, 
across all domains of science, many studies are not validated 30, 31 . Reliably replicating 
results with consideration of resource limitations is essential for evidence based 
medicine.  
Mixed Results from Historic Replication Efforts 
Lack of validation may be the result of there being no attempts made to replicate 
a study or the failure of attempts to replicate published results. In some cases, 
replication is not attempted or published. As noted earlier, a systematic review of risk 
prediction models based on EHR data revealed only 26 of 107 studies performed 
validation across sites 18 . Even when replication is attempted, lack of reproducibility has 
not been seen to correlate with journal impact factor, the number of publications about a 
specific finding, or the number of collaborators on the publication 32 . In one review, only 
one-third to one-half of studies in high-ranking psychology journals demonstrated 
replicable results 16 . In the pharmaceutical industry, target validation is often attempted 
before advancing a potential drug to phase II trials. In an industry sponsored study, 
despite basing this validation on published material, key data were only reproduced in 
25% of cases 32 . This low rate held true even when cell lines or assay formats were 
modified. The results which were reproducible were demonstrable irrespective of 
modifying the experiment environment, while the majority of results were not 
reproducible whatever the experimental conditions. A similar set of experiments revealed 
only 11% of pre-clinical oncology results could be replicated 33 . These contradictory 
results may stem from errors or multiplicity in the original study, errors in the attempted 
replication, insufficient information in the publication to facilitate replication, insufficient 
infrastructure or data at an independent site to replicate the study, or a study 
demonstrating an effect that may exhibit reproducibility but not replicability. The inability 
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to replicate a study calls into question the published results and makes it challenging to 
have confidence in clinical guidelines stemming from this work. 
Definitions 
 In order to promote and adopt practices toward reproducible research, a clear 
definition of reproducibility is essential. Despite being a priority in computer science 34-37 , 
bioinformatics 38 , biostatistics 39 , epidemiology 40 , and clinical trials 41 , as well as being 
promoted by the NIH 42 , no common, agreed upon and accepted definition of 
reproducibility is currently in use across scientific disciplines 30, 43 .  
Historically, Claerbou defined reproducible research within computer science as 
providing sufficient code and original data to allow the reader of the publication to be 
able to view the entire process from raw data collection to publication of results 44 . Other 
researchers, however, define reproducibility as “the provision of sufficient 
methodological detail about a study so it could, in theory or in actuality, be exactly 
repeated by investigators” 43 . Further confusing matters, the terms reproducibility, 
replication, duplication, and generalization are often used interchangeably or 
inconsistently in publications.  
 For the remainder of this work, I will adhere to definitions recommended to the 
National Science Foundation (NSF) 29  (Table 1). Herein, reproducibility “refers to the 
ability of a researcher to duplicate the results of a prior study using the same materials 
and procedures as were used by the original investigator” 29 . While replicability is “the 
ability of a researcher to duplicate the results of a prior study if the same procedures are 
followed but new data are collected” 29 . Goodman et al help clarify the distinctions 
between reproducibility and replicability. They synonymize reproducibility with “methods 
reproducibility” 30 . In essence, this consists of the original researcher providing raw data 
and all source code and software to a novel investigator. The novel investigator may 
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then use the same data and same programs to attempt to generate the same results. 
Contrarily, replicability is explained as “results reproducibility”. In this case, the original 
researcher provides a detailed protocol and clear explanation of results to a novel 
investigator. The novel investigator may then conduct as similar an experiment as 
possible with new data collection in a new environment to see if the same results are 
produced. Thus reproducibility serves to validate the methods and replication offers a 









Obstacles to Replication – Publication and Local Infrastructure 
 Many challenges exist hindering researchers’ ability to replicate studies. These 
challenges occur both in the current publication environment as well as in the local 
infrastructure researchers work in. The current publication environment suffers from 
publication bias, has no systematic means of publishing sufficient data and protocols, 
and has no consistent metric to assess the replicability or reproducibility of a study. The 
peer review process is not able to detect all errors 45 , and rejected manuscripts are often 
published in another location 46, 47 . While irreplicable results are rarely the result of 
fraudulence 48 , obstacles continue to impede the publication of replicable work.  
Publication Bias: 
 Many studies over the past decades demonstrate a bias in published journals 
toward studies showing positive results 14, 49-51 . This “publication bias” as well as delay in 
publication (median of 21 months between completion of trial and publication in a 
journal) limits clinician access to complete data, may lead to duplicated research, 
publication of spurious results, and limits improvements to the quality of medical care 
implemented 14, 52, 53 . In addition, this publication practice may lead to the “file-drawer” 
problem where significant, negative results are tucked away privately and Type I errors 
are published 54 . Future clinical guidelines and clinical trials will thus be based on 
incorrect conclusions. Publication bias may also promote multiplicity 30 . Multiplicity is the 
practice of testing many hypotheses, multiple associations, innumerable models, 
endpoints not defined a priori, hypothesizing after the results are known (HARKing), and 
often failing to publish this winding protocol which eventually led to a significant result 55-
63 . Many negative results lost in file drawers may replicate well if they were published. 
Type I errors have a low likelihood of replicating no matter how carefully a protocol is 
observed. Effects called significant after irregular statistical analyses will likely fail to be 
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dubbed significant when a single, standard analysis is performed on novel data 64 . 
These issues are exacerbated by some of the aforementioned challenges in clinical 
research. For instance, a small sample size leads to low statistical power and may 
hamper a researcher’s ability to demonstrate statistical significance with traditional 
analyses.  
Data and Protocol Sharing: 
 In addition to publication bias leading to the dissemination of non-replicable 
studies, the current publication environment has no systematic means of sharing 
detailed protocols and raw data for EHR based studies 65 . This is due both to current 
systems as well as culture. Currently, biomedical journals have no unified approach for 
authors to submit code or software used to extract, transform, or analyze data. 
Additionally, no uniform repository or approach exists for making raw data available. 
Culturally and legally, if such a repository were made available, patient privacy for EHR 
based studies may preclude sharing of data from any point in the pipeline. Researchers 
desiring to replicate or reproduce prior studies are haltered by this lack of consistent 
sharing of code or data. 
Next, researchers are further limited due to inconsistent publication of written 
descriptions of protocols. While clinical research may involve extremely detailed 
phenotypes and inclusion and exclusion criteria to define the cohort of interest, studies 
have demonstrated the practice of incomplete protocol or phenotype publication. In a 
review of research studies using UK EHR data, only 5.1% published the entire set of 
terms sufficient to implement the EHR-derived phenotype 66 . Even if listed, EHR-based 
phenotypes are usually published as human-readable, complex documents rather than 
machine-readable programs 67 . Also, these complex documents of innumerable terms 
often still lack sufficient context, such as noting if the diagnosis being queried was the 
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primary cause of admission 43 . In a separate review, only one of 400 biomedical studies 
published a complete protocol 68 . With the diversity of proprietary formats for EHR data 
collection and storage, research pipelines involving data extraction, pre-processing, and 
manipulation are similarly diverse. However, associated programmatic code is rarely 
published 43 . The combination of a lack of a systematic approach to sharing 
programmatic code or data coupled with a culture of publishing incomplete protocols 
leads to published studies that will not be replicable. To facilitate reproducibility, many 
studies developing risk models report model coefficients 18 . There is no systematic 
approach to this practice and the calculation of such coefficients may remain a black 
box. Independent researchers are left to interpret the limited methods and may not be 
able to conduct similar analyses or identify a similar population. 
Cultural Limitations: 
 Finally, in addition to publication bias and lack of infrastructure or culture for 
publishing sufficient methods and data for reproducible research, there is no systematic 
metric in place to assess the replicability of a published study or reward authors for 
adhering to replication practices. Journals could incentivize publication of raw data and 
programmatic code, note if authors pre-registered hypotheses, indicate if all co-authors 
have reviewed and have access to the raw data, or otherwise note via reviewer 
feedback if the publication provides sufficient information for replicability 69 .  
Policy Changes Increasing Replicability of Published Studies 
 Recently, approaches have been proposed for overcoming the aforementioned 
obstacles to replication. First, clinical research has had safeguards in place for some 
time to protect patients and maintain a high level of scientific integrity. These safeguards 
are not as developed or mandated in pre-clinical or basic science research. When 
human subjects are involved, a detailed protocol, including justifications for sample size 
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and planned analysis, must be submitted to and reviewed and approved by a local IRB. 
Being required to state hypotheses and analysis approach before any patient data 
collection will prevent at least some multiplicity. Modifications are possible and 
wandering statistical analysis may still occur prior to final publication of the results, 
however, the checkpoints currently in place promote replicable studies. Reporting of 
some of these details is outlined in the revised CONSORT (Consolidated Standards of 
Reporting Trials) guidelines 70 . Herein researchers should ensure they report on the 22 
points of a standardized checklist as well as clearly outline the experimental design in a 
flowsheet detailing enrollment, intervention allocation, follow-up and analysis. In this 
way, other researchers may evaluate the scientific merit and reliability of the results 
being published. 
 Next, the FAIR (Findable, Accessible, Interoperable, Reusable) Data Principles 13  
set forth by a diverse set of stakeholders from academia, industry, publishers and 
funding agencies, outline the desiderata of reproducible and replicable science. While 
not prescribing specific structure or location for data sharing, these principles provide 
clear definitions and represent the cultural recognition of the need for revisions. The 
authors clearly relate the interoperability and openness of data to scientific advancement 
and make plain the necessity of having data and protocols both human and machine 
readable. Furthermore, example repositories for diverse data types are noted as starting 
points for seamless data sharing. As these principles are adopted and as a greater 
infrastructure is developed for standard data sharing in each scientific domain, 
replication will be enabled to a much greater degree. 
 Next, in 2014, Francis Collins announced plans the NIH was implementing 
toward reproducibility and replication in science 42 . These plans were designed to 
provide better training toward replicable science as well as provide forums for scientific 
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discussion and repositories for raw data. For researchers, a training module was to be 
developed emphasizing reproducibility and good experimental design. For reviewers of 
grant applications, a systematic checklist was proposed. This checklist would include an 
evaluation of the planned analyses, a review of the antecedent work the current grant is 
based on, and may necessitate replicating previous studies if their results were 
questionable. The NIH plan further called for a Data Discovery Index (DDI) where 
researchers could locate and access unpublished, primary data. With this repository, the 
new researcher could then cite the data source if used thereby giving credit for original 
data collection. Finally, Collins proposed the development of PubMed Commons, a 
forum for open discourse about scientific articles. Collaborations, clarifications, 
questions, and criticisms for published work could be documented at this site. These 
plans may help shift the paradigm of researchers and other stakeholders, elevating the 
importance of publishing replicable results and rewarding the replication of findings. 
 Additional guidelines are being set forth from a variety of disciplines. In 2007 the 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 71  
guidelines outlined what should be included for an accurate and complete report of 
observational studies. As clinically captured data have become more available and 
abundant, further recommendations were made in the REporting of studies Conducted 
using Observational Routinely collected health Data (RECORD) statement 72 . This 13 
point checklist outlines recommendations for reporting on the type of study, provenance 
of data, data cleaning and analysis, any data linkages, and the location and time of the 
study as well as a description of the participants, results, generalizability, and 
accessibility of protocol and code. These guidelines are available to researchers, editors, 
and other stakeholders. They provide examples of good reporting, though, no consistent 
standard is prescribed. 
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 With these cultural and policy advances toward increased replicability of 
published results, an effective means of conducting clinical research and replicating 
published results must be developed. With the challenges described above, it is not 
feasible, and may not be ethical, to replicate clinical trials at novel sites. However, 
validating and extending existing results is critical to improve patient care. The increased 
use of electronic health records in conjunction with the growing number and 
infrastructure of distributed research networks may provide a framework for collecting 
clinical data and independently replicating clinical results.  
Potential Solutions for Making More Data Actionable 
Increased Adoption of Electronic Health Records 
 Historically, paper charts were the repository for patient information. These bulky 
files included quickly scrawled clinical impression and were stored at the site of care. In 
recent years, electronic health records have replaced this archaic system. For instance, 
in 2001, only 18% of office-based physicians utilized any type of EHR 73 . Stimulated by 
President Bush’s 2004 Executive Order 13335, which created the position of National 
Coordinator for Health Information Technology, and incentivized through the Health 
Information Technology for Economic and Clinical Health (HITECH) Act of 2009, in 2013 
at least 78% of office-based physicians had implemented an EHR 73, 74 . Private acute 
care hospitals saw similar increases in EHR adoption, rising from 9% in 2008 to 59% in 
2013 and 75% in 2014 75, 76 .  
Clinical Benefits of Electronic Health Records 
 Electronic capture and storage of patient data is not merely a new approach to 
record keeping, rather, EHRs offer benefits toward interoperability, patient safety, and 
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efficiency. Interoperability across the healthcare community is becoming a national goal. 
In 2015 Karen B. DeSalvo, MD, MPH, MSc, the National Coordinator (ONC) for Health 
Information Technology, published “A Shared Nationwide Interoperability Roadmap” 
outlining critical actions both the public and private sector of healthcare must adopt to 
enable an interoperable ecosystem of health IT within a decade 77 . As vendors and the 
healthcare community adhere to the ONC standards in the creation and use of EHRs, 
the ability to share clinical information across institutions and care settings will come to 
fruition.  
 As interoperability is achieved, advances in patient safety are enabled. With 
standards employed, clinical decision support (CDS) systems may be centrally 
developed and tested and then applied across diverse EHRs. These CDS systems 
evaluate drug-drug interactions, may alert the health care team to abnormal or extreme 
lab values or vital signs, and may recommend the most efficacious therapy for the 
current condition. Historically these were developed ad hoc or required onerous 
adaptation at each site. Adhering to interoperability standards further advances patient 
safety as clinicians may more readily obtain a complete patient history. Rather than 
bulky charts being lost or requiring excessive time to sift through faxed copies, EHRs 
allow electronic transfer of this critical, clinical information. In the past, the “curly braces” 
problem has prohibited efficient sharing of data across sites 78 . Some of this concern is 
resolved as sites follow ONC guidelines. Clinicians may then have access to a more 
complete patient history to allow them to make the best therapeutic choice. In the future, 
patient safety may also be enhanced as interoperable EHRs are used for clinical 
research. Access to patient information across sites will enable pragmatic trials and 
retrospective studies to be conducted leading to greater clinical evidence. In each of 
these ways, interoperable EHRs move health care toward a safer patient experience. 
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 Finally, adoption of EHRs enhances efficiency. While a handwritten chart exists 
in only a single physical location, EHRs allow patient information to be accessed and 
updated irrespective of geographic location. A single copy of a paper chart may be 
reviewed by only a single individual at any one time. EHRs allow all members of the 
health care team to review information simultaneously. Reviewing paper charts may 
necessitate examining many pages of scrawled notes. EHRs allow for electronic 
searching, data summary, calculations, and other heuristics to be employed quickly. 
Efficiency is increased with the use of EHRs as geographic limitations are removed, 
multiple individuals are able to collaborate simultaneously, and technological advances 
for data interpretation and searching are employed.  
Clinical Research Benefits of Electronic Health Records 
Overview 
 While the re-use of EHR data is rife with challenges, use of EHRs for 
comparative effectiveness research may decrease the cost of time and resources spent 
on eligibility screening and recruitment, allow study of a more representative population, 
incorporate more diverse data elements, and increase efficacy of trials that are 
underway. Payne et al. conducted a survey of IT use in clinical translational research 
and noted specific benefits of utilizing EHRs 79 . These researchers note that the data 
contained in EHRs may be used at many steps of the clinical trial process, including 
hypothesis formation, recruitment, analysis, and especially data collection 79 . Similar to 
records for clinical care, historically, data collection for clinical trials has depended on 
paper forms, with data extrapolated and codified manually 79 . These paper forms must 
then be transcribed into databases for analysis, a process introducing further opportunity 
for errors 79 . The increased use of time and resources as well as the introduction of 
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greater potential for human errors are paramount. Payne et al. report that harnessing 
EHR technology has significantly decreased time-consuming and redundant data entry 
and simultaneously demonstrated increases in data quality 79 .  
Eligibility Screening 
 Furthermore, recent work has shown with high fidelity electronic records, 
eligibility screening may be largely automated. Ni et al. demonstrated this principle and 
noted a 92% reduction in workload and a 450% increase in trial screening efficiency 80 . 
While the use of EHRs aids in screening, efforts to establish automated screening must 
be made at each participating site with unique EHRs. 
Patient Population  
 In addition, data from operational EHRs compliments information gathered from 
well-controlled clinical trials. First, EHRs include data on an entire patient population, not 
a highly selected cohort. Data is collected on this population continuously rather than 
only at a few time points during a year. In contrast to the very limited population with 
strict adherence to study protocol, EHRs offer data on a very broad population that 
reflects actual care and patient conformance to prescribed therapy 81 . Also, within a trial 
only a small subset of data elements are collected and analyzed. In contrast, within an 
EHR data is diverse, not focused on a single disease or known risk factors. In this way, 
EHRs provide an abundance of data elements for the formulation of novel hypotheses 
and foundation for analyses. While not the same, with careful consideration, data 
gathered from an EHR may be valid to answer clinical research questions. 
 Finally, as EHRs are used for research, translating results into decision support 
or deploying risk calculators in clinics is much simpler than historic methods 18 . It is plain 
that EHRs may be used for secondary purposes of data acquisition and maintenance for 
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clinical research with meaningful impact on diminishing time and expense of conducting 
trials. However, EHR data is not collected for research – potentially leading to problems 
with quality, completeness and comprehensiveness of these data.  
Concerns with Secondary Use of EHR Data for Clinical Research –  
 Whether on paper or electronically, data is recorded in the medical record by 
many members of the health care team, by equipment, and in some instances by 
patients. While the volume of data abound, there are concerns with use of these data 
directly for clinical research. Data captured in the EHR are recorded for clinical and 
billing use. As such, these data may be inaccurate, incomplete, transformed locally, 
lacking necessary granularity, or irreconcilable with approved research protocols 82 . 
Each of these potential limitations must be taken into consideration prior to drawing 
conclusions from analysis of these data. 
Inaccurate Data:  
Numerous studies evaluating data from diverse EHR vendors and locations have 
demonstrated spurious data recorded for patient care 82 . Extracted data may include 
pregnant males, treatments apparently prior to birth or following death, and patients 
being emergently intubated only to be released a short time later 83, 84 . Without quality 
analysis in place, inappropriate conclusions may be drawn from secondary use of EHR 
data. 
Incomplete Data:  
Incomplete data exists at various levels. First, a patient rarely receives all 
medical care throughout his/her life at a single institution. Whether traveling, moving, or 
changes in management of local institutions, a patient is likely to have clinical data 
maintained at a plethora of medical centers and clinics. Nasir et al have shown 19.1% of 
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readmissions for heart failure patients were to a different hospital than the original 85 . 
Similarly, Bourgeois et al found 31% of patients in Massachusetts visited two or more 
hospitals over a five-year period 86 . This fragmentation means no single clinic will be 
able to access a complete medical picture for the patient. In addition, as data are 
recorded for clinical care, only necessary studies are conducted and pertinent findings 
recorded. While vital signs may be recorded at nearly every visit, complete visual 
examination findings may not be found during a visit for a appendectomy, even if the 
patient is suffering from diabetic retinopathy at the time. This may lead to censoring, a 
property where events outside the dates of observation are absent or ambiguous 87 . The 
date of recorded diagnosis in the EHR is rarely the date of onset of the disease 82 . Next, 
EHRs are inherently limited on data from healthy individuals and biased toward those 
needing medical care. Finally, as hospital and clinical environments differ between 
institutions, the normal labs and findings regularly recorded will differ in like manner. 
Various elements may be routine at one institution and routinely absent at a neighboring 
medical center. Managing missing variables and accepting the absence of some findings 
is requisite for research involving EHR data. 
Transformed Data:  
Data in the EHR is recorded for clinical care and later processed for 
administrative and billing purposes. In many instances, all of the data is not available to 
the researcher. Claims data may be given in lieu of full access to source data. As data is 
processed, data quality for research may decline. First, studies have shown 88  
prognostic indicators, patient reports, and disease burden are not well represented in 
billing data. In addition, unintentional errors may creep in through the administrative 
process. These may be due to coding errors, inexperience, insufficient clinician 
oversight, upcoding to maximize payment, underreporting quality measures, and poor 
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verbal or written communication 89 . Beyond these errors, standard coding has limitations 
and perils for research. Semantic drift may occur over time wherein certain diagnostic or 
other codes and vocabulary change, making longitudinal studies difficult to interpret 90 . 
In addition, relying solely on diagnostic codes may drastically underrepresent the study 
population of interest 91 . Extensive data are often retained in clinical, pathology, 
radiology, or other notes requiring sophisticated natural language processing (NLP) 
techniques to extract them with unknown efficacy 92 . Which data are available and the 
processing of these data within the EHR must be considered when planning and 
conducting any research study relying on such patient information. 
Data Provenance:  
Data stored in the EHR may originate from a variety of sources, including any 
member of the health care team, equipment or instruments, the laboratory, pathology 
reports, radiology reports, and the patient himself. In some instances, multiple sources 
may provide insight into a single issue. Administration of a medication is a prime 
example 82 . A patient may report what medication he is taking and what was 
administered during his stay. These data will be stored in the medication reconciliation 
form. There are orders for medications, dispensing records from the pharmacy, and the 
medication administration record. Each of these elements is stored in the EHR and none 
of these elements is definitive to the question of what medication was physically given to 
the patient. Selecting any one of these as a proxy for the fact of interest has implications 
that must be reconciled.  
Data Lacking Sufficient Granularity:  
While data recorded in the EHR is extensive and varied, research protocols may require 
data elements not present. In a review of 98 outcomes studies utilizing EHR data, 55% 
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of these studies supplemented EHR data with non-EHR data 93 . In addition, as noted 
earlier, some data made available to researchers represent only a summary of the 
patient’s condition 82 . A plethora of clinical findings and laboratory values may contribute 
to the diagnosis made by a clinician. The final ICD code may be all the researcher has 
available. Individual elements contributing to the diagnosis are masked from the 
researcher and may inhibit drawing meaningful conclusions from EHR data. 
Increased Developments of Distributed Research Networks 
Overview 
 As described above, with considerations of the limitations and potential bias 
introduced by re-using clinically collected data, EHRs may prove a valuable tool for 
comparative effectiveness research. This resource may be bolstered as it is used in 
conjunction with distributed research networks (DRNs). While EHRs contain a diversity 
of data, these data are still limited to a single clinic or academic institution. Studying rare 
diseases or small effects may remain outside the potential for a single researcher. DRNs 
offer an opportunity for collaboration, data sharing, and federated queries to maximize 
sample size and generalizability of the results. Many of the challenges to clinical 
research noted earlier may be addressed through DRNs. A variety of DRNs have 
developed in recent history Observational Medical Outcomes Partnership (OMOP) 
launched in 2008 94 , Sentinel System (FDA drug monitoring system with 28 
collaborators) launched in 2008 95 . I will focus on the National-Patient Centered Clinical 
Research Network (PCORnet) to describe the potential benefits for comparative 
effectiveness research. 
Example of a Distributed Research Network – PCORnet 
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Collins et al. describe “PCORnet aims to build a national research network, 
linked by a common data platform and embedded in clinical care delivery systems. This 
network will enable studies, and in particular randomized trials, that have been 
impractical to conduct to date—and do so with economies of scale” 2 . These leaders 
summarize the potential benefits of a massive network of linked EHRs stating, “a 
network of electronic medical records representing over 100 million covered lives will 
make large-scale observational and interventional trials faster to launch, more 
representative of diverse real world populations, and capable of providing much-needed 
answers to comparative effectiveness research questions with greater accuracy” 2 . 
Additionally, they note that PCORnet will facilitate conducting these effective trials at 
“affordable cost” 2 . With the tremendous promise PCORnet offers, as with any 
intervention or prescribed behavioral change in medicine, evaluating its efficacy is 
essential. 
The Greater Plains Collaborative 
 In 2013, the Patient-Centered Outcomes Research Institute (PCORI) funded 11 
clinical data research networks (CDRNs) and 18 patient-powered research networks 
(PPRNs) that compose PCORnet 96, 97 . Fleurence et al. describe the commitments for 
each CDRN including building a large patient cohort with comprehensive clinical data, 
developing necessary policies to ensure patient privacy and data security while allowing 
for data sharing and participation in multi-network randomized trials and observational 
studies, and developing policies for data standardization 97 . This system of multicenter 
research allows many advantages, including “greater sample size and power, the ability 
to study effects of practice pattern and treatment variation, the inclusion of diverse 
populations, and the possibility of supporting analyses that assess heterogeneity of 
treatment effect” 97-99 . Efficient multi-site analyses are facilitated by the creation of a 
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common data model (CDM) that allows for queries to be shared rather than large 
amounts of patient data being transferred. Developing the infrastructure for this research 
has been ongoing (Phase I). Recently, PCORI awarded Phase II funding to ensure 
sustainability and continued progress for three additional years.  
 The Greater Plains Collaborative (GPC) is one of these 11 CDRNs. The GPC 
encompasses over 10 million patients from over 20 hospitals, 700 clinical locations, and 
8,000 providers for all levels of care 100 . The patients included embody a diverse mix of 
rural populations and urban communities, including often underrepresented minorities. 
The GPC institutions are committed at the highest levels to this collaborative work. As 
evidence of this commitment, the GPC has established a master data-sharing 
agreement as well as reciprocal IRB agreements to allow collaborative research queries 
to be run and facilitate multi-site studies. Additionally, the GPC contains a robust 
collaborative team of informaticists. Teams from each participating site have worked to 
load data into the vendor neutral informatics for integrating biology and the bedside 
(i2b2) data warehouse. Data sources are diverse and range across commercial EHRs 
including Epic and Cerner, tumor registries from the North American Association of 
Central Cancer Registries (NAACCR), the Social Security Administration’s Data Master 
File for mortality, Health Information Exchange data such as NeHII and the Indiana 
Health Information Exchange and patient-reported outcomes via Research Electronic 
Data Capture (REDCap) surveys 100 . While the availability of such data has great 
potential for research, Waitman et al. note that application of such data to determining 
clinical effectiveness has not been convincingly demonstrated to date 100 .  
i2b2 
 As noted above, the GPC is utilizing Informatics for Integrating Biology and the 
Bedside (i2b2) to achieve its goals of collaborative clinical research. I2b2 is operational 
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at more than 60 academic medical centers, HMOs, and private companies. This 
software resides in the public domain (http://www.i2b2.org) and allows for immense 
individual adaptation and development while maintaining interoperability with a common 
messaging protocol that allows communication through web services and XML 101 . The 
goal of i2b2 is “to provide clinical investigators broadly with the software tools necessary 
to collect and manage project-related clinical research data in the genomics age as a 
cohesive entity, a software suite to construct and manage the modern clinical research 
chart” 101 . This suite allows integration of a variety of data types and allows queries to be 
created at one site and shared with many locations to probe locally secure data.  
 The University of Nebraska Medical Center (UNMC) clinical research data 
warehouse (CRDW) is an IRB approved environment built on i2b2. Patient-centric data 
is extracted from affiliated health care organization electronic health records (EHR), 
combined with national registries, mapped to Office of the National Coordinator (ONC) 
designated terminology standards and fully de-identified. 
With data extraction and curation efforts at a plethora of sites, PCORnet seeks to 
bridge the gap to this secondary use of clinically captured data by tapping into this 
torrent of information from the EHR. A variety of standard and proprietary coding 
systems are used to organize this massive dataset. While information about medications 
prescribed, hospital admissions and diagnoses, family history, allergies, complications, 
and even genomic information may be stored, querying this data in a meaningful way for 
clinical research is often prohibitively cumbersome. Querying large patient sets spanning 
multiple institutions has historically been onerous due in part to differences in local 
coding and representation of facts. With the CDM and an infrastructure for querying it as 





 While this pooling of data under a common umbrella may appear to be the 
panacea for obstacles encompassing clinical research, recent studies from other 
collaborative groups demonstrate heterogeneous data sets may yield disparate results 
despite application of identical methods 3, 102 . Heterogeneity of treatment effect and 
patient differences may be masked as observational studies amalgamate large 
populations 103, 104 . Significant, yet opposite, effects from distinct populations 
participating in the network may average out to no effect or an effect in one direction. 
Overhage et al. demonstrated the efficacy of using the Observational Medical Outcomes 
Partnership (OMOP) common data model across multiple sites and maintaining data 
integrity to investigate safety surveillance, however, they made no inquiry as to individual 
site result variations 105 .  
 One critical, and often overlooked element of the design process, is the selection 
of an appropriate data source to query. Selection of a data source may often be made 
on the basis of convenience or accessibility rather than on any standard guidelines or 
rationale 19 . While attaining necessary statistical power and having data elements 
needed to ask the desired questions are critical elements of a well-designed 
observational study, recent studies demonstrate that the choice of database plays a 
major role and that applying the same study methods to different datasets may yield 
disparate results 3 . 
 As with the use of EHRs for clinical research, adopting federated queries in a 
DRN has challenges that must be considered. The impact of heterogeneity of data and 
the effect of transforming data to a common data model require further investigation. 
Despite these potential issues, the infrastructure and participants in a DRN offer 
valuable solutions to many of the challenges I have described regarding comparative 
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effectiveness research. Sample sizes may be dramatically increased. Costs for large-
scale trials may diminish drastically. The population and the data captured as data are 
populated from the EHR will be real-world rather than a potentially biased trial 
environment. With the ability to conduct trials, it will be critical to ensure the validity of 
both novel results as well as previously published material. 
Leveraging EHRs and DRNs to Replicate and Extend Clinical Research 
Addressing Challenges to Replication Research 
Use of EHR data for observational and retrospective studies provides a potential 
alternative to fully duplicating clinical trials to assess the original hypothesis 106, 107 . 
Tannen et al demonstrated the potential to use observational studies from operational 
EHRs to successfully replicate the findings of a series of cardiovascular clinical trials 106 . 
Observational studies are increasing in popularity. During the 1990s, nearly 80,000 
observational studies were published. In the following decade, this number rose to 
263,557 108 . Overhage et al note that well designed observational studies may yield 
effect estimates comparable to those reported in randomized controlled trials (RCTs) 19 . 
However, not all studies are well designed and may produce spurious or conflicting 
results. Young boldly states “Any claim coming from an observational study is most likely 
wrong” 108 . While this may be hyperbole, as with any scientific claim, the results of 
observational studies or clinical trials should be replicated to enhance validity. 
Remaining Gaps in this Process 
 With the availability of clinical data extractable from widespread EHRs coupled 
with the infrastructure and collaborations made possible with growing distributed 
research networks, replication of studies may be accomplished more efficiently. The 
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challenges of excessive cost and time requirements, the difficulty in enrolling a 
sufficiently large and sufficiently diverse study population, the obstacle of data collection 
and storage, and the hurdles of selecting an appropriate data source and maintaining 
patient privacy may in large measure be met through these new tools. As these 
challenges are overcome, efficiently replicating a study becomes feasible. 
 As described earlier, the NIH and multiple scientific journals are calling for 
cultural and policy changes toward reproducibility and replicability in science, including 
clinical research. As repositories are developed to make data and protocols available 
and as providing these data becomes expected rather than the exception, replication of 
studies may increase. Despite these changes, no metric for evaluating an articles 
replicability nor a metric for assessing a local infrastructure have come to light.  
 In this dissertation, I first evaluate UNMC’s CRDW infrastructure as a potential 
tool to rapidly replicate risk models. I explore the limitations resulting from incomplete 
protocol publication as well as the requirements for data volume and variety at the 
replication site. With the identification of missing data in terms of a computable 
phenotype for pregnancy and variables related to a patient’s socioeconomic status, I 
explore the development of such a phenotype and demonstrate the integration of extra-
EHR variables into the CRDW. In this way, I demonstrate and approach and 
considerations researchers seeking to replicate studies may use as well as provide a 
means for incorporating census data with clinical data in a queryable fashion. While this 
dissertation cannot address all outstanding obstacles and concerns relevant to 
conducting replication research, this work does demonstrate replication and provides 




CHAPTER 1 – ATTEMPTED REPLICATION OF A READMISSION 
RISK MODEL FOR HEART FAILURE PATIENTS 
Introduction 
 Clinical research results are being published at an unprecedented rate. A 
majority of these studies, however, involve relatively few patients and are completed at a 
single institution 8 . With minorities often underrepresented and such a small sample of 
the disease population enrolled, widespread application of results in clinical practice may 
not be warranted 10, 11 . One means to validate conclusions and extend the results to a 
more general population is replication of studies at novel sites. While conducting a 
second clinical trial to address the same hypothesis may be infeasible and potentially 
unethical, an observational study may provide reliable results using a fraction of the 
resources. Observational studies have been shown to be an effective means to 
reproduce results initially documented via clinical trials 106, 107 . Successfully replicating a 
study requires elements to be in place at the new site as well as sufficient 
documentation to be provided in the publication of the original study. The new site must 
have sufficient data for the population in question and a means of interrogating these 
data. The published study must detail the phenotype of the disease population in a way 
that can be reproduced at novel sites. Any risk models or calculations must be clearly 
explained if they are to be replicated. 
 In this and the following chapter, I describe initial evaluations of two studies and 
of UNMC’s infrastructure in terms of the ability to replicate what was published from 
other sites. I describe the local site and publication requirements, the selection of the 





 As described earlier, small sample size is the leading cause of early termination 
of clinical trials. For studies running to completion, small sample size limits statistical 
power and the conclusions which can be drawn from the study. A researcher may miss a 
novel effect or may over-analyze in an attempt to find significance, both resulting in 
publication of false findings. Data extraction from the entire population recorded in an 
EHR may mitigate this problem. Rather than attempting to enroll dozens or even 
hundreds of patients, researchers have a pool of thousands or hundreds of thousands of 
patients to identify eligible patients from. All eligible patients may be enrolled in an 
observational study. In the case of rare conditions or diseases, extending the study to an 
entire distributed research network may see a ten-fold increase in the number of 
patients. In this way, even for rare diseases, it is likely a sufficient sample size may be 
identified to aid in drawing statistically sound conclusions. 
Diverse Population 
 While a sufficiently large sample size is critical for drawing meaningful 
conclusions, it is critical that the study population is representative of the target 
population. The availability of diverse data within an EHR as well as increased diversity 
across a distributed research network, make it possible to have a representative study 
population, similar to what is described in the study being replicated. If the site 
attempting to replicate clinical studies only has limited date from a small registry, an 




 Beyond having a sufficiently large and diverse sample, replicating clinical 
research may require a diverse set of data domains. Having a single domain, such as 
diagnostic codes, is useful for identifying information about disease incidence or 
prevalence. However, having only this information precludes further analysis in terms of 
disease progression, susceptibility, or outcomes. For these types of studies, additional 
data domains may be required. From the EHR, diagnostic history, laboratory data, 
medication orders and dispensing history, demographic information, procedures, and 
family history are often available. Some studies may involve extra-EHR data elements 
such as socioeconomic status, location information, or patient-reported outcomes from 
surveys. In order to attempt to replicate a study, all data elements from the original study 
must be available at the independent site. Missing data elements or data domains will 
limit the extent to which researchers can replicate prior results. 
Infrastructure to Interrogate Data 
 With a data repository in place, to effectively replicate a study, researchers need 
an efficient means of interrogating the data, locally, or across a distributed research 
network. If individual data elements must have custom ETLs produced and custom SQL 
queries written, there will be a great deal of duplicated effort across studies and costs for 
developer time and infrastructure building may exceed the benefits of attempting to 
replicate a previous study’s findings. With a clinical data research warehouse (CRDW) 
established, containing the majority of common data elements for most studies, a query 
platform may put in place to make data available to researchers. Across PCORnet, SAS 
queries are shared for this purpose (see appendix A for local instructions for running 
federated queries). Dozens of academic medical centers and other institutions have 
deployed i2b2 for local and federated queries. With minimal addition, these platforms 
allow researchers for diverse clinical studies to rapidly query existing data. Having this 
33 
 
infrastructure in place allows observational or retrospective studies to be accomplished 
with a fraction of the resources of conducting a new clinical trial. 
Publication Requirements 
Phenotype Description 
 While having a local infrastructure with sufficient data volume, data variety, and a 
querying mechanism in place is essential to be able to replicate studies, results and 
methods must be published in a replicable manner. A clear description of inclusion and 
exclusion criteria composing a phenotype is critical. Results may vary unnecessarily 
from the original study if a clear phenotype is absent. It is insufficient to simply state all 
patients with a disease of interest are included. Describing how this disease was defined 
for the study is essential. For instance, a diabetic study may include patients based on 
ICD diagnostic codes alone, may require one or multiple hemoglobin A1C (HbA1C) 
measures within a certain time frame, may be based on medication history, or some 
combination of any of these criteria. Each of these criteria should be provided in a 
human readable and machine parsable and interoperable format, possibly in the 
supplemental material to a published study. Without these clear descriptions, a 
replication attempt may study a very different population relative to what was originally 
documented. 
Transparent Statistical Analysis 
 Finally, with the data and infrastructure in place and a study publishing a clear 
description of inclusion and exclusion criteria, it is also critical that the published work 
clearly document the statistical analysis and computations performed. Researchers have 
a vast arsenal of statistical means at their disposal, each of which may be appropriate in 
some situations. Understanding the original hypothesis, significance level, and any 
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model computation is requisite for a researcher attempting to replicate the study. A risk 
model whose components remain in a black box may not be replicable. If coefficients 
and how they were obtained is clear, a similar approach to developing a replicate is 
possible. If a winding path of statistical analysis with multiple endpoints and subsets of 
the population were employed and not published, replication may be infeasiable,  
Study Selection 
With the criteria described above, I evaluated a series of published risk models to 
attempt to replicate. This chapter focuses on efforts with one of these studies. While 
UNMC has a CRDW with an i2b2 infrastructure for querying a diverse set of clinical data, 
some studies required extra-EHR data or published insufficient information to enable an 
attempt at replication 109 . 
This initial evaluation centered on a study of 30-day hospital readmission for 
heart failure patients 109 . Readmission to a hospital within 30 days of discharge is a 
pervasive problem. With 19.6% of Medicare beneficiaries being readmitted to a hospital 
within 30 days of discharge the cost is estimated to be between $17.4 and $26 billion per 
annum 110, 111 . Section 3025 of the Affordable Care Act established the Hospital 
Readmissions Reduction Program (HRRP), which financially penalizes hospitals with 
excess readmissions (subpart 1 of 42 CFR part 412 (§412.150 through §412.154). 
Effective strategies to reduce unplanned readmissions are complex, resource intensive, 
and often short-lived 111, 112 .  
 Identifying patients prior to discharge at the greatest risk for readmission may 
focus finite resources. Heart failure (HF) represents the primary cause of hospitalizations 
in patients over age 65 and is among the leading causes for preventable readmissions 
within 30 days 113, 114 . Understanding if the results published by this study are valid and 
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extendable to the population at UNMC is a necessary precursor to implementing any 
future change in clinical workflow or policy. 
 A number of models have been proposed and used to predict risk for 30-day 
readmission for heart-failure patients. For this assessment of coverage of UNMC’s 
CRDW I selected Amarasingham’s 2010 model for a number of reasons. First, this 
model encompasses much of preceding models 115 . Next, Amarasingham et al 
demonstrated the validity of their model in comparison to a CMS model and the Acute 
Decompensated Heart Failure Registry (ADHERE) model 109 . Finally, Amarasingham et 
al designed this model to utilize data commonly available in a basic EHR within the first 
24 hours of hospital admission, making it likely UNMC’s CRDW would contain much of 
the needed information. Additionally, this may facilitate future efforts of real-time 
application of the model within the EHR. 
 My initial hypothesis was the infrastructure established around UNMC’s CRDW is 
sufficient to replicate a study that developed a risk model for readmission in heart failure 
patients. To address this hypothesis, I surveyed the necessary data elements from the 
study and produced the necessary queries to obtain sufficient data on the heart failure 
population at UNMC. 
Methods –  
Infrastructure 
Overview 
 The clinical data research warehouse (CRDW) at the University of Nebraska 
Medical Center (UNMC) is a composite of de-identified data from a variety of sources 
(Figure 1). The development and use of this registry of patient data was approved by the 
institutional review board (IRB) at UNMC (IRB # 132-14-EP). Extracted patient-centric 
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data are transformed to adhere to vocabulary standards recommended by the office of 
the national coordinator (ONC) and loaded into informatics for integrating biology and 
the bedside (i2b2). Data are further transformed to conform to the National Patient-
Centered Clinical Research Network (PCORnet) common data model (CDM) to allow 






Figure 1. Overview of UNMC’s CRDW. Data originate from both local and national 
sources. These data are extracted, transformed to ONC recommended vocabulary 




 Data for the clinical research are extracted from enterprise specific as well as 
national data sources. The bulk of data originate in Epic One Chart (Epic Systems 
Corporation, 1979 Milky Way, Verona, WI 53593), the electronic health record (EHR) at 
Nebraska Medicine. Local tissue biobank data and information from clinical research 
stored in Research Electronic Data Capture (REDCap) may also be incorporated to 
provide a more complete patient picture. These data are supplemented with information 
from the national level, including data from the Social Security Death Index (SSDI 
www.ntis.gov/products/ssa-dmf.aspx), the North American Association of Central Cancer 
Registries (NAACCR www.naaccr.org), and from the United States Census 
(www.census.gov).  
 UNMC’s CRDW has de-identified information for more than 2 million patients. 
The majority of this data were recorded since 2012 when Nebraska Medicine adopted an 
Epic EHR. However, some data, especially demographic and laboratory information, has 
coverage originating many years earlier. For more than half a million patients, relatively 
complete medical information exists for the past several years in this database. 
De-Identification: 
All data stored in UNMC’s CRDW is fully de-identified according to guidelines 
associated with the Health Insurance Portability and Accountability Act (HIPAA) Privacy 
Rule 116 . Protected health information (PHI), including patient names, addresses, e-mail 
addresses, phone numbers, social security numbers (SSN), fax numbers, health 
insurance beneficiary numbers, account numbers, medical record numbers, 
certificate/license numbers, vehicle identification numbers, and other unique identifying 
numbers are excluded from the data warehouse. All dates, including birth dates, 
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encounter dates, death dates, and diagnoses or procedure dates, are obfuscated. On a 
per patient basis, dates are shifted by a random number from -1 to -30. Date shifting is 
consistent across all of a single patient’s encounters and characteristics. Geographical 
identifiers are obfuscated to ensure the covered population is greater than 20,000 
individuals. To accomplish this, zip codes are truncated after two or three digits.  
Standardization 
 As data are extracted from disparate and often proprietary formats, we dedicated 
considerable effort to transform elements to ONC recommended vocabulary standards 
77, 117 . Where feasible, standards were adopted or recommended to facilitate 
interoperability. Per ONC guidelines, encounter diagnoses were mapped to international 
classification of disease (ICD) versions 9 and 10, demographic data such as race and 
ethnicity conform to Office of Management and Budget (OMB) standards, laboratory 
information are represented via Logical Observation Identifiers Names and Codes 
(LOINC www.loinc.org), medication information is presented with appropriate National 
Drug Codes (NDC) and RxNorm codes, and clinical findings are reported as 
Systematized Nomenclature of Medicine – Clinical Terms (SNOMED-CT) terms (See the 
Interoperability Standard Advisory from the Office of the National Coordinator for Health 
IT 118  for further details of datatypes and standards).  
Informatics for Integrating Biology and the Bedside (i2b2) 
 The CRDW is built on the Informatics for Integrating Biology and the Bedside 
(i2b2) research environment. This is an NIH-funded National Center for Biomedical 
Computing (NCBC) devoted to translational research (http://www.i2b2.org). In particular, 
it is a scalable, open-source informatics framework and architecture that can be used to 
host a research data warehouse 119 . Developed within the Partner’s Health Care, i2b2 is 
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now deployed at more than 60 academic medical centers across the country. This web-
based service allows authorized users to query de-identified patient data for exploratory 
analysis and cohort identification. With a common messaging protocol, queries may be 
developed locally, tested on a single date warehouse, and then shared across large 
networks to interrogate data covering many more patients. In this way, the query, rather 
than patient data, is shared between institutions. 
Model Replication 
Defining the Study Population 
Eligible patients (table 2) have a documented diagnosis of heart failure based on 
ICD 9 code 109, 120  and were admitted to a Nebraska Medicine hospital at least once from 
May 2012 to December 2015. Visits for rehabilitation (DRG 462) were excluded. 
Additionally, admissions where the patient expired or left against medical advice (ICD10 
CM Z53.21, ICD9CM: V64.2) were not considered as index hospitalizations 110 . A 30-
day readmission was defined as an admission to the hospital for any cause within 30 





Table 2. Eligibility Criteria for Inclusion in the Amarasingham Model. All patients were 





 For assessing the coverage of data, we considered all inpatient encounters for 
eligible patients during the date range specified. Patient counts were generated using 
i2b2 queries. 
 Variable Definitions 
 Age was defined by the age at the initial visit. Laboratory values were defined by 
relevant LOINC codes. These were not defined by the original authors. History of 
depression or anxiety was defined by the following ICD-9-CD codes: 293.83, 293.84, 
297.1, 297.9, 300.0, 300.00, 300.01, 300.02, 300.09, 300.11, 300.23, 300.29, 300.4, 
300.9, 301.6, 301.83, 301.9, 306.1, 306.4, 308.0, 308.3, 308.9, 309.0, 309.24, 309.28, 
309.29, 309.9, 311, and 312.20. Appendix B contains a printed version of a sample i2b2 
query’s generated SQL for identifying the variables from the original risk model. 
Obtaining Missing Data Elements 
 Clinicians and laboratory technicians were consulted to determine if missing data 
elements were routinely ordered or recorded at Nebraska Medicine. Following the 
pattern for previous data extracts, data elements were identified in Clarity data tables, 
and extracted, transformed to align with ONC standards where applicable, and loaded 
into the star schema supporting i2b2. In addition to loading new facts, metadata was 
created as necessary to allow querying in the web client. As part of this metadata 
creation and updates, metadata xml was created for many existing labs in order to allow 
the user to query lab values rather than just the presence or absence of results. Finally, 
quality assessment on new and existing data was performed to ensure proper loading 
and mapping. This was done by sampling patients and encounters and reviewing 





The CRDW at UNMC has excellent overall coverage of the variables in the 
Amarasingham risk model (34/40, 85%) (Table 3). All variables in the demographics and 
laboratory values are covered. Vital signs will be fully covered if the Tabak mortality 
score is calculated and recorded. Socioeconomic status and health system interactions 





Table 3. Amarasingham Model Data Coverage in UNMC’s CRDW. The majority (34/40) 





 I rejected my hypothesis that the current CRDW at UNMC was sufficient to fully 
replicate this risk model for readmission in heart failure patients. Inability to replicate the 
study stemmed both from insufficient information being published and from lack of 
sufficient data variety being available and incorporated into the CRDW. 
 First, the authors failed to publish how the risk model coefficients were calculated 
for application of their scoring. Attempts to reach the author for clarification went 
unanswered. In addition, standard LOINC codes for laboratory values were not 
published necessitating the replication effort to include attempting to identify appropriate 
laboratory tests. Without these data, full replication is impossible. 
 In addition to insufficiencies in the published study, limitations in data variety in 
the CRDW prevented full replication of the risk model. Socioeconomic status required 
linking EHR data to U.S. Census data which had not been completed at UNMC. Multiple 
variables, including number of home address changes, payer information, and missed 
scheduled visits may be extracted from the EHR in the future. Finally, arrival time at the 
ED was excluded as this work was completed in a de-identified database.  
While data elements present in the de-identified CRDW did not allow for full 
replication of this risk model, this assessment helps prioritize efforts to load additional 
clinical data elements into the CRDW. 
Limitations 
 Data for this study come only from Nebraska Medicine and do not reflect 
readmissions to other hospitals. Nasir et al indicate same-hospital readmission rate is 
not a reliable indicator of all-hospital readmission rates. They showed only 80.9% of 
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readmissions for heart failure patients were to the index hospital 85 . However, same-
hospital data may be a useful benchmark for internal quality improvement. Readmission 
data for all hospitals in the area may be available through NeHII and may be used in 
future studies. 
Future Research 
 Future research may focus on validating the existing model and investigating 
new variables to include. Additionally, the queries used in this research effort may be 
shared with other sites using i2b2 to expand the study cohort. Further research can be 
formed with similar methods for other patient cohorts who are commonly readmitted 
(COPD, Pneumonia, AMI, TKA/THA, and septicemia patients). Eventually, this predictive 
model may be applied in real-time to identify patients at risk for readmission before they 




CHAPTER 2 – ATTEMPTED REPLICATION OF AN IN-HOSPITAL 
MORTALITY RISK MODEL 
Introduction 
As the heart failure study proved irreplicable, I selected another risk model 
addressing in-hospital mortality. Tabak’s 2014 model for mortality risk has demonstrated 
validity relative to published models and was designed to use data commonly available 
in an EHR in the first 24 hours of a patient visit 121 . This risk model is based on age, 
gender, and 23 laboratory findings. 
Methods 
Infrastructure 
 See chapter one for a full description of the development and contents of the 
UNMC CRDW. Data coverage and encounter data were collected via i2b2 queries and 
SQL scripts targeting the de-identified database (Appendix C).  
Assessing Coverage 
 For assessing the coverage of our current data, we considered all encounters 
with any discharge disposition recorded (Logical Observation Identifiers Names and 
Codes (LOINC) 75528-0 and 75527-2) for a three-year period (de-identified 5/1/2012 – 
5/1/2015). Patient counts to assess data coverage were generated using i2b2 queries 
using pertinent LOINC and Current Procedure Terminology, 4th Version (CPT-4) codes.  
Defining the Study Population 
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 Data were analyzed for patients discharged from a Nebraska Medicine hospital 
between 1/1/2013 and 12/31/2017 (de-identified date range). Patients with a discharge 
were defined by having a discharge disposition recorded based on LOINC code 75528-0 
and a vital status recorded at discharge based on LOINC code 75527-2. Those patients 
with missing data or a status of unknown, no information, or other recorded were 
excluded. Only inpatient encounters were considered. Encounters with a length of stay 
less than 24 hours were excluded. 
Outcome variable 
  The outcome variable for this study was inpatient mortality. Inpatient mortality 
was defined by a vital status at discharge of “Expired” (LOINC 75527-2 code “E”) or a 
discharge disposition of expired (LOINC 75528-0). Encounters with unknown, other, or 
no information recorded for vital status at discharge were excluded.  
Statistical Analysis 
  Using the coefficients provided by Tabak et al, a risk score was calculated for all 
encounters in the cohort. This score was used as the predictor variable with inpatient 
mortality as the dependent variable to fit a logistic regression model.  
Missing Values 
 For missing lab values, we followed Tabak et al’s procedure of assigning a score 
based on the reference range for the missing variable 121 . For each lab, if multiple values 
exist, the earliest recorded value in the encounter is used.  
Creating a Receiver Operator Characteristic (ROC) curve and computing the area 
under the curve (AUC) 
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 With missing values imputed as described above, a risk score was calculated for 
each encounter as the sum of scores for each data element. For each risk score, the 
number of expired and living patients at discharge was identified and the sensitivity and 
specificity for each score as a cutoff was computed. Next, for each risk score the true 
positive rate (sensitivity) and the false positive rate (1 – specificity) were tabulated. 
Based on this table, an ROC curve was plotted and the area under the curve was 
calculated (concordance (c)-statistic). Analyses performed with R (R Core Team (2016). 
R: A language and environment for statistical computing. R Foundation for Statistical 
Computing, Vienna, Austria. URL https://www.R-project.org/.). 
Logistic Regression and Comparing c-statistics 
 Using functions available in R packages (glm) we fit a logistic regression to our 
data. We compared the coefficients generated from these data to those reported by 
Tabak et al. To assess the predictive power of our model, we computed the c-statistic for 
the logistic regression. We then compared this c-statistic to that published by Tabak et al 
121 . A c-statistic of 0.5 indicates a predictive model no better than chance. As the c-
statistic increases toward 1.0, the discriminatory power of the model is greater. The c-
statistic defines the probability that a patient selected from the outcome group will have a 
risk score greater than a patient selected from the group without the outcome of interest. 
Results 
Data Coverage 
 All variables employed by the Tabak risk model were present in the CRDW at 
UNMC (25/25, 100%) (see table 4). The Demographics variables had the best coverage, 
with over 99% of encounters having this data available. Serum chemistry variables 
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demonstrated good coverage with between 57% and 80% of all encounters having 
recorded values. Arterial blood gas labs and cardiac markers demonstrated the lowest 
coverage. Less than 16% of encounters had arterial blood gas values. Three of the six 
hematology and coagulation variables were represented in over 80% of the encounters 
while the other three variables had less than 40% of encounters with results (see table 
4). 
Encounter Characteristics 
 For the specified date range, 79,039 distinct adult patients were identified having 
a total of 136,084 distinct, inpatient encounters lasting longer than 24 hours. The number 
and percentage of these encounters with each of the risk score variables is displayed in 
table **5. For these encounters, 3,047 (2.24%) resulted in a discharge disposition of 
expired. The average total score for encounters where the patient expired was 77.0 (SD 
23.0) while the average total score for encounters where the patient was discharged 














Receiver Operator Curve 
 Using the total score with Tabak’s reported coefficients as the predictor, a 
receiver operator characteristic curve was computed (Figure 3a). As it is up and to the 
left, the curve demonstrates the high predictive value of the model. The area under the 
curve (AUC) is 0.94. As the dataset is highly unbalanced, we also created a precision-





Figure 3. Receiver Operator Characteristic (ROC) curve and Precision-Recall (PR) 
Curve based on Tabak mortality score. ROC (A) and PR (B) Curves based on scores 
calculated from 136,084 inpatient encounters for adults at Nebraska Medicine between 





 Using the ranges assigned by Tabak et al for age, gender, and each laboratory 
test, we used multiple logistic regression to compute new coefficients for a risk model 
score (Table 5).  Recomputed coefficients demonstrated medium correlation to the 







, n (%) 
Coeff. Std. 
Error 
P Sig. Tabak 
Coeff. 
Diff. 
30-34 9,026 (6.6) 53 (0.6) 0.24 0.19 0.212     0.21 0.03 
35-39 7,316 (5.4) 56 (0.8) 0.38 0.19 0.046 *   0.67 -0.29 
40-44 7,117 (5.2) 70 (1) 0.34 0.18 0.057 .   0.83 -0.49 
45-49 8,284 (6.1) 134 (1.6) 0.68 0.16 < 0.001 *** 1.12 -0.44 
50-54 11,197 (8.2) 198 (1.8) 0.79 0.15 < 0.001 *** 1.28 -0.49 
55-59 13,545 (10) 286 (2.2) 0.89 0.14 < 0.001 *** 1.47 -0.58 
60-64 13,857 
(10.2) 
374 (2.8) 1.14 0.14 < 0.001 *** 1.64 -0.50 
65-69 12,970 (9.5) 387 (3.1) 1.24 0.14 < 0.001 *** 1.8 -0.56 
70-74 10,600 (7.8) 360 (3.5) 1.44 0.14 < 0.001 *** 1.96 -0.52 
75-79 8,946 (6.6) 308 (3.6) 1.57 0.14 < 0.001 *** 2.11 -0.54 
80-84 7,403 (5.4) 313 (4.4) 1.81 0.14 < 0.001 *** 2.32 -0.51 
85-89 7,624 (5.6) 317 (4.3) 1.93 0.14 < 0.001 *** 2.51 -0.58 
>89 448 (0.3) 113 
(33.7) 





0.12 0.04 0.007 **  0.14 -0.02 
Albumin <= 2.4 
g/dL 4 
7,222 (5.3) 795 
(12.4) 
1.17 0.07 < 0.001 *** 0.89 0.28 
Albumin 2.5 - 
2.7 g/dL 
6,298 (4.6) 374 (6.3) 0.72 0.08 < 0.001 *** 0.47 0.25 
Albumin 2.8 - 3 
g/dL 
9,305 (6.8) 453 (5.1) 0.63 0.07 < 0.001 *** 0.26 0.37 
Albumin 3.1 - 
3.3 g/dL 
12,842 (9.4) 431 (3.5) 0.44 0.07 < 0.001 *** 0.08 0.36 
AST 31 - 40 U/L 8,997 (6.6) 349 (4) 0.31 0.07 < 0.001 *** 0.14 0.17 
AST 41 - 60 U/L 7,401 (5.4) 397 (5.7) 0.46 0.07 < 0.001 *** 0.28 0.18 
AST 61 - 100 
U/L 
5,149 (3.8) 310 (6.4) 0.41 0.08 < 0.001 *** 0.37 0.04 
AST > 100 U/L 6,553 (4.8) 578 (9.7) 0.60 0.07 < 0.001 *** 0.6 0.00 
Total Bilirubin 
1.5 - 2 mg/dL 
4,552 (3.3) 249 (5.8) 0.25 0.08 0.003 **  0.07 0.18 
Total Bilirubin 
> 2.0 mg/dL 
6,414 (4.7) 571 (9.8) 0.36 0.07 < 0.001 *** 0.29 0.07 
Calcium <= 7.9 
mg/dL L 
7,523 (5.5) 590 (8.5) -0.03 0.07 0.635     0.26 -0.29 




583 (3.7) -0.08 0.06 0.145     0.09 -0.17 
Calcium > 10.1 
mg/dL 
3,727 (2.7) 132 (3.7) 0.40 0.11 < 0.001 *** 0.22 0.18 




800 (6.2) -0.12 0.07 0.072 .   0.09 -0.21 
pro BNP 8001 - 
18000 
12 (0) 2 (20) 2.16 0.83 0.009 **  0.35 1.81 
57 
 
pro BNP > 
18000 
9 (0) 0 (0) -9.18 99.82 0.927     0.68 -9.86 
BNP 1201 - 
2400 
1,594 (1.2) 144 (9.9) 0.21 0.11 0.057 .   0.11 0.10 
BNP > 240 733 (0.5) 89 (13.8) 0.58 0.14 < 0.001 *** 0.28 0.30 
Glucose <= 70 
mg/dL 
1,754 (1.3) 113 (6.9) 0.45 0.13 < 0.001 *** 0.43 0.02 




525 (3.3) 0.26 0.06 < 0.001 *** 0.16 0.10 




781 (4.1) 0.28 0.05 < 0.001 *** 0.32 -0.04 
K <= 3.2 mEq/L 8,065 (5.9) 255 (3.3) 0.09 0.08 0.242     0.19 -0.10 
K 5 - 5.3 mEq/L 3,812 (2.8) 212 (5.9) 0.05 0.09 0.572     0.1 -0.05 
K > 5.3 mEq/L 3,564 (2.6) 287 (8.8) 0.11 0.08 0.206     0.21 -0.10 
Na <= 130 8,503 (6.2) 445 (5.5) 0.12 0.07 0.066 .   0.28 -0.16 
Na 131 - 135 27,553 
(20.2) 
836 (3.1) 0.07 0.05 0.162     0.09 -0.02 
Na 144 - 145 1,876 (1.4) 96 (5.4) 0.40 0.13 0.002 **  0.27 0.13 
Na > 145 995 (0.7) 114 
(12.9) 
0.69 0.13 < 0.001 *** 0.61 0.08 




576 (4.2) 0.01 0.06 0.898     0.11 -0.10 
Alk Phos 221 - 
630 U/L 
4,109 (3) 238 (6.1) 0.04 0.09 0.675     0.34 -0.30 
Alk Phos > 630 
U/L 
636 (0.5) 59 (10.2) 0.31 0.17 0.068 .   0.54 -0.23 
BUN 26 - 30 
mg/dL 
7,032 (5.2) 319 (4.8) 0.33 0.07 < 0.001 *** 0.24 0.09 
BUN 31 - 40 
mg/dL 
7,783 (5.7) 386 (5.2) 0.15 0.07 0.035 *   0.37 -0.22 
BUN 41 - 55 
mg/dL 
5,692 (4.2) 344 (6.4) 0.23 0.08 0.005 **  0.53 -0.30 
BUN > 55 
mg/dL 
5,630 (4.1) 452 (8.7) 0.36 0.09 < 0.001 *** 0.68 -0.32 
pH Arterial <= 
7.2 
1,401 (1) 384 
(37.8) 
1.72 0.09 < 0.001 *** 1.38 0.34 
pH Arterial 7.21 
- 7.3 
2,942 (2.2) 466 
(18.8) 
1.27 0.07 < 0.001 *** 0.87 0.40 
pH Arterial 7.31 
- 7.35 
3,355 (2.5) 376 
(12.6) 
1.11 0.07 < 0.001 *** 0.66 0.45 
pH Arterial > 
7.48 
1,497 (1.1) 180 
(13.7) 
0.58 0.10 < 0.001 *** 0.5 0.08 
PO2 <= 50 479 (0.4) 81 (20.4) 0.90 0.15 < 0.001 *** 0.79 0.11 
PO2 50.1 - 55 486 (0.4) 81 (20) 0.91 0.15 < 0.001 *** 0.57 0.34 
PO2 > 140 7,781 (5.7) 639 (8.9) 0.34 0.06 < 0.001 *** 0.78 -0.44 
pCO2 Arterial 
<= 35 
6,758 (5) 881 (15) 0.97 0.06 < 0.001 *** 0.56 0.41 
pCO2 Arterial 
>50 
3,513 (2.6) 533 
(17.9) 
0.86 0.08 < 0.001 *** 0.46 0.40 
PTT <= 22 653 (0.5) 43 (7) 0.72 0.19 < 0.001 *** 0.22 0.50 
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PTT 45.1 - 55 1,324 (1) 148 
(12.6) 
0.33 0.11 0.003 **  0.21 0.12 
PTT > 55 1,532 (1.1) 225 
(17.2) 
0.61 0.10 < 0.001 *** 0.28 0.33 
PT INR 1.11 - 
1.4 
12,828 (9.4) 664 (5.5) 0.22 0.06 < 0.001 *** 0.23 -0.01 
PT INR 1.41 - 2 6,000 (4.4) 471 (8.5) 0.41 0.07 < 0.001 *** 0.44 -0.03 
PT INR 2.1 - 5 5,942 (4.4) 456 (8.3) 0.68 0.07 < 0.001 *** 0.34 0.34 
PT INR > 5 765 (0.6) 81 (11.8) 0.68 0.15 < 0.001 *** 0.51 0.17 
Bands 7 - 13% 5,126 (3.8) 451 (9.6) 0.85 0.07 < 0.001 *** 0.37 0.48 
Bands 14 -32% 6,641 (4.9) 644 
(10.7) 
0.80 0.06 < 0.001 *** 0.59 0.21 
Bands > 32% 2,565 (1.9) 309 
(13.7) 
0.87 0.08 < 0.001 *** 0.79 0.08 
Hemoglobin <= 
10 g/dL 
24,558 (18) 1,107 
(4.7) 
0.20 0.05 < 0.001 *** 0.16 0.04 
Hemoglobin > 
18 g/dL 
477 (0.4) 24 (5.3) 0.18 0.25 0.474     0.25 -0.07 
Platelets <= 
115*109/L 
10,019 (7.4) 667 (7.1) 0.34 0.06 < 0.001 *** 0.63 -0.29 
Platelets 115.1 
– 150*109/L 
11,084 (8.1) 352 (3.3) 0.07 0.07 0.284     0.13 -0.06 
Platelets > 
420*109/L 





480 (1.9) -0.11 0.06 0.059 .   0.27 -0.38 





453 (3.2) 0.30 0.06 < 0.001 *** 0.28 0.02 
WBC 14.2 - 
19.8 
*1,000/mm3 




3,380 (2.5) 282 (9.1) 0.32 0.08 < 0.001 *** 0.78 -0.46 
Troponin I 0.05-
0.1 or CPK MB 
3-5 ng/mL 
5,542 (4.1) 435 (8.5) 0.62 0.06 < 0.001 *** 0.15 0.47 
Troponin I 0.11-
0.2 or CPK MB 
6-10 ng/mL 
1,709 (1.3) 193 
(12.7) 
0.86 0.10 < 0.001 *** 0.29 0.57 
Troponin I 0.21-
0.3 or CPK MB 
11-34 ng/mL 
744 (0.5) 99 (15.3) 0.94 0.14 < 0.001 *** 0.54 0.40 
Troponin I >0.3 
or CPK MB >34 
ng/mL 
2,810 (2.1) 392 
(16.2) 





            
 
Table 5. Logistic Regression Coefficients for Variables in Tabak Mortality Score. AST = 
Aspartate Aminotransferase, Pro-BNP = pro-B-type natriuretic peptide, BNP = B-type 
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natriuretic peptide, K = Potassium, Na = Sodium, Alk Phos = Alkaline Phosphatase, BUN 
Blood Urea Nitrogen, PTT = Prothrombin Time, Prothrombin Time International 







Figure 4. Correlation of Newly Calculated and Tabak Model Coefficients. Labeled points 






 Sufficient data volume and variety were included in UNMC’s CRDW to enable 
replication of the readmission risk model. Replication was further facilitated as the 
authors published clear methods on how they computed the coefficients for the risk 
model. In addition, the original article clearly defined the characteristics of the 
encounters to be included in the analysis. With the infrastructure in place and sufficient 
details published, we successfully replicated this risk model and extended the results to 
a novel population. This lends further credence to the original work and supports use of 
the model for further studies or applications within CDS. 
 A few points comparing newly calculated coefficients to the originally published 
values stand out. The Pro-BNP values demonstrate a large discrepancy between this 
replication effort and the original study. This is most likely due to the very low encounter 
counts recording this laboratory value (21 total encounters with abnormal values 
recorded). The apparent protective effect of a grossly elevated pro-BNP is most likely an 
artifact of zero of the nine encounters resulting in an expired patient. Further analysis of 
this model may benefit from excluding this variable as it has such a low encounter count. 
The coefficient for age > 89 being slightly different from the original study is likely also 
due to a low encounter count for this category coupled with a slightly higher incidence of 
mortality for this category. Further study may require a threshold for a minimum 
encounter count for a variable to be included in the analysis. 
Limitations 
 This study was limited as data were obtained solely from Nebraska Medicine 
affiliated hospitals. The study being replicated collected data from 70 hospitals and 
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accumulated nearly ten times the number of encounters to include. Artifacts due to the 
local environment and workflows may introduce bias in our analysis. In addition, the 
demographics included in our study sample may not be representative of the entire 
United States and may not be applicable in all areas.  
Future Research 
 With successful replication of this readmission risk model, applying this 
replication methodology to additional risk models is possible. The pattern of evaluating 
the publication and assessing the coverage of the CRDW infrastructure provides a 
means to potentially replicate any clinical research. 
 In addition, with the validation and extension of the risk model described in this 
chapter, further analyses on subsets of the population are possible. Refining the risk 
model for specific diseases as well as considering additional variables with high 
predictive power are possible.  
 Finally, incorporating this risk model score into the CRDW and eventually into 
CDS is possible. Within i2b2, the score can be calculated and stored on a per encounter 
basis. Metadata may be developed to allow researchers to use this score within clinical 
queries. As the efficacy of the risk model are further demonstrated, incorporating this risk 





CHAPTER 3 – DEVELOPING A COMPUTABLE PHENOTYPE FOR 
PREGNANCY 
Introduction 
 Distributed research networks relying on data extracted from the EHR offer a 
variety of benefits for comparative effectiveness research (CER) and conducting 
pragmatic trials. Data are collected for millions of patients including diverse 
demographics and clinical environments and are representative of actual care 97-99. 
Federated queries allow patient screening and subsequent data collection with a fraction 
of previously required resources. However, to be effective, queries must be applicable 
across all sites. Each query represents a computable phenotype, i.e. a set of 
characteristics and clinical features more commonly observed in patients with a disease 
or condition than individuals in the general population 122. Some elements of these 
phenotypes recur as building blocks for queries in other studies. For instance, many 
queries seek to identify a population with diabetes. Some of these may focus on 
individuals of a certain age, only inpatients, or only those with specified comorbidities. In 
each instance, the base population of those with diabetes must be defined. For many 
diseases, professional societies have put forth detailed guidelines that can be adopted to 
construct interoperable computable phenotypes.  
 One common condition for which a computable phenotype has not been well-
defined is pregnancy. While the EHR is replete with data on this condition and being 
pregnant is very often an inclusion or exclusion criteria for clinical research, no standard 
EHR definition has been put forth to consistently identify a pregnant population 123 . 
Defining this element has often been done ad hoc with limited success 124 . Some 
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challenges to creating a common definition include the variety of measures and findings 
that may indicate a pregnancy, the diverse location in the EHR these elements may be 
stored, inconsistent coding across sites, and the varying levels of care sought during 
pregnancy.  
 In this chapter, I describe the process of identifying variables commonly available 
in basic EHRs to inform future development of a computable phenotype for pregnancy. 
Our approach was to analyze a validated pregnant population and compare features to 
an age-matched control population to identify candidate variables. In future work, these 
will be incorporated into the development of a multiple logistic regression model that may 
be validated against a test population and shared with other sites. 
Methods 
Data Source 
 As described in chapter 1, all data were extracted from the electronic health 
record at Nebraska Medicine. These data were transformed to adhere to ONC 
recommended standard terminologies, fully de-identified, and loaded into an i2b2 
infrastructure to allow querying. In the course of this study, additional variables were 
added to the ETL processes and additional metadata was added to i2b2 to facilitate 
querying these new data elements. For instance, flowsheet rows regarding fetal 
measurements were added to the extract. Also, metadata was created to allow for 
identifying positive and negative pregnancy tests rather than simply the presence or 
absence of these test. 
Candidate Variable Identification 
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Identifying candidate variables associated with pregnancy was both a stepwise 
and an iterative process. An initial population with high confidence of pregnancy was 
identified. This population was used to assess a plethora of variables for inclusion. 
Clinician review by James R. Campbell, MD (Professor, Internal Medicine Division of 
General Medicine-Academic) and Teresa Berg, MD (Director - Maternal-Fetal Medicine; 
Director, Prenatal Diagnostic Center; McGoogan Professor of Obstetrics and 
Gynecology) pared down the candidate variable list. Based on this analysis, additional 
variables were extracted from the EHR and the i2b2 metadata was created or refined as 
necessary to allow querying. Finally, Pearson chi square analysis demonstrated 
association between identified variables and pregnancy. All elements of this study were 
approved by the UNMC IRB (#601-17-EP). 
Initial Pregnant Population 
 Within the EHR at Nebraska Medicine, during routine care clinicians may indicate 
if an encounter is part of an episode. Episodes may be related to surgery, 
anticoagulation, pregnancy, delivery, or a number of other longitudinal situations. In 
consultation with domain experts (Campbell and Berg) and in conjunction with a limited 
chart review, I discovered the flag of pregnancy episode had a high specificity and 
limited sensitivity for identifying currently pregnant patients. The initial pregnant 
population was limited to those females ages 15-50 years old with an encounter flagged 
as part of a pregnancy episode during 2015 or 2016.  
Variable Frequency Analysis 
 For the population identified as described above, all extracted data elements 
recorded during encounters within the pregnancy episode were identified. These data 
included vital signs, visit diagnoses, procedures, medications ordered or dispensed, 
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demographic information, laboratory values, clinical findings, location of visit, and 
diagnostic related group (DRG) information. The total number and percentage of 
patients with each fact was identified. 
Clinician Review 
 In consultation with doctors Cambpell and Berg, this survey of variables was 
grouped and pared down. The initial survey identified each separate diagnostic code and 
multiple variations of the same laboratory test. The clinicians eliminated non-specific 
facts (such as common labs for all patients regardless of pregnancy status) as well as 
grouped similar diagnostic codes at a higher level (i.e. rather than considering Z34.00: 
“Encounter for supervision of normal first pregnancy, unspecified trimester”, Z34.01: 
“Encounter for supervision of normal first pregnancy, first trimester”, Z34.02: “Encounter 
for supervision of normal first pregnancy, second trimester”, and Z34.03: “Encounter for 
supervision of normal first pregnancy, third trimester” independently, the facts were 
grouped to become “ENC DX: Supervision of pregnancy - ICD10CM:Z33-34”). 
Updating Data Extraction and i2b2 Metadata 
 This survey of data and clinician review identified two types of gaps in what was 
previously extracted for obstetric data. First, certain flowsheet rows were missing. Next, 
the i2b2 metadata allowed for queries to determine if a laboratory test was performed 
while not allowing querying of the results of the test. To resolve the first concern, the 
ETL from the research copy of the clinical data research warehouse was updated to 
include flowsheet information relative to fetal ultrasounds and measurements. In 
addition, episode data was not originally extracted from the EHR into the CRDW. For 
these novel data elements, i2b2 metadata was also created to allow for querying. 
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 Next, the analysis demonstrated the metadata previously deployed was 
insufficient to query laboratory values for various pregnancy tests. For these instances, 
metadata XML was developed to query the lab values. This necessitated interpreting 
numeric values as well as free text in some instances to identify each laboratory value 
as positive, negative, or unknown.  
Statistical Analysis 
 With this enhanced list of candidate variables, contingency tables were created 
to compare the pregnant cohort to a control population using Pearson Chi-Square tests 
for significance for each refined variable. The control group consisted of female patients 
ages 15-50 years old without a pregnancy episode noted during 2015-2016 who had at 
least one face to face encounter at a Nebraska Medicine affiliated hospital or clinic 
during this time frame. Patient counts for each population for each variable were 
identified using i2b2 queries. 
Refining the Pregnant Cohort and Control Population for Model Development 
Identifying Pregnancy Beginning and End Dates 
With candidate variables identified, a verified cohort of all pregnant patients 
during the date window of interest was required (Figure 5). This needed to include 
patients with and without pregnancy episodes noted in the EHR. The bounds of a 
pregnancy were calculated from information extracted from the EHR. The end date for a 
pregnancy was identified first by the delivery date noted in the obstetric history. If this 
date was not available, the date of a delivery encounter was used. If this was not 
identified, the start date of a delivery episode was used to denote the end date of a 
pregnancy. If none of these were available, the estimated delivery date recorded for the 
pregnancy episode was used. The start date for a pregnancy was calculated based on 
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the end date as recorded above. If available, the end date minus the gestational age 
recorded at delivery was used. When not available, the estimated delivery date – 280 









 Using i2b2, we identified all females ages 15-50 who were seen at Nebraska 
Medicine for any care during 2015-2016. We excluded patients with a pregnancy 
episode identified during these years. For both the control and pregnant cohort, patients 
were required to reside within 50 miles of UNMC. Patients outside of 50 miles often only 
came to UNMC for specialty care or emergent conditions. During these encounters, 
pregnancy was noted. However, obstetric care and associated records were maintained 
elsewhere and not available for inclusion in this analysis. All patients were required to 
have at least one face to face encounter during the study window. 
Results 
Variable Identification 
 Table 6 and Figure 6 provide demographic details about the initial pregnancy 
episode and control population used to refine the list of potential variables. In both 
instances, the majority of the population was White and the mean age was 
approximately 30 years old. Table 7 summarizes the curated list of variables associated 
with pregnancy. The reported p-values in this table are the results from the Pearson Chi-






Table 6. Demographics of 














White or Caucasian 3,523 (64.8) 55,486 (74.0)
Black or African American 909 (16.7) 7,163 (9.6)
Asian 136 (2.5) 1,975 (2.6)





 (n = 74,949)
Minimum Age 15 15
Maximum Age 47 50


































Table 7. Comparison of Frequency of Finding in Pregnant vs. Non-pregnant Populations. 







ICD10CM:Z33-34 Supervision of pregnancy 4,408 (81.0) 1,127 (1.5) <0.001
ICD10CM:O60-O94 Complications of delivery 1,463 (26.9) 374 (0.5) <0.001
ICD10CM:O009-O29, 
O98,O99
Disorders during pregnancy 3,915 (72.0) 1,564 (2.1) <0.001
ICD10CM:O31-O41 Pregnancy complications 1,308 (24.0) 330 (0.4) <0.001
CPT4:76801-76828 Obstetric ultrasound 4,064 (74.7) 1,285 (1.7) <0.001
LOINC:882-1 ABO and Rh group [Type] 3,513 (64.6) 2,402 (3.2) <0.001
LOINC:20415-6
B-hCG in serum by 
immunoassay (Positive)
879 (16.2) 724 (1.0) <0.001
LOINC:20415-6
B-hCG in serum by 
immunoassay (Negative)
129 (2.4) 659 (0.9) <0.001
LOINC:2106-3 hCG in urine (Positive) 178 (3.3) 120 (0.2) <0.001
LOINC:2106-3 hCG in urine (Negative) 353 (6.5) 6,455 (8.6) <0.001
LOINC:2118-8
hCG in serum/plasma 
(Positive)
45 (0.8) 74 (0.1) <0.001
LOINC:2118-8
hCG in serum/plasma 
(Negative)
124 (2.3) 2,089 (2.8) 0.03036
SNOMEDCT:173300003 Disorder of pregnancy 3,434 (63.1) 1,293 (1.7) <0.001
SNOMEDCT:77386006 Patient currently pregnant 3,434 (63.1) 1,293 (1.7) <0.001
SNOMEDCT:16356006 Multiple pregnancy 110 (2.0) 26 (0.0) <0.001
OB Clinical Encounter at 
UNMC
Visit to obstetric clinic 3,993 (73.4) 9,949 (13.3) <0.001
LOINC:11881-0
Uterus fundal height tape 
measure
3,373 (62.0) 337 (0.4) <0.001
LOINC:55283-6 Fetal heart rate (Positive) 3,552 (65.3) 348 (0.5) <0.001
LOINC:57088-7
Fetal movement - reported 
(Positive)










 This survey of the EHR identified a series of variables highly associated with 
pregnancy. None of these variables taken independently was highly sensitive. Variations 
in clinical workflow, physician preference, and charting practice within an institution, and 
likely exacerbated across multiple institutions, may account for differences in data 
elements being recorded during pregnancy. From initial chart review, some of these 
variables demonstrated high specificity. 
Limitations 
 A number of considerations must be made when evaluating these data. First, this 
survey of the EHR was limited to the environment in a single academic medical center 
with a single EHR. Workflows and technical bias may be introduced as a similar review 
is conducted at other institutions using disparate, proprietary EHRs. I attempted to 
mitigate the potential of overfitting to UNMC’s environment by identifying a variety of 
variables from several data domains likely to be recorded in the majority of basic EHRs. I 
did not simply rely on a single diagnosis or a specific procedure. Rather, data came from 
procedures, clinical findings, diagnoses, laboratory tests, and obstetric measures. In 
addition, interoperability and replicability are enhanced as I relied on ONC 
recommended standard vocabularies to define these variables. With the exception of 
visiting a UNMC obstetric clinic, all other variables were defined using accepted 
terminologies. 
 This review, as well as future creation of a predictive model, was also limited as 
there is no current and consistent gold standard for identifying a pregnant patient. I used 
episode data as a specific surrogate for such a standard, however, I noted sensitivity 
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was lacking. As thousands of patients deliver each year at a Nebraska Medicine 
hospital, performing a chart review on all patients to be included in the study as well as 
matched controls becomes a major undertaking. Failure to review all charts may lead to 
bias as certain individuals are false positives or false negatives as well as having 
difficulty in identifying meaningful dates for a pregnancy. I attempted to address this 
challenge by accepting all pregnancy and delivery episodes as being pregnant. As this is 
a multistep process for a clinician to indicate, the likelihood of false positives is reduced. 
In addition, I began to refine the population for chart review by identifying patients with 
high likelihood of pregnancy (i.e. those with multiple, specific findings from the variable 
list). In this way, future chart review would be limited to those with a lower suspicion of 
pregnancy as well as matched controls. 
 Finally, there is the potential for bias as I relied on clinician input to refine the list 
of variables. Each clinician has a unique background which may affect how she 
considers characteristics of pregnancy. I limited the potential for bias in two ways. First, I 
conducted a survey of all recorded facts for patients during the time of interest and 
examined those with greatest frequency. Any common data elements recorded during 
pregnancy should be captured in this way. Secondly, I relied on multiple clinicians to 
review and refine the list of variables. Each could add to or comment on the list to refine 
it effectively. Bias may be further mitigated as these variables are shared with other 
domain experts, especially outside this institution, to gain greater perspectives toward 
general applicability. 
Future Research 
 The methods and results reported in this chapter represent initial stages of a 
larger effort to develop a computable phenotype for pregnancy status. This initial survey 
demonstrated variables exist in a basic EHR that are associated with pregnant status. 
75 
 
Immediate next steps will be to continue chart review to identify well-characterized 
pregnant patients with definitive start and end dates for the pregnancy. Chart reviews will 
also be required to validate a matched control population for comparison. With these 
populations identified, each variable will be given an effective time period for which it is 
an indicator of pregnancy. For instance, a positive urine pregnancy test may indicate a 
pregnancy six weeks prior to and up to 34 weeks following the date the event was 
recorded. 
 With a pregnant cohort and age-matched control identified as well as variables 
with date ranges associated, a multiple logistic regression approach will be taken to 
identify a predictive model. The population will be divided into a training and a test 
group, each with a portion of pregnant and control patients. Random sampling at various 
time points during the years of interest will be used to fit the model based on the training 
group. Each patient will have a well-defined period of pregnancy and non-pregnancy. 
Once refined, this predictive model will be evaluated against the test subset of patients. 
The effectiveness of the model will be evaluated with a receiver operator 
characterization curve and its sensitivity and specificity will be noted. 
 With a well-characterized model, interoperability and extendability will be 
evaluated. Using the infrastructure and collaboration within the GPC, the variables and 
model will be shared throughout the distributed research network. This will begin with a 
survey of sites to determine how many of the 14 variables are currently recorded and 
extracted from local EHRs. If sufficient data coverage exists, and with IRB approval, a 
sampling of patients and subsequent chart review will be used to evaluate the 
applicability and effectiveness of the model. 
 With this further refinement, the eventual goals are to publish the model in a 
fashion it may be re-used for clinical research, including pragmatic trials and 
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observational studies. Further evaluation of the model across larger networks may 
further refine it. Once widely validated, incorporating the predictive model into the EHR 
will be planned. Using this model in clinical decision support to identify potentially 
pregnant patients prior to procedures, medication administration, or imaging will 




CHAPTER 4 – INCORPORATING A LOCATION-BASED 
SOCIOECONOMIC INDEX INTO A DE-IDENTIFIED I2B2 CLINICAL 
DATA WAREHOUSE 
Introduction 
 Clinical research data warehouses are often populated with de-identified patient 
data extracted from an electronic health record (EHR) 125 . With the continuing 
advancement and adoption of EHRs, the amount of information available for reuse in 
clinical research continues to rise 73-76 . However, for complete patient characterization, 
these data need to be linked to other sources 93 . For instance, while a patient’s race, 
gender, and smoking status are often well-documented in the EHR, other elements of 
socioeconomic status are often unstructured or absent from the clinical record and 
unavailable for incorporation into a research data warehouse. These non-clinical 
elements describing a patient’s social, economic, and environmental determinants of 
health (healthypeople.gov) are a major contributing factor in readmission, morbidity, and 
mortality 126 . 
 With the paucity of data in the EHR related to socioeconomic status, researchers 
have relied on insurance type as a proxy for this measure 127 . Data elements related to a 
patient’s neighborhood socioeconomic status (NSES) may reliably be obtained from 
extra-EHR sources such as American Community Survey (ACS) data from the U.S. 
census. Neighborhood resources have robust effects on health 128-131 , because of their 
correlation with individual socioeconomic status and as an independent source of 
influence. The demographic composition of residential areas also has important links to 
health behaviors and health outcomes 132-135 . Linking measures of the local residential 
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context to clinical data from the EHR can provide insights into these socioeconomic and 
demographic correlates of health for researchers. 
Using Geographic Information System (GIS) software, a patient’s physical 
address can be linked to a variety of location-based datasets such as the EPA’s Air 
Quality System 136  or the ACS (https://www.census.gov/programs-surveys/acs/). While 
efforts are being made to integrate these elements directly into the EHR, to date, no 
EHR has demonstrated widespread integration of such “community vital signs” 137 . 
Implementing this linkage for clinical research with an EHR-agnostic approach 
introduces additional challenges related to patient privacy and data standardization. The 
Health Information Portability and Accountability Act (HIPAA) privacy rule, the Health 
Information Technology for Economic and Clinical Health Act of 2009, and the Federal 
Policy for the Protection of Human Subjects are designed to safeguard protected health 
information (PHI), including street address and geocodes 138 . These safeguards may 
prohibit researchers from sharing the information required for geocoding with an 
academic or business partner third party, hampering the ability to link clinical and NSES 
data within an institutional review board (IRB) approved process. Additionally, data that 
would identify a patient’s location with too much granularity may not be displayed in a 
de-identified data warehouse. For instance, HIPAA requires zip codes be obfuscated if 
the population is below 20,000 for that area. Many details are available from the ACS for 
significantly smaller populations, requiring obfuscation before being made available in a 
de-identified system. 
  One approach to maximize sample population while maintaining patient privacy 
is to participate in a distributed research network (DRN). The National Patient-Centered 
Clinical Research Network (PCORnet) and its participating Clinical Data Research 
Networks (CDRNs) illustrate how patient data may be stored locally and federated 
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queries may be shared across the network 2, 97, 100 . However, interoperability of research 
queries across a CDRN is challenging as variability may be introduced into a 
collaborative study if geocoding is performed independently at each site with disparate 
methods 139-141 . This variability may affect analysis and conclusions in health care 
studies 142 . As clinical and socioeconomic data are linked, successful collaboration and 
data analysis is dependent on a means of querying these data from each site for a 
variety of studies. 
In this chapter, we provide a model for combining socioeconomic and clinical 
data while maintaining patient privacy and allowing rapid querying in a de-identified data 
warehouse. We describe an algorithm for extracting socioeconomic status data from the 
American Community Survey (ACS), geocoding patient data without involving a third 
party, and combining these data within an Informatics for Integrating Biology & the 
Bedside (i2b2 - www.i2b2.org) framework for interrogation. Due to the volume and 
variety of data within the ACS, we extracted only elements to calculate a validated 
socioeconomic index 126 . We demonstrate this data extraction and incorporation into the 
research infrastructure using an example of evaluating the impact of NSES on 
emergency department (ED) utilization. The approach we describe may be fully 
deployed at other sites and will allow for collaborative research and federated queries 
while keeping PHI secure 143  
Methods 
Clinical Data 
 Patient data were extracted from a research copy of the EHR data warehouse at 
the University of Nebraska Medical Center (UNMC). This system contains data 
originating from multiple hospitals and clinics in urban, suburban, and rural Nebraska. 
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Clinical and demographic data are extracted, standardized based on Office of the 
National Coordinator (ONC) recommended vocabularies, and transformed for use within 
an Informatics for Integrating Biology & the Bedside (i2b2) clinical data warehouse 118, 119 
. Data are transformed and staged on an identified server and then de-identified and 
made accessible to researchers via i2b2 in a fully de-identified database on a separate 
server (Figure 7). This data extraction and use in a de-identified data warehouse was 












 Current and historic patient address information was extracted from the EHR and 
stored on a secure server. TIGER/Line Shapefiles and other location-based files needed 
for geocoding were obtained via FTP from the United States Census Bureau and loaded 
onto the server alongside patient address data. These files were for year 2017 and for 
the states of Nebraska and Iowa. Using these data, PostGIS version 2.4 144  geocoding 
software running on PostgreSQL version 10.1 was used to identify the longitude and 
latitude for each patient address. Subsequently, the U.S. census block group for each 
successfully geocoded address was determined via PostGIS. For this study, we 
geocoded only patient addresses for Nebraska and Iowa. In the extraction, we 
eliminated P.O. Box addresses and those addresses with null or invalid street addresses 
(Figure 8). Invalid street addresses were defined as those consisting of all alpha or all 






Figure 8. Identifying patients with a well-geocoded address  
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 We compared demographic data for the geo-coded population relative to those 
patients we excluded from analysis. Rural versus urban location was based on United 
States Department of Agriculture (USDA) Rural Urban Commuting Area (RUCA) codes 
mapped to zip codes (https://ruralhealth.und.edu/ruca , https://www.ers.usda.gov/data-
products/rural-urban-commuting-area-codes/documentation/). Financial class for the 
patient was defined as the primary insurance category listed on the patient’s account in 
the EHR. Age was calculated from the date of the data extract (December 2017).  
Census Variable Extraction and Socioeconomic Index Calculation 
 Based on the index and variables described by Bird et al, a set of equivalent 
variables which could be computed from the U.S. Census Bureau’s annual American 
Community Survey (ACS) were identified 126 . Table 8 identifies the Bird variables from 
the 2000 decennial census and the field and computation employed from the 2011-2015 
five-year estimates from the ACS. Using the U.S. Census Bureau API, ACS estimates 
for each variable for each block group in the U.S. were extracted and stored locally. 
These raw estimates were transformed and normalized for all Nebraska and Iowa block 
groups to have a mean of 0 and a standard deviation of 1 as described by Bird 126 . The 
Bird NSES is computed as the sum of the standardized values for each of the six 
variables, where the standardized values are multiplied by -1 for variables where a 
higher positive value indicates lower socioeconomic status. This method results in higher 
Bird index values corresponding to a higher socioeconomic status. If any of the six 
variables were unavailable from the ACS for a specific block group, the Bird index was 
not computed for that block group. Standardized values for the six variables as well as 





Table 8. Description of Variables to compute neighborhood socioeconomic status  
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Identifying Patient NSES and i2b2 Fact Creation 
 Patient addresses from Nebraska and Iowa were linked to census block groups. 
Patient identifiers were linked to the Bird index and standardized ACS variables 
associated with their block group. Data were de-identified and loaded into the database 
on the de-identified server used by i2b2. De-identification included using a randomly 
generated patient number, shifting all dates for each patient randomly by -1 to -365 
days, and excluding any HIPAA identifiers. For each block group, we ensured the level 
of granularity of the reported NSES index was only sufficient to match at least seven 
block groups. This ensures the patient remains anonymized in a population of at least 
20,000 people. For each patient, seven records were inserted into the database: the Bird 
NSES index and the six standardized variables necessary for its computation. 
Metadata Creation and i2b2 Querying 
 The demographics portion of the i2b2 ontology cell was updated to support 
interrogation of ACS based facts (Figure 9). A folder for neighborhood socioeconomic 
status was added with subfolders for the Bird NSES index and the six, standardized 
variables of interest. ACS variables were identified with the field label as well as a brief 
description to ensure they are both standardized and human readable. Metadata XML 







Figure 9. Integration of ACS Metadata into the Demographics Hierarchy of an i2b2 Client  
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Example Use Case: Emergency Department Utilization 
All patients with a computed Bird socioeconomic status index who were seen in 
any Nebraska Medicine affiliated hospital or clinic between January 2013 and December 
2017 were identified. An odds ratio was computed comparing the number of patients 
with zero emergency department (ED) visits to those patients with one or more ED visits 
during 2013 to 2017. These patients were stratified on the basis of above average or 
below average Bird index. ED visits included encounters with any resulting discharge 
disposition, including hospital admission or expiration. In addition, for patients with an 
ED encounter and two or more total face to face encounters within the target date range, 
an ED frequency metric was computed. For each patient, the total number of ED 
encounters was divided by the time between the earliest and latest face to face 
encounter of any type. A one-tailed student’s t-test with alpha of 0.05 was used to 
compare this metric between the high and low NSES populations (R Core Team (2016). 
R: A language and environment for statistical computing. R Foundation for Statistical 
Computing, Vienna, Austria. URL https://www.R-project.org/.). Results 
Results 
Geocoding 
 We geocoded only patients with a Nebraska or Iowa address, representing the 
majority (507,586 / 534,735 (94.9%)) of Nebraska Medicine patients. Patients were 
excluded from analysis if: 1. The patient address failed to geocode or have a block group 
assigned (1,330), 2. The patient street address was unknown or invalid (28,893), or, 3. 
The geo-rating assigned by PostGIS was greater than 10 indicating a low confidence in 
the geo-code assignment (81,179). The final geo-coded population consisted of 396,913 
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patients who have had an encounter at Nebraska Medicine, a well-geo-coded address, 
and a block group assigned (Figure 8).  
 Figure 10 illustrates the comparison of the included versus the excluded 
population for analysis. The percentage of the excluded population living in a rural zip 
code was 23.7% compared to only 9.8% of the included population. The racial 
composition of the included and excluded populations were very similar with each 
demonstrating a majority white (78.9% and 80.8%, included and excluded populations, 
respectively) with a lower percentage of black (9.5% and 7.6%) and other races (11.7% 
and 11.6%) in the both populations. The populations demonstrated little difference in 
gender proportion (54.7% and 52.7% female, inclusion and exclusion population, 
respectively). The included population had a higher percentage of private / commercial 
insurance (48.09% vs. 45.44%) while having a slightly lower Medicare percentage 
(16.5% vs. 20.1%). The included population had a lower age relative to the excluded 






Figure 10. Comparison of Geo-coded and Excluded Patient Population  
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Neighborhood Socioeconomic Status Variables 
 For the six variables we computed from the ACS data, values were present for at 
least 98% of block groups in Nebraska and Iowa. We were able to compute a Bird index 
for 4,208 of 4,263 (98.7%) of all block groups in these states. 
ED Utilization 
 Using the i2b2 data warehouse, 360,947 patients were identified as being seen 
in any Nebraska Medicine hospital or clinic between January 2013 and December 2017 
who also had an assigned Bird index. Of these 214,325 (59.38%) had above average 
index values and 146,622 (40.62%) had below average values. For patients with a below 
average index value for their neighborhood, 60,309 (41.13%) had at least one visit to an 
emergency department during the study period for any reason. During the same period, 
59,550 (27.78%) of patients with an above average index had an emergency department 
encounter (Figure 11). Patients living in an area with a below average index have 1.82 
times the odds of visiting the emergency department compared to patients with living in 






Figure 11. ED Utilization Stratified by NSES  
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 For patients with at least two total face-to-face encounters and at least one 
emergency department visit between 2013 and 2017, there were 39,697 patients 
residing in areas with high NSES and 39,535 patients in areas with below average 
NSES. Figure 12 displays the distribution of ED utilization rates for each of these 
populations. The average number of visits to the ED per year were 2.11 for patients with 
an above average NSES and 2.40 for patients with below average NSES. A student’s t 
test demonstrated that patients with below average NSES had a mean emergency 
department visit rate of at least 0.2 visits per year higher than those with above average 











With evidence of the impact of environmental factors on health, facilitating 
comparative effectiveness clinical research incorporating social determinants of health is 
paramount 145 . Advances in geoinformatics make it possible to link patient locationto 
data provided by the U.S. Census Bureau. We demonstrated an approach to link social 
determinants of health data from the American Community Survey to clinical data in a 
de-identified data warehouse. All elements of this approach may be completed at 
individual sites, avoiding the need to send PHI to a third party. When sites utilize the 
same geocoding and linkage process, collaborations are possible without introducing 
unnecessary variability between sites. Institutions who implement this approach using 
i2b2 may share federated queries across networks such as PCORnet and the GPC, to 
increase the patient sample size for analysis 146 . Facilitating this research will inform 
efforts to incorporate location-based census data directly into the EHR and future clinical 
decision support (CDS) at the point of care.  
This study is an example using only a single socioeconomic index. While many 
indexes have been published to estimate socioeconomic status, we selected Bird’s 
model as it is well-validated and fully reproducible using data elements from the ACS 147-
151 . Future work includes incorporating other well-validated models based on extant ACS 
data using the process described in this manuscript. These may readily be incorporated 
into the database within the ontology cell of i2b2. We demonstrated the efficacy of 
querying these data with a use case based on evidence from prior studies. We noted 
both a higher proportion and more frequent per patient utilization of the ED for patients 
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living within areas of lower NSES relative to patients from areas of above average 
NSES. 
Limitations 
This study is limited by only including patients from Nebraska and Iowa. 
Additionally, the clinical data utilized does not encompass all hospitals and clinics 
patients may visit. Integrating health information exchange data would enhance the 
clinical picture and facilitate studies investigating readmission.  
 This study is also limited by the quality of data available in the EHR. For 
instance, 28,893 / 508,315 (5.68%) of all addresses were unable to be geocoded as they 
were recorded as some variant of unknown, were null, or were P.O. Boxes rather than a 
physical address of a residence. In addition, there is varying quality of confidence in the 
results returned by the geocoding software with 81,179 / 508,315 (15.97%) having a 
geo-rating with low confidence (PostGIS geo-rating > 10). As addresses are non-uniform 
and may contain errors, some may not geocode accurately. By excluding patients and 
potentially mismapping a small portion of the patient population, the potential for bias is 
introduced. While race and gender showed no significant difference between the 
included and excluded populations, as is evidenced in other studies, rural locations had 
a lower percentage of successful geocoding 152 . Differences in these populations were 
also seen for age (included population slightly younger) and financial class (Medicare 
patients more likely to be excluded). Recognizing these population differences is 
essential as they may impact analyses when future studies rely on these data 153 . While 
the geocoding for this study did not reach 100% completeness or 100% accuracy, 
results were comparable with other first-pass geocoding efforts 152, 154-159 . A refinement 
of the geocoding process may reduce this bias and increase confidence of results 
relying on the generated data. Perfecting geocoding is beyond the scope of the current 
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demonstration. An enhanced geocoding process could readily be integrated into this 
model for incorporating census data into a de-identified data warehouse. 
Future Research 
To demonstrate reproducibility and extend the results demonstrated in this paper, 
collaborations to implement this data integration approach will occur in existing 
distributed research networks (Greater Plains Collaborative (GPC) and The National 
Patient-Centered Clinical Research Network (PCORnet)). Within the GPC, sites have 
implemented de-identified data warehouses on an i2b2 platform. Across PCORnet, each 
participant transforms clinical data to adhere to the common data model (CDM). While 
the i2b2 querying approach will not be able to be demonstrated throughout PCORnet, 
the CDM and established federated query protocols will allow collaboration. 
 Future efforts will also address incorporating additional socioeconomic indices 
and ACS variables into the de-identified clinical data warehouse 148, 150, 160 . As part of this 
effort, a standard approach to identifying these indices and component variables within 
an i2b2 ontology will be proposed for interoperability. Integration of additional indices will 
allow both the comparison of the efficacy of indices in a variety of contexts as well as the 
application of validated indices within many disease phenotypes. 
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 In this dissertation I have demonstrated an approach to assessing the utility of a 
clinical research data warehouse for effectively and efficiently replicating clinical 
research. With the gaps identified in this assessment, I also performed preliminary work 
toward developing a computable and shareable phenotype for pregnancy status based 
on EHR data. Finally, I developed and deployed a methodology for linking EHR data to 
socioeconomic data contained within the U.S. Census within an i2b2 infrastructure. 
While replication of all studies remains a future goal, the results described in this 
dissertation represent progress toward this end and provide areas of consideration as 
institutions establish clinical data research warehouses or participate in distributed 
research networks. 
Assessing Risk Models and Infrastructure for Replication 
 First, using two risk models based largely on data from basic EHRs, I assessed 
their replicability with the infrastructure established at UNMC. While I surveyed a variety 
of risk models, those included in this dissertation clearly demonstrated significant points 
in the replication process. First, these models were clinically meaningful and based on 
EHR data. While not always the case, these two models each provided meaningful 
results for a clinically significant concern (readmission in heart failure patients and risk of 
in-hospital mortality). If the initial results are not clinically significant, attempting to 
replicate the model may be superfluous. This may be due to being statistically significant 
but not clinically meaningful (i.e. less than a one-point systolic blood pressure difference) 
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which may be detectable with very large sample sizes, or, due to being relevant to only a 
very specific subset of the population that may not be represented at all sites (i.e. a very 
rare disease or an effect linked to geographic region). Next, each model was largely 
based on data likely to be found in a basic EHR. Other models may be based on data 
from surveys, disease registries, or public records. While replication of these models 
may be possible, this would require incorporation of novel data sets for each model 
rather than clinical data that may be re-used for a plethora of models. The 
generalizability and replicability of risk models relying on extra-EHR data is hampered by 
the resource cost of instantiating these data.  
 Next, beyond the clinical significance and the reliance on EHR data, to assess 
the utility of UNMC’s CRDW to replicate risk models, I surveyed the specific data 
elements the risk model was built on. Each of the risk models in this dissertation were 
designed to largely use data collected on the majority of patients within the first 24 hours 
of hospital admission. UNMC’s CRDW demonstrated excellent coverage of 
demographics data and a large portion of encounters had laboratory data as well. One 
element limiting the replicability of the heart failure risk model was the inclusion of 
additional data elements, such as socioeconomic status based on census data, number 
of address changes in recent history, and the number of missed visits. While visit and 
address information are recorded in the EHR, these may not be commonly extracted into 
a clinical research data warehouse. Developing ETLs for specific data elements requires 
an investment of time and resources. Prioritizing these extracts to the data elements 
used most frequently is essential. In addition, extra-EHR data, such as that found in the 
U.S. Census may be linked to EHR data, however, as demonstrated later in the 
dissertation, significant resource investment is required. One contribution of these efforts 
toward replication was the prioritization of future data extracts into UNMC’s data 
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warehouse. Assessing specific data elements is essential to evaluating a site’s ability to 
replicate a study. 
 An essential element of this data survey is the definition of each data element. 
For a significant amount of clinical data, the ONC has recommended standard 
vocabularies for use in recording and describing data. If employed and well-documented, 
these standards facilitate interoperability of healthcare data as well as enhance 
replicability of published research. For the two risk models described in this work, neither 
fully described all clinical elements with these recommended vocabularies. 
Amarisingham et al had a well-defined phenotype for the heart failure patients based on 
ICD-9 CM codes. However, in both studies, only the laboratory name was given rather 
than a series of LOINC codes. This necessitated the replication effort to include a lookup 
of a significant number of laboratory codes and may represent a departure from the 
original studies. In neither case was the phenotype or inclusion criteria published in a 
machine parseable form. My work involved manually parsing the descriptive text and 
interpreting definitions for each data element. To enhance replicability to make this effort 
more efficient, authors may publish a human readable description in conjunction with a 
fully machine-readable document using standard terminologies. 
 In addition to ensuring data elements are present in the data warehouse, 
ensuring data volume is sufficient for the study is critical. I assessed data volume for 
each model by developing and executing a series of queries in i2b2. This provided 
simple patient counts for each variable of interest. Some data may be extracted but exist 
at a very low rate. For instance, while all laboratory elements for the heart failure model 
were extracted from the EHR, no patients in this cohort had a pro-BNP recorded. For a 
rare disease, it is possible an insufficient number of patients may exist at a single 
institution necessitating collaboration across a network. This was not a concern for the 
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two models described in this dissertation as the i2b2 queries demonstrated a large 
patient population for the common cohorts of heart failure and hospital admission. 
Ensuring both data variety and data volume are important elements in ensuring a site 
has the capability of replicating published research. 
 Along with assessing the clinical relevance and potential generalizability of a risk 
model and surveying the specific data elements required in the model, an evaluation of 
the statistical methods the authors used is critical when determining if a model may be 
replicated. While Amarasingham’s risk model for readmission in heart failure patients 
may have demonstrated significance, neither the publication nor attempts to reach the 
author were sufficient to elicit a replicable set of methods. While data limitations 
precluded replication of this model, even if all data were present, the absence of clear 
methods prevents replication of the work. At best, I could demonstrate correlation 
between the same set of variables and readmission rate. It would be guesswork to 
determine if the variable had relative contributions as described by the authors. Whereas 
the methods for the first model remained somewhat a black box, Tabak’s mortality risk 
model had well-described analyses and model development. Prior to investing significant 
resources toward extracting additional data elements or linking to external data sources, 
it is essential to ensure the analyses are well-described and well-designed. 
 To summarize, any attempt toward replicating a published risk model with clinical 
data requires assessment both of the published work and of the infrastructure at the new 
site. In this dissertation I demonstrated these processes with two separate models. In 
each instance, I ensured the model had clinically significant results, was applicable to 
the population at this site, and published sufficient methods to allow me to perform 
similar analyses and model development. In addition, I surveyed data available within 
the clinical research data warehouse to ensure volume and variety sufficient to model 
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the methods in the original work. Neither paper published fully defined criteria using 
standard terminologies. One model failed to publish a complete description of the 
methods. This model also employed extra-EHR data not available within UNMC’s data 
warehouse at the time of the replication attempt. My overall assessment indicated one of 
the two studies may be replicable at UNMC. The other study may have valid results, 
however, due to infrastructure limitations and publication omissions, replication is not 
possible. 
Replication Attempt of Risk Model 
 With the model assessment in place, an attempt to replicate Tabak’s mortality 
model was possible. In order to replicate this study, definitions of data elements needed 
to be interpreted, local data needed to be queried, and analysis of the data as described 
by the original study was required.  
 As described above and documented in Appendix C, I translated the narrative 
description of laboratory values and inclusion criteria into LOINC codes to interrogate the 
clinical data at UNMC. Multiple LOINC codes were possible for the majority of laboratory 
tests described. Through i2b2 queries I answered which codes were used in the EHR 
and populated in the data warehouse. In consultation with James R. Campbell, MD, a 
clinician and the institution’s terminologist, I ensured the codes I selected were 
comprehensive and accurate. Once defined, these codes are shareable to any other site 
desiring to replicate this or a similar study. 
 With standard codes in place, clinical data needed to be queried. While feasibility 
counts for the study were obtained using i2b2 queries, data extraction required SQL 
scripts to be written. Scripts were designed to identify the inpatient encounters of 
interest, extract raw values for each of the necessary laboratory values, and calculate a 
total score for each patient encounter. These scripts rely on standard terminologies and 
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the i2b2 star schema data structure. They may readily be shared and adapted to other 
sties who have implemented i2b2. In this way, this work may be re-used to facilitate 
future replication. 
 Finally, with standard definitions in place and re-usable SQL scripts developed to 
extract the data, the methods described in the study were replicated. Using R, a 
precision recall as well as a receiver operator characteristic curve were created to 
assess the predictive value of the total calculated score. This demonstrated similar 
predictive power to what was described by the original study. In addition, multiple logistic 
regression analysis was used to develop a new risk model using the same variables. 
This model demonstrated similar predictive power to the original model.  
 Through the assessment described above, I demonstrated that a replication 
attempt using the Tabak mortality risk model was possible. With the data extraction and 
statistical analysis performed in R, I demonstrated replication of the study. The published 
results were validated by this work and extended to a novel population. Future 
replication at other sites is possible as standard definitions are now in place and data 
extraction and analysis code is available for re-use. 
Creating a Computable Phenotype for Pregnancy 
 In this dissertation I described initial steps toward creating a computable 
phenotype for pregnancy status based on data commonly recorded within an EHR in the 
course of typical care. Based on a number of queries from participation in a distributed 
research network which had variable or poor definitions of pregnancy, the need for a 
consistent and interoperable phenotype was recognized. While fully-defining, validating, 
and sharing such a phenotype will take a greater investment of resources and input from 
a variety of experts, this dissertation demonstrates a series of variables for incorporation 
into a fully-defined phenotype. Through frequency analysis, expert input, and statistical 
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analysis, a number of data elements were seen to correlate with being pregnant. This 
dissertation provides definitions for these data elements using standard terminologies 
(LOINC, SNOMED-CT, CPT, and ICD*) to enable interoperability of the definition. This 
work also demonstrates how these variables may be extracted from the EHR as well as 
how to identify temporal bounds for pregnancy from the EHR.  
Incorporating Location-Based Data into the i2b2 Infrastructure 
 As with the necessity to develop a computable phenotype for pregnancy, the 
need for a means of incorporating queryable location-based data into the clinical 
research data warehouse stemmed from working with other studies. As described 
above, Amarasingham’s risk model for readmission in heart failure patients requires 
socioeconomic variables available within the U.S. Census. While many studies rely on 
these data, the novel contribution of the results presented herein is a demonstration of a 
replicable means of incorporating these data into an i2b2 infrastructure in a de-identified 
data warehouse. 
 Geocoding has greatly advanced in recent years and there are countless 
approaches to translating addresses into longitude and latitude and later linking this to 
census data. One important element of the approach taken in this dissertation is the 
geocoding was all done in house. Patient data remained on a secure server, never 
requiring a third party or any data transfer which may increase the risk of exposing PHI. 
While enhancements to geocoding are beyond the scope of this dissertation, 
demonstrating an approach to securely geocode patient data in an IRB approved 
manner was critical. Of note, alternative geocoding processes may readily be 
implemented into the pipeline described in this dissertation. 
 Beyond demonstrating a secure approach to geocoding patient addresses, this 
dissertation demonstrates a method for maintaining HIPAA compliance while exposing 
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patient neighborhood socioeconomic status. HIPAA geographic requirements mandate 
de-identification ensures that a patient’s geographic location may not be identified to a 
catchment area with fewer than 20,000 people. We de-identified the data in a number of 
ways. First, rather than publishing raw data from the ACS, standardized data and 
summary indices were displayed in the i2b2 environment for researchers. As we publish 
our methods and as other researchers could potentially work back to which blockgroup a 
standardized variable originated in, we also truncated these published variables to 
ensure a sufficient number of blockgroups are identified with any given published result. 
In this way, only a group of blockgroups could ever be identified for a single patient, 
ensuring at least 20,000 people were located in this geographic region. 
 To demonstrate the validity of this approach, we replicated a well-published 
result of ED utilization. Using i2b2 queries for feasibility queries and SQL scripts for data 
extraction, we demonstrated increased ED utilization based on residence in an area with 
below average socioeconomic status. While this result is not novel, our work serves to 
validate the result on a novel population. Furthermore, our results demonstrate the 
efficacy of our approach to incorporating socioeconomic variables in a fully-deidentified 
i2b2 data warehouse. Our approach is both efficacious and replicable.  
Assessment of Hypothesis 
 The methods and results presented in this dissertation formed to evaluate the 
hypothesis that the data and infrastructure of UNMC’s clinical research data warehouse 
were sufficient to allow for replication of risk models and other clinical studies. As was 
demonstrated early on, this hypothesis was rejected and required modifications. Early 
work demonstrated inability to replicate studies was due to two major categories. First, 
insufficiency of extracted data types in the CRDW, and, second, insufficiency of 
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published methods and analyses to allow any site to replicate the study. The first 
category led to the work toward developing a shareable, computable phenotype for 
pregnancy and the process of incorporating socioeconomic variables from the census 
into the data warehouse.  
 From the results described in this dissertation, a refined hypothesis that may 
undergo continued testing is the CRDW infrastructure is sufficient to allow replication of 
studies publishing clear methods and analyses. Some studies may require investment of 
resources to extract additional clinical variables or link to extra-EHR data sources. The 
assessment pattern described herein allows rapid identification of the replicability of a 
study and identification of any missing variables requiring ETL development. In this way, 
if a study may be replicable, additional data elements can be prioritized in the extraction 
workflow.  
Generalizability of the Results 
 The results documented in this dissertation are not without limitations. This work 
was done in a clinical data research warehouse based on EHR data with some 
transformations. These data were standardized to ONC recommended vocabularies, 
either within the EHR or after extraction. In addition, these data were de-identified during 
extraction, precluding incorporation of some identifying variables per HIPAA guidelines. 
Finally, these data were stored in a form to foster interoperability via i2b2 as well as the 
PCORnet CDM. The standardization made the data survey for required elements much 
simpler. The methods described herein to assess the utility of a CRDW for replication of 
a study may be more challenging to employ without standard vocabularies in place.  
 The results of replicating the risk model for in-hospital mortality are expected to 
be highly generalizable. With the methods available, the specific variables well-defined, 
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and the model validated on two independent hospital environments, other sites with a 
typical hospital census should find high utility in the model. Generalizability could be 
further validated by evaluating the mode’s performance across the GPC or all of 
PCORnet’s DRNs. 
 The methods and results reported regarding incorporating location-based data 
into a de-identified clinical data warehouse should also be generalizable. The ED 
utilization result was validated in a novel population with novel calculation of 
socioeconomic status. As with the risk models reported on, further validation and 
generalizability may be achieved if this hypothesis were tested across a DRN rather than 
at a single site. The methods to incorporate and use these data were designed to be 
portable and reproducible. Ideally, other sites could implement this workflow and have 
queryable variables in a de-identified i2b2 data warehouse. 
Future Work 
  The results and methods presented in this dissertation facilitate both immediate 
next steps for research and long-term expansions of these concepts. Future research is 
possible focusing on three distinct areas. First, further validating the risk models 
described herein as well as additional risk models. Next, continuing the development of 
a computable phenotype for pregnancy status and sharing this phenotype. Finally, 
incorporating and utilizing additional location-based variables from the ACS into the de-
identified i2b2 data warehouse. 
Future Research Replicating Risk Models and Observational Studies 
In-hospital Mortality Model 
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 First, the risk model for in-hospital mortality may be further validated and used as 
a test case for replication research across a distributed research network. I 
demonstrated a means of assessing the replicability of a study at a single site. I also 
validated this previously published risk model. With similar methods, an assessment of 
the replicability of this model across the GPC is possible. Shared i2b2 queries or SQL 
may be minimally modified to survey other sites to ensure data volume and variety are 
queryable relative to this risk model. Independent models could be constructed at each 
site, or, with IRB approval, de-identified encounter level data could be analyzed at a 
central site to test the validity of the model on a larger population covering much of the 
Midwest. While greater adaptation would be required, SAS scripts or SQL could be 
made to query the PCORnet CDM. If a data survey indicated the necessary information 
is currently populated in the CDM, any participating site across the country could 
execute the queries and the model could be replicated at dozens of sites. 
Potential Problem of Heterogeneity 
 Attempting to replicate risk models and observational studies across diverse 
distributed research networks offers advantages of large sample size and a more 
diverse study cohort. However, as described earlier, there is evidence this may introduce 
bias due to the heterogeneity of the databases and environments being combined. One 
area of necessary future research beyond the scope of this dissertation is to determine if 
bias is introduced from pooling diverse data sets. If so, does this significantly affect the 
outcomes of federated queries? Will pooling the data across many sites mask individual 
variations in results, or, does conforming to the common data model allow the same 
results to be observed with greater statistical significance? 
Higgins et al. proposed a means to increase the efficacy of meta-analyses, taking 
into account the potential heterogeneity of studies being included 161 . While this is 
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certainly valuable and will add credence to the conclusions of meta-analyses, further 
efforts to provide a means to validate the results of collaborative studies from various 
medical centers is needed to ensure individual variation is not simply being averaged 
and true results lost. Madigan et al performed such a study in the OMOP DRN. 
Attempting to replicate that analysis across the GPC or across PCORnet will provide 
valuable data about potential bias. The results of such an analysis will have significant 
impact on future use of data from large networks. 
Additional Study Replication 
 The work presented in this dissertation represented a survey of a series of risk 
models and efforts to replicate only two of them. Countless risk models and 
observational studies have been published while very few have been replicated or 
validated. Applying the principles outlined in this dissertation will facilitate a researcher’s 
effort to determine if a study is replicable and what resource investment is required to 
allow replication at any site or across a network. This process may be followed for 
specific populations, such as those with a given disease, or for a variety of risk models 
ranging from mortality to other outcomes. Such replication studies will direct resource 
utilization in incorporating further data into research data warehouses as well as identify 
valid risk models that may be incorporated into an operational EHR for CDS. 
Future Research Developing a Computable Phenotype for Pregnancy Status 
Temporal Variable Definitions 
 The results described in this dissertation represent the foundation for future 
research in developing a computable phenotype for pregnancy status. An important 
initial next step is to define the temporal relevance of the variables described. One 
challenging element of identifying pregnancy status is its transient nature. Recognizing a 
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patient was pregnant two years ago has very little baring on her current pregnancy 
status. In like manner, a positive pregnancy test from many months ago may be 
meaningless for the patient today. Each of the variables described in this dissertation will 
need to have a temporal window associated with it. From the date of the finding, how far 
along can the pregnancy be and how much longer would the pregnancy be expected to 
last? In this way, rather than a single point in time, each variable will have a window 
wherein pregnancy is more likely. 
Multiple Logistic Regression Modelling 
 With the variables defined temporally, a multiple logistic modelling approach may 
be taken to create a predictive model. The patients identified in this dissertation with 
well-defined temporal bounds on pregnancy episodes may be randomly divided into a 
training and a test group. Age-matched non-pregnant controls may also be included. 
Further chart review may be required to ensure pregnancy status of both groups. 
Sampling may occur at various time points during the year of interest. At each time point, 
the pregnancy status of each patient will be identified and the predictive model 
computed. With a model in place, it can be evaluated using the test population.  
Evaluation and Validation at Novel Sites 
 With a predictive model developed at UNMC, efforts may be made to replicate 
and validate this model at additional sites. The first step in this process will be to survey 
other sites to ascertain what proportion of the variables identified are commonly 
available. ETLs for obtaining these data may also be shared as necessary. If sites are 
able to extract the necessary data elements, the predictive model may be shared and 
assessed against novel patient populations. IRB approval for chart reviews at each site 
may be necessary to validate the results. The data survey and model testing may be 
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done across the GPC where federated queries are supported. To enable testing this 
model within PCORnet, an evaluation of the variables in light of the CDM would be 
necessary. If the CDM has enough data variety to encompass all elements of the model, 
federated queries could be generated and shared with participating sites. Validation 
across many sites would allow for refinement of the model and development of a 
shareable computable phenotype suitable for consistent incorporation into future studies. 
Future Research Incorporating Location-based Data into the i2b2 Infrastructure 
Incorporating Additional Variables in a Standardized Fashion 
 As described in this dissertation, some risk models incorporate data extracted 
from sources beyond the EHR. I demonstrated a means of coupling ACS data with 
clinical data within a de-identified i2b2 infrastructure. Further work is required to 
instantiate additional variables in a standardized fashion. The approach of extraction of 
data, linking to patient data, and de-identification may be applied to any single ACS 
variable or combination of variables to compute indices for socioeconomic status. To 
facilitate interoperability a standard ontology may be developed to identify which ACS 
variable is being incorporated. While the ACS has an identifiable code for each data 
broad element (percent unemployment), each variable within the ACS is often reported 
for different subsets of the population (i.e. percent unemployment for males, percent 
unemployment for females). For this reason, it is insufficient to identify the variable in the 
database with only the ACS identifier as this may represent dozens of values. 
Developing a standard approach is further hampered as ACS values may be used to 
compute novel values more meaningful for research. Additionally, as demonstrated 
herein, these computed values may be combined to calculate indices or standardized for 
a population of interest. Input from terminologists, epidemiologists, and clinical 
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researchers may guide the development of a standard ontology for incorporating ACS 
variables into a clinical data research warehouse. 
Linking Address Changes with Appropriate Socioeconomic Data 
 Along with a standard approach to incorporating additional ACS variables, 
developing an approach to deal with address changes and updated ACS data is 
imperative. The ACS is updated on an annual basis and reports data for a five-year 
period at the block group level. Patients may move one or more times within the 
catchment area of an academic medical center. The relation between socioeconomic 
variables and clinical outcomes may be identified more accurately if patients are 
assigned to the appropriate date range of data for their location during that period. This 
is a two-fold effort. First, a patient’s location may be stored as a fact with a start date and 
an end date. Any changes in location should be mapped to a new block group with 
potential changes in socioeconomic status variables. Next, the temporal nature of a 
patient’s location should be linked to the appropriate ACS data set. This is important as 
areas change over time and as block group boundaries change over time. Mapping a 
patient’s location to the most accurate data will facilitate drawing meaningful clinical 
conclusions.  
Utilizing Included Variables and Indices for Research 
 As the geocoding process becomes more refined and as additional variables and 
indices from the ACS are incorporated with clinical data, clinical researchers will have 
access to extra-EHR data shown to have a major impact on health outcomes. 
Development of novel as well as refinement of existing socioeconomic indices will be 
facilitated. A better understanding of elements impacting a patient’s clinical outcomes 
may be developed. With the ability to query a plethora of variables in a de-identified 
113 
 
database, the variables with the greatest clinical relevance may be identified. These data 
may direct data collection within the clinical environment to describe a patients 
socioeconomic status and the potential for interventions. In this way, data on a patient’s 
neighborhood extracted from the census may be supplemented by a subset of data 
offered by the patient. 
Conclusions 
 The data and methods presented in this dissertation represent a step toward 
facilitating replication in clinical research. I have presented both an approach for 
evaluating a study and a data set for replication efforts as well as laid the groundwork for 
filling in commonly missing elements. Further research is needed in many areas to build 
on the conclusions drawn and to fully develop a computable phenotype for pregnancy 
status. The approach to replicability evaluation as well as the pipeline for incorporating 
socioeconomic data into a de-identified data warehouse may be shared and employed at 
novel sites and across distributed research networks. With the incorporation of extra-
EHR data in a queryable fashion along with an approach to using EHR data for 
replication of risk models and observational studies, additional studies may be validated 
and extended to novel populations. In this way, the data driving clinical guidelines and 
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APPENDIX A - LOCAL INSTRUCTIONS FOR RUNNING 
FEDERATED SAS QUERIES FROM PCORNET 
SAS Based Queries 
1. Create trac ticket: 
o Attach zipped query package 
o Assign to Respond to Queries milestone 
o Paste name of query and description into trac ticket 
o Assign to honest broker to run SAS 
2. Load query package into SAS: 
o Download and extract zipped query package 
o Load file structure into DEID /d02/queries/BJG/PopMedNet_Queries 
▪ This may be done manually in SAS Studio, OR, 
▪ This may be done with WinSCP 
3. Update the SAS script: 
o In SAS Studio, in the query package > sasprograms folder, open the 
master.sas file 
o d02 folder is popmednet work 
o Update user inputs: 
▪ DMID = C4 
▪ SiteID = UN 
▪ Threshold = 11 
▪ Attrition Table = Y 
▪ All data tables in lowercase 
▪ indata = '/d02/queries/data/' (Most current, approved CDM 
datasets (Instructions to build SAS datasets) 
▪ infolder = 
/d02/queries/BJG/PopMedNet_Queries/QUERY_FOLDER/infolder
/ 
▪ drnoc = 
/d02/queries/BJG/PopMedNet_Queries/QUERY_FOLDER/drnoc/ 






▪ May be more or less user inputs to define 
o Save changes to master.sas 
4. Run query: 
o With master.sas open, hit run button (running man icon at top of 
screen) 
o When complete, review the log to check for errors or warnings 
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o Review the workplan and ensure the dmlocal and drnoc folders have 
all expected files created 
5. Share results: 
o Either manually or using WinSCP, extract all files from the drnoc folder 
for the query 
o Zip files in folder with the query name and attach to the trac ticket 
o Assign trac ticket to jmcclay with next task for data oversight 
committee review 
o Once data oversight committee has approved the request, results may 







APPENDIX B – HEART FAILURE RISK MODEL SAMPLE I2B2 
QUERY 
insert into BlueHeronData.QUERY_GLOBAL_TEMP (encounter_num, patient_num, 
panel_count) 
with t as (  
 select  /*+ index(observation_fact fact_cnpt_pat_enct_idx) */  f.encounter_num, 
f.patient_num   
from BlueHeronData.observation_fact f  
where   
f.concept_cd IN (select concept_cd from  BlueHeronData.concept_dimension   where 
concept_path like '\i2b2\Demographics\Marital Status\%')    
group by  f.encounter_num , f.patient_num  
 )  
select t.encounter_num, t.patient_num, 0 as panel_count  from t  
<*> 
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =1 where 
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count =  0 and exists ( select 1 from ( 
select  /*+ index(observation_fact fact_cnpt_pat_enct_idx) */  f.encounter_num, 
f.patient_num   
from BlueHeronData.observation_fact f  
where   
f.CONCEPT_CD IN (select CONCEPT_CD from  
BlueHeronData.CONCEPT_DIMENSION   where CONCEPT_PATH LIKE 
'\i2b2\Procedures\cpt?_codes\99201-99499\99221-99239\99221-99223\%' {ESCAPE '?'} 
)   
  AND  ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS') 
AND f.start_date <= to_date('31-Dec-2016 00:00:00','DD-MON-YYYY HH24:MI:SS') )  
group by  f.encounter_num , f.patient_num ) t where 
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num  and 
BlueHeronData.QUERY_GLOBAL_TEMP.encounter_num = t.encounter_num   )  
<*> 
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =1 where 
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count =  0 and exists ( select 1 from ( 
select  /*+ index(observation_fact fact_cnpt_pat_enct_idx) */  f.encounter_num, 
f.patient_num   
from BlueHeronData.observation_fact f  
where   
f.CONCEPT_CD IN (select CONCEPT_CD from  
BlueHeronData.CONCEPT_DIMENSION   where CONCEPT_PATH LIKE 
'\i2b2\Procedures\cpt?_codes\99201-99499\99221-99239\99231-99239\%' {ESCAPE '?'} 
)   
  AND  ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS') 
AND f.start_date <= to_date('31-Dec-2016 00:00:00','DD-MON-YYYY HH24:MI:SS') )  
group by  f.encounter_num , f.patient_num ) t where 
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num  and 




update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where 
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count =  1 and exists ( select 1 from ( 
select  /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num   
from BlueHeronData.observation_fact f  
where   
f.concept_cd IN (select concept_cd from  BlueHeronData.concept_dimension   where 
concept_path like 
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8359777\A8342219\A8345316\%')   
  AND  ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS') 
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )  
group by  f.patient_num ) t where 
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num    )  
<*> 
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where 
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count =  1 and exists ( select 1 from ( 
select  /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num   
from BlueHeronData.observation_fact f  
where   
f.concept_cd IN (select concept_cd from  BlueHeronData.concept_dimension   where 
concept_path like 
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8359777\A8342219\A8345316\402.
11\%')   
  AND  ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS') 
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )  
group by  f.patient_num ) t where 
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num    )  
<*> 
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where 
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count =  1 and exists ( select 1 from ( 
select  /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num   
from BlueHeronData.observation_fact f  
where   
f.concept_cd IN (select concept_cd from  BlueHeronData.concept_dimension   where 
concept_path like 
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8359777\A8342219\A8345317\402.
91\%')   
  AND  ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS') 
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )  
group by  f.patient_num ) t where 
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num    )  
<*> 
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where 
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count =  1 and exists ( select 1 from ( 
select  /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num   
from BlueHeronData.observation_fact f  
where   





04.01\%')   
  AND  ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS') 
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )  
group by  f.patient_num ) t where 
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num    )  
<*> 
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where 
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count =  1 and exists ( select 1 from ( 
select  /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num   
from BlueHeronData.observation_fact f  
where   
f.concept_cd IN (select concept_cd from  BlueHeronData.concept_dimension   where 
concept_path like 
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8359777\A10863172\A10863171\4
04.03\%')   
  AND  ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS') 
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )  
group by  f.patient_num ) t where 
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num    )  
<*> 
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where 
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count =  1 and exists ( select 1 from ( 
select  /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num   
from BlueHeronData.observation_fact f  
where   
f.concept_cd IN (select concept_cd from  BlueHeronData.concept_dimension   where 
concept_path like 
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8359777\A10863172\A8345328\40
4.11\%')   
  AND  ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS') 
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )  
group by  f.patient_num ) t where 
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num    )  
<*> 
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where 
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count =  1 and exists ( select 1 from ( 
select  /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num   
from BlueHeronData.observation_fact f  
where   
f.concept_cd IN (select concept_cd from  BlueHeronData.concept_dimension   where 
concept_path like 
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8359777\A10863172\A8345328\40
4.13\%')   
  AND  ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS') 
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )  
group by  f.patient_num ) t where 




update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where 
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count =  1 and exists ( select 1 from ( 
select  /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num   
from BlueHeronData.observation_fact f  
where   
f.concept_cd IN (select concept_cd from  BlueHeronData.concept_dimension   where 
concept_path like 
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8359777\A10863172\A8359867\40
4.91\%')   
  AND  ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS') 
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )  
group by  f.patient_num ) t where 
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num    )  
<*> 
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where 
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count =  1 and exists ( select 1 from ( 
select  /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num   
from BlueHeronData.observation_fact f  
where   
f.concept_cd IN (select concept_cd from  BlueHeronData.concept_dimension   where 
concept_path like 
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8359777\A10863172\A8359867\40
4.93\%')   
  AND  ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS') 
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )  
group by  f.patient_num ) t where 
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num    )  
<*> 
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where 
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count =  1 and exists ( select 1 from ( 
select  /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num   
from BlueHeronData.observation_fact f  
where   
f.concept_cd IN (select concept_cd from  BlueHeronData.concept_dimension   where 
concept_path like 
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8360933\A8339688\A19383986\%')   
  AND  ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS') 
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )  
group by  f.patient_num ) t where 
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num    )  
<*> 
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where 
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count =  1 and exists ( select 1 from ( 
select  /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num   
from BlueHeronData.observation_fact f  
where   
f.concept_cd IN (select concept_cd from  BlueHeronData.concept_dimension   where 
concept_path like 
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8360933\A8339688\425.4\%')   
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  AND  ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS') 
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )  
group by  f.patient_num ) t where 
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num    )  
<*> 
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where 
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count =  1 and exists ( select 1 from ( 
select  /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num   
from BlueHeronData.observation_fact f  
where   
f.concept_cd IN (select concept_cd from  BlueHeronData.concept_dimension   where 
concept_path like 
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8360933\A8339688\425.5\%')   
  AND  ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS') 
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )  
group by  f.patient_num ) t where 
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num    )  
<*> 
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where 
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count =  1 and exists ( select 1 from ( 
select  /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num   
from BlueHeronData.observation_fact f  
where   
f.concept_cd IN (select concept_cd from  BlueHeronData.concept_dimension   where 
concept_path like 
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8360933\A8339688\425.7\%')   
  AND  ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS') 
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )  
group by  f.patient_num ) t where 
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num    )  
<*> 
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where 
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count =  1 and exists ( select 1 from ( 
select  /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num   
from BlueHeronData.observation_fact f  
where   
f.concept_cd IN (select concept_cd from  BlueHeronData.concept_dimension   where 
concept_path like 
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8360933\A8339688\425.8\%')   
  AND  ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS') 
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )  
group by  f.patient_num ) t where 
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num    )  
<*> 
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where 
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count =  1 and exists ( select 1 from ( 
select  /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num   
from BlueHeronData.observation_fact f  
where   
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f.concept_cd IN (select concept_cd from  BlueHeronData.concept_dimension   where 
concept_path like 
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8360933\A8339688\425.9\%')   
  AND  ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS') 
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )  
group by  f.patient_num ) t where 
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num    )  
<*> 
update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count =2 where 
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count =  1 and exists ( select 1 from ( 
select  /*+ index(observation_fact fact_cnpt_pat_enct_idx) */ f.patient_num   
from BlueHeronData.observation_fact f  
where   
f.concept_cd IN (select concept_cd from  BlueHeronData.concept_dimension   where 
concept_path like 
'\i2b2\Diagnoses\A18090800\A8359006\A8359014\A8360933\A8339687\%')   
  AND  ( f.start_date >= to_date('01-May-2012 00:00:00','DD-MON-YYYY HH24:MI:SS') 
AND f.start_date <= to_date('31-Dec-2015 00:00:00','DD-MON-YYYY HH24:MI:SS') )  
group by  f.patient_num ) t where 
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num    )  
<*> 
 update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count = -1  where 
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count =  2 and exists ( select 1 from ( 
select  /*+ index(observation_fact fact_cnpt_pat_enct_idx) */  f.encounter_num, 
f.patient_num   
from BlueHeronData.observation_fact f  
where   
f.concept_cd IN (select concept_cd from  BlueHeronData.concept_dimension   where 
concept_path LIKE '\ICD10CM?_2015AA\(Z00-Z99) Fact~rmj9\(Z40-Z53) 
Enco~eivf\(Z53) Persons~y7wq\(Z53.2) Proced~esd4\(Z53.21) Proce~0aof\%' {ESCAPE 
'?'} )    
group by  f.encounter_num , f.patient_num ) t where 
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num  and 
BlueHeronData.QUERY_GLOBAL_TEMP.encounter_num = t.encounter_num   )   
<*> 
 update BlueHeronData.QUERY_GLOBAL_TEMP set panel_count = -1  where 
BlueHeronData.QUERY_GLOBAL_TEMP.panel_count =  2 and exists ( select 1 from ( 
select  /*+ index(observation_fact fact_cnpt_pat_enct_idx) */  f.encounter_num, 
f.patient_num   
from BlueHeronData.observation_fact f  
where   
f.concept_cd IN (select concept_cd from  BlueHeronData.concept_dimension   where 
concept_path like '\i2b2\DRG\SURG\Orthopedics\BILATERAL OR MULTIPLE MAJOR 
JOINT PROCS OF LOWER EXTREMITY W MCC\%')    
group by  f.encounter_num , f.patient_num ) t where 
BlueHeronData.QUERY_GLOBAL_TEMP.patient_num = t.patient_num  and 




 insert into BlueHeronData.DX (  patient_num  , encounter_num  ) select * from ( select 
distinct  patient_num  , encounter_num from BlueHeronData.QUERY_GLOBAL_TEMP 
where panel_count = 2 ) q  
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APPENDIX C – READMISSION RISK MODEL SQL SCRIPT 









lab_mapping_table varchar2(100):='LAB_LOINC_MAPPING'; --change cursor if 
changing table name 
missing_value_threshold integer:=30; --Number of missing lab values allowed to 





cursor sel_cur is  
    select distinct(LAB_LABEL)  







select sysdate into my_date from dual; 
DBMS_OUTPUT.PUT_LINE('***Start of TABAK_SCORING_PROC'); 
dbms_output.PUT_LINE('***Creating '||lab_mapping_table||' table at ' || 
my_date); 
 
/*  Ensure table is created prior to running procedure. 
--CREATE LAB_LOINC_MAPPING TABLE:    
    sql_string := q'[ 
        CREATE TABLE JGARDNER.]'||lab_mapping_table||q'[ 
            (   LAB_LABEL VARCHAR2(150), 
                LAB_LOINC VARCHAR2(13), 
                REFERENCE_LOW NUMBER(6,2), 
                REFERENCE_HIGH NUMBER(6,2)) 
        ]'; 
         
    DBMS_OUTPUT.PUT_LINE(sql_string); 
    execute immediate sql_string; 
 
    sql_string:=q'[CREATE TABLE JGARDNER.TABAK_SUMMARY 
            (LAB_LABEL VARCHAR2(50), 
            ENCOUNTERS INTEGER, 
            PERCENT_OF_ENCOUNTERS NUMBER(10,7))]; 
    --DBMS_OUTPUT.PUT_LINE(sql_string); 
    execute immediate sql_string; 
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    */ 
--TRUNCATE TABAK_SUMMARY TABLE: 
execute immediate 'TRUNCATE TABLE JGARDNER.TABAK_SUMMARY'; 
 
--TRUNCATE LAB_MAPPING_TABLE: 
execute immediate 'TRUNCATE TABLE JGARDNER.'||lab_mapping_table; 
 
--INSERT VALUES INTO LAB_LOINC_MAPPING TABLE:        
    sql_string := q'[INSERT ALL  
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('ALBUMIN', 'LOINC:1751-7', 3.3, NULL) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('ALBUMIN', 'LOINC:2862-1', 3.3, NULL)        
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('AST', 'LOINC:1920-8', NULL, 30) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('AST', 'LOINC:88112-8', NULL, 30) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('AST', 'LOINC:30239-8', NULL, 30) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('TOTAL_BILIRUBIN', 'LOINC:1975-2', NULL, 1.4) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('TOTAL_BILIRUBIN', 'LOINC:42719-5', NULL, 1.4) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('CALCIUM', 'LOINC:17861-6', 8.5, 10.1) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('CALCIUM', 'LOINC:17863-2', 8.5, 10.1) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('CALCIUM','LOINC:17864-0', 8.5, 10.1) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('CALCIUM','LOINC:42567-8', 8.5, 10.1) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('CALCIUM', 'LOINC:57333-7', 8.5, 10.1) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('CALCIUM', 'LOINC:34907-6', 8.5, 10.1) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('CREATININE', 'LOINC:2160-0', NULL, 2) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
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            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('PRO_BNP', 'LOINC:71425-3', NULL, 8000) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('PRO_BNP', 'LOINC:33762-6', NULL, 8000) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('PRO_BNP', 'LOINC:83107-3', NULL, 8000) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('BNP', 'LOINC:42637-9', NULL, 1200) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('BNP', 'LOINC:30934-4', NULL, 1200) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('GLUCOSE', 'LOINC:2339-0', 71, 135) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('GLUCOSE', 'LOINC:2340-8', 71, 135)          
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('GLUCOSE', 'LOINC:2345-7', 71, 135) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('GLUCOSE', 'LOINC:14749-6', 71, 135) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('GLUCOSE', 'LOINC:1558-6', 71, 135)          
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('GLUCOSE', 'LOINC:14771-0', 71, 135) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('GLUCOSE', 'LOINC:15074-8', 71, 135) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('GLUCOSE', 'LOINC:32016-8', 71, 135)             
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('GLUCOSE', 'LOINC:1556-0', 71, 135) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('GLUCOSE', 'LOINC:27353-2', 71, 135) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('POTASSIUM', 'LOINC:75940-7', 3.3, 4.9) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('POTASSIUM', 'LOINC:22760-3', 3.3, 4.9) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('POTASSIUM', 'LOINC:42569-4', 3.3, 4.9) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
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            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('POTASSIUM', 'LOINC:77142-8', 3.3, 4.9) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('POTASSIUM', 'LOINC:51618-7', 3.3, 4.9) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('POTASSIUM', 'LOINC:2823-3', 3.3, 4.9) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('POTASSIUM', 'LOINC:6298-4', 3.3, 4.9) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('SODIUM', 'LOINC:2951-2', 136, 143) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('SODIUM','LOINC:2947-0', 136, 143) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('SODIUM','LOINC:42570-2', 136, 143) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('SODIUM','LOINC:77139-4', 136, 143) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('ALKALINE_PHOS','LOINC:1783-0', NULL, 115) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('ALKALINE_PHOS','LOINC:15148-0', NULL, 115) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('ALKALINE_PHOS','LOINC:6768-6', NULL, 115) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('BUN','LOINC:3094-0', NULL, 25) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('BUN','LOINC:6299-2', NULL, 25) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('BUN','LOINC:12964-3', NULL, 25) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('BUN','LOINC:35234-4', NULL, 25) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('PH_ARTERIAL','LOINC:2744-1', 7.36, 7.48) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('PH_ARTERIAL','LOINC:33254-4', 7.36, 7.48) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('PO2_ARTERIAL','LOINC:2703-7', 55.1, 140) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
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            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('PO2_ARTERIAL','LOINC:19255-9', 55.1, 140) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('PCO2_ARTERIAL','LOINC:2019-8', 36, 50) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('PCO2_ARTERIAL','LOINC:32771-8', 36, 50) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('PTT','LOINC:3173-2', 23, 45) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('PTT','LOINC:14979-9', 23, 45) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('PTT','LOINC:40100-0', 23, 45) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('PT_INR','LOINC:6301-6', NULL, 1.1) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('PT_INR', 'LOINC:34714-6', NULL, 1.1) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('PT_INR', 'LOINC:38875-1', NULL, 1.1) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('BANDS', 'LOINC:26508-2', NULL, 6) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('BANDS', 'LOINC:13354-6', NULL, 6) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('BANDS', 'LOINC:26510-8', NULL, 6) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('BANDS', 'LOINC:764-1', NULL, 6) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('BANDS', 'LOINC:35332-6', NULL, 6) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('HB', 'LOINC:718-7', 11, 18) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('HB', 'LOINC:721-1', 11, 18) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('PLATELETS', 'LOINC:26515-7', 150.1, 420) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('PLATELETS', 'LOINC:777-3', 150.1, 420) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
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            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('WBC', 'LOINC:6690-2', 4.4, 10.9) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('WBC', 'LOINC:26464-8', 4.4, 10.9) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('WBC', 'LOINC:751-8', 4.4, 10.9) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('TROPONIN_1', 'LOINC:16255-2', NULL, 0.04) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('TROPONIN_1', 'LOINC:42757-5', NULL, 0.04) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('TROPONIN_1', 'LOINC:10839-9', NULL, 0.04) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('TROPONIN_1', 'LOINC:49563-0', NULL, 0.04) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('CPK_MB', 'LOINC:13969-1', NULL, 2) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('CPK_MB', 'LOINC:83092-7', NULL, 2) 
        INTO JGARDNER.]'||lab_mapping_table||q'[ 
            (LAB_LABEL, LAB_LOINC, REFERENCE_LOW, REFERENCE_HIGH) 
            VALUES ('CPK_MB', 'LOINC:49551-5', NULL, 2) 
    SELECT * FROM DUAL 
    ]'; 
 
    --DBMS_OUTPUT.PUT_LINE(sql_string); 
    execute immediate sql_string; 
                 
             
--Create potential encounter table:          
table_name:='TEMP_POTENTIAL_ENCS'; 
dbms_output.PUT_LINE('***Creating '||table_name||' table at ' || my_date); 
drop_table(table_name); 
 
    sql_string := q'[  
    CREATE TABLE JGARDNER.]'||table_name||q'[ AS 
        SELECT VD.PATIENT_NUM, VD.ENCOUNTER_NUM, VD.START_DATE, 
                VD.DISCHARGE_DISPOSITION, VD.DISCHARGE_STATUS, 
                VD.END_DATE - VD.START_DATE AS LOS 
            FROM BLUEHERONDATA.VISIT_DIMENSION VD 
            WHERE VD.ENC_TYPE IN ('IP','EI')  
            AND VD.DISCHARGE_DISPOSITION IS NOT NULL 
            AND VD.DISCHARGE_STATUS IS NOT NULL 
            AND VD.DISCHARGE_STATUS != 'OT' 
            AND VD.DISCHARGE_DISPOSITION IN ('A','E') 
            AND VD.END_DATE BETWEEN 
                TO_DATE('1/1/2013','mm/dd/yyyy') AND 
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                TO_DATE('12/31/2017','mm/dd/yyyy') 
            --AND (END_DATE - START_DATE) > 1 
    ]';  
 
    --DBMS_OUTPUT.PUT_LINE(sql_string); 
    execute immediate sql_string; 
     
    --Count encounters 
        sql_string:=q'[select count(*) 
            from JGARDNER.TEMP_POTENTIAL_ENCS]'; 
        --DBMS_OUTPUT.PUT_LINE(sql_string); 
        execute immediate sql_string into total_encs; 
     
 
--Variables: 
    --1 Age (at start of encounter encounter) 
    --Create potential encounter table:          
    table_name:='TEMP_AGE_AT_ENCOUNTER'; 
    dbms_output.PUT_LINE('***Creating '||table_name||' table at ' || my_date); 
    drop_table(table_name); 
 
    sql_string := q'[  
        CREATE TABLE JGARDNER.]'||table_name||q'[ AS 
            select PE.PATIENT_NUM, PE.ENCOUNTER_NUM, 
                round((PE.start_date - PD.birth_date)/365.25,1) AGE_AT_ENC 
            FROM BLUEHERONDATA.PATIENT_DIMENSION PD 
            JOIN JGARDNER.TEMP_POTENTIAL_ENCS PE 
                ON PD.PATIENT_NUM = PE.PATIENT_NUM 
        ]';  
 
    --DBMS_OUTPUT.PUT_LINE(sql_string); 
    execute immediate sql_string; 
     
     
    --2 Gender: 
    table_name:='TEMP_PATIENT_GENDER'; 
    dbms_output.PUT_LINE('***Creating '||table_name||' table at ' || my_date); 
    drop_table(table_name); 
 
    sql_string := q'[  
        CREATE TABLE JGARDNER.]'||table_name||q'[ AS 
        SELECT PE.PATIENT_NUM, PD.SEX_CD GENDER 
            FROM BLUEHERONDATA.PATIENT_DIMENSION PD 
            JOIN JGARDNER.TEMP_POTENTIAL_ENCS PE 
                ON PD.PATIENT_NUM = PE.PATIENT_NUM 
            WHERE PD.SEX_CD IN ('Female','Male') 
            GROUP BY PE.PATIENT_NUM, PD.SEX_CD 
        ]'; 
     
    --DBMS_OUTPUT.PUT_LINE(sql_string); 
    execute immediate sql_string; 
     






        fetch sel_cur into sel_rec; 
        exit when sel_cur%NOTFOUND; -- no more items, all done 
        dbms_output.PUT_LINE('***Creating 
JGARDNER.TEMP_'||sel_rec.LAB_LABEL||' table at ' || my_date); 
        table_name:='JGARDNER.TEMP_'||sel_rec.LAB_LABEL; 
        drop_table(table_name); 
        sql_string := q'[CREATE TABLE JGARDNER.TEMP_]'||sel_rec.LAB_LABEL||q'[ 
as 
            SELECT PATIENT_NUM, ENCOUNTER_NUM, START_DATE, CONCEPT_CD, 
                    NVAL_NUM, UNITS_CD, LAB_LABEL 
                FROM         
                    (SELECT PE.PATIENT_NUM, PE.ENCOUNTER_NUM, O.START_DATE, 
O.CONCEPT_CD,  
                            O.NVAL_NUM, O.UNITS_CD, 
']'||sel_rec.LAB_LABEL||q'[' AS LAB_LABEL, 
                            ROW_NUMBER() OVER (PARTITION BY O.ENCOUNTER_NUM 
                                ORDER BY O.START_DATE ASC) R_NUM 
                        FROM JGARDNER.TEMP_POTENTIAL_ENCS PE 
                        LEFT JOIN BLUEHERONDATA.OBSERVATION_FACT O 
                            ON PE.ENCOUNTER_NUM = O.ENCOUNTER_NUM 
                        WHERE PE.LOS > 1 --Eliminate outpatient surgical 
procedures 
                            and CONCEPT_CD IN (select LAB_LOINC from 
JGARDNER.]'||lab_mapping_table||q'[ 
                            where LAB_LABEL = ']'||sel_rec.LAB_LABEL||q'[')) 
                WHERE R_NUM = 1 
            ]'; 
        --DBMS_OUTPUT.PUT_LINE(sql_string); 
        execute immediate sql_string; 
         
    --Count table 
        sql_string:=q'[select count(*) 
            from JGARDNER.TEMP_]'||sel_rec.LAB_LABEL; 
        --DBMS_OUTPUT.PUT_LINE(sql_string); 
        execute immediate sql_string into lab_count_variable; 
         
        sql_string:=q'[select round((]'||to_char(lab_count_variable)||q'[/ 
                    ]'||to_char(total_encs)||q'[)*100,7) 
                    from dual]'; 
        --DBMS_OUTPUT.PUT_LINE(sql_string); 
        execute immediate sql_string into percent_of_encs; 
 
        --Populate summary table 
        sql_string := q'[INSERT INTO JGARDNER.TABAK_SUMMARY 
                (LAB_LABEL, ENCOUNTERS, PERCENT_OF_ENCOUNTERS) 
                VALUES (']'||sel_rec.LAB_LABEL||q'[', 
                    ]'||to_char(lab_count_variable)||q'[, 
                    ]'||to_char(percent_of_encs)||q'[) 
            ]'; 
        --DBMS_OUTPUT.PUT_LINE(sql_string); 
        execute immediate sql_string; 




close sel_cur;  
 
    -- raw scoring: 
    table_name:='TEMP_TABAK_RAW_SCORE'; 
    dbms_output.PUT_LINE('***Creating '||table_name||' table at ' || my_date); 
    drop_table(table_name); 
 
    sql_string := q'[  
        CREATE TABLE JGARDNER.]'||table_name||q'[ AS 
        SELECT PE.PATIENT_NUM, PE.ENCOUNTER_NUM, PE.START_DATE, 
            PE.DISCHARGE_DISPOSITION, PE.DISCHARGE_STATUS, 
            PE.LOS, 
            AAE.AGE_AT_ENC, 
            PG.GENDER, 
            TEMP_ALBUMIN.CONCEPT_CD ALBUMIN_CONCEPT_CD,  
                TEMP_ALBUMIN.NVAL_NUM ALBUMIN_NVAL_NUM,  
                TEMP_ALBUMIN.UNITS_CD ALBUMIN_UNITS_CD, 
            TEMP_AST.CONCEPT_CD AST_CONCEPT_CD,  
                TEMP_AST.NVAL_NUM AST_NVAL_NUM,  
                TEMP_AST.UNITS_CD AST_UNITS_CD, 
            TEMP_TOTAL_BILIRUBIN.CONCEPT_CD TOTAL_BILIRUBIN_CONCEPT_CD,  
                TEMP_TOTAL_BILIRUBIN.NVAL_NUM TOTAL_BILIRUBIN_NVAL_NUM, 
                TEMP_TOTAL_BILIRUBIN.UNITS_CD TOTAL_BILIRUBIN_UNITS_CD, 
            TEMP_CALCIUM.CONCEPT_CD CALCIUM_CONCEPT_CD, 
                TEMP_CALCIUM.NVAL_NUM CALCIUM_NVAL_NUM, 
                TEMP_CALCIUM.UNITS_CD CALCIUM_UNITS_CD, 
            TEMP_CREATININE.CONCEPT_CD CREATININE_CONCEPT_CD, 
                TEMP_CREATININE.NVAL_NUM CREATININE_NVAL_NUM, 
                TEMP_CREATININE.UNITS_CD CREATININE_UNITS_CD, 
            TEMP_PRO_BNP.CONCEPT_CD PRO_BNP_CONCEPT_CD, 
                TEMP_PRO_BNP.NVAL_NUM PRO_BNP_NVAL_NUM, 
                TEMP_PRO_BNP.UNITS_CD PRO_BNP_UNITS_CD, 
            TEMP_BNP.CONCEPT_CD BNP_CONCEPT_CD, 
                TEMP_BNP.NVAL_NUM BNP_NVAL_NUM, 
                TEMP_BNP.UNITS_CD BNP_UNITS_CD, 
            TEMP_GLUCOSE.CONCEPT_CD GLUCOSE_CONCEPT_CD, 
                TEMP_GLUCOSE.NVAL_NUM GLUCOSE_NVAL_NUM, 
                TEMP_GLUCOSE.UNITS_CD GLUCOSE_UNITS_CD, 
            TEMP_POTASSIUM.CONCEPT_CD POTASSIUM_CONCEPT_CD, 
                TEMP_POTASSIUM.NVAL_NUM POTASSIUM_NVAL_NUM, 
                TEMP_POTASSIUM.UNITS_CD POTASSIUM_UNITS_CD, 
            TEMP_SODIUM.CONCEPT_CD SODIUM_CONCEPT_CD, 
                TEMP_SODIUM.NVAL_NUM SODIUM_NVAL_NUM, 
                TEMP_SODIUM.UNITS_CD SODIUM_UNITS_CD, 
            TEMP_ALKALINE_PHOS.CONCEPT_CD ALKALINE_PHOS_CONCEPT_CD, 
                TEMP_ALKALINE_PHOS.NVAL_NUM ALKALINE_PHOS_NVAL_NUM, 
                TEMP_ALKALINE_PHOS.UNITS_CD ALKALINE_PHOS_UNITS_CD, 
            TEMP_BUN.CONCEPT_CD BUN_CONCEPT_CD, 
                TEMP_BUN.NVAL_NUM BUN_NVAL_NUM, 
                TEMP_BUN.UNITS_CD BUN_UNITS_CD, 
            TEMP_PH_ARTERIAL.CONCEPT_CD PH_ARTERIAL_CONCEPT_CD, 
                TEMP_PH_ARTERIAL.NVAL_NUM PH_ARTERIAL_NVAL_NUM, 
                TEMP_PH_ARTERIAL.UNITS_CD PH_ARTERIAL_UNITS_CD, 
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            TEMP_PO2_ARTERIAL.CONCEPT_CD PO2_ARTERIAL_CONCEPT_CD, 
                TEMP_PO2_ARTERIAL.NVAL_NUM PO2_ARTERIAL_NVAL_NUM, 
                TEMP_PO2_ARTERIAL.UNITS_CD PO2_ARTERIAL_UNITS_CD, 
            TEMP_PCO2_ARTERIAL.CONCEPT_CD PCO2_ARTERIAL_CONCEPT_CD, 
                TEMP_PCO2_ARTERIAL.NVAL_NUM PCO2_ARTERIAL_NVAL_NUM, 
                TEMP_PCO2_ARTERIAL.UNITS_CD PCO2_ARTERIAL_UNITS_CD, 
            TEMP_PTT.CONCEPT_CD PTT_CONCEPT_CD,  
                TEMP_PTT.NVAL_NUM PTT_NVAL_NUM,  
                TEMP_PTT.UNITS_CD PTT_UNITS_CD, 
            TEMP_PT_INR.CONCEPT_CD PT_INR_CONCEPT_CD, 
                TEMP_PT_INR.NVAL_NUM PT_INR_NVAL_NUM, 
                TEMP_PT_INR.UNITS_CD PT_INR_UNITS_CD, 
            TEMP_BANDS.CONCEPT_CD BANDS_CONCEPT_CD, 
                TEMP_BANDS.NVAL_NUM BANDS_NVAL_NUM, 
                TEMP_BANDS.UNITS_CD BANDS_UNITS_CD, 
            TEMP_HB.CONCEPT_CD HB_CONCEPT_CD, 
                TEMP_HB.NVAL_NUM HB_NVAL_NUM, 
                TEMP_HB.UNITS_CD HB_UNITS_CD, 
            TEMP_PLATELETS.CONCEPT_CD PLATELETS_CONCEPT_CD, 
                TEMP_PLATELETS.NVAL_NUM PLATELETS_NVAL_NUM, 
                TEMP_PLATELETS.UNITS_CD PLATELETS_UNITS_CD, 
            TEMP_WBC.CONCEPT_CD WBC_CONCEPT_CD, 
                TEMP_WBC.NVAL_NUM WBC_NVAL_NUM, 
                TEMP_WBC.UNITS_CD WBC_UNITS_CD, 
            COALESCE(TEMP_TROPONIN_1.CONCEPT_CD,TEMP_CPK_MB.CONCEPT_CD) AS 
TROP_CPK_CONCEPT_CD, 
                COALESCE(TEMP_TROPONIN_1.NVAL_NUM,TEMP_CPK_MB.NVAL_NUM) AS 
TROP_CPK_NVAL_NUM, 
                COALESCE(TEMP_TROPONIN_1.UNITS_CD,TEMP_CPK_MB.UNITS_CD) AS 
TROP_CPK_UNITS_CD, 
                COALESCE(TEMP_TROPONIN_1.LAB_LABEL,TEMP_CPK_MB.LAB_LABEL) AS 
TROP_CPK_LAB_LABEL, 
            30 AS TOTAL_LABS, 
            999 AS TOTAL_SCORE 
        FROM JGARDNER.TEMP_POTENTIAL_ENCS PE 
        LEFT JOIN TEMP_ALBUMIN 
            ON PE.ENCOUNTER_NUM = TEMP_ALBUMIN.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_ALBUMIN.PATIENT_NUM 
        LEFT JOIN TEMP_AST 
            ON PE.ENCOUNTER_NUM = TEMP_AST.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_AST.PATIENT_NUM 
        LEFT JOIN TEMP_TOTAL_BILIRUBIN 
            ON PE.ENCOUNTER_NUM = TEMP_TOTAL_BILIRUBIN.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_TOTAL_BILIRUBIN.PATIENT_NUM 
        LEFT JOIN TEMP_CALCIUM 
            ON PE.ENCOUNTER_NUM = TEMP_CALCIUM.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_CALCIUM.PATIENT_NUM 
        LEFT JOIN TEMP_CREATININE 
            ON PE.ENCOUNTER_NUM = TEMP_CREATININE.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_CREATININE.PATIENT_NUM 
        LEFT JOIN TEMP_PRO_BNP 
            ON PE.ENCOUNTER_NUM = TEMP_PRO_BNP.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_PRO_BNP.PATIENT_NUM 
        LEFT JOIN TEMP_BNP 
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            ON PE.ENCOUNTER_NUM = TEMP_BNP.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_BNP.PATIENT_NUM 
        LEFT JOIN TEMP_GLUCOSE 
            ON PE.ENCOUNTER_NUM = TEMP_GLUCOSE.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_GLUCOSE.PATIENT_NUM 
        LEFT JOIN TEMP_POTASSIUM 
            ON PE.ENCOUNTER_NUM = TEMP_POTASSIUM.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_POTASSIUM.PATIENT_NUM 
        LEFT JOIN TEMP_SODIUM 
            ON PE.ENCOUNTER_NUM = TEMP_SODIUM.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_SODIUM.PATIENT_NUM 
        LEFT JOIN TEMP_ALKALINE_PHOS 
            ON PE.ENCOUNTER_NUM = TEMP_ALKALINE_PHOS.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_ALKALINE_PHOS.PATIENT_NUM 
        LEFT JOIN TEMP_BUN 
            ON PE.ENCOUNTER_NUM = TEMP_BUN.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_BUN.PATIENT_NUM 
        LEFT JOIN TEMP_PH_ARTERIAL 
            ON PE.ENCOUNTER_NUM = TEMP_PH_ARTERIAL.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_PH_ARTERIAL.PATIENT_NUM 
        LEFT JOIN TEMP_PO2_ARTERIAL 
            ON PE.ENCOUNTER_NUM = TEMP_PO2_ARTERIAL.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_PO2_ARTERIAL.PATIENT_NUM 
        LEFT JOIN TEMP_PCO2_ARTERIAL 
            ON PE.ENCOUNTER_NUM = TEMP_PCO2_ARTERIAL.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_PCO2_ARTERIAL.PATIENT_NUM 
        LEFT JOIN TEMP_PTT 
            ON PE.ENCOUNTER_NUM = TEMP_PTT.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_PTT.PATIENT_NUM 
        LEFT JOIN TEMP_PT_INR 
            ON PE.ENCOUNTER_NUM = TEMP_PT_INR.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_PT_INR.PATIENT_NUM 
        LEFT JOIN TEMP_BANDS 
            ON PE.ENCOUNTER_NUM = TEMP_BANDS.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_BANDS.PATIENT_NUM 
        LEFT JOIN TEMP_HB 
            ON PE.ENCOUNTER_NUM = TEMP_HB.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_HB.PATIENT_NUM 
        LEFT JOIN TEMP_PLATELETS 
            ON PE.ENCOUNTER_NUM = TEMP_PLATELETS.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_PLATELETS.PATIENT_NUM 
        LEFT JOIN TEMP_WBC 
            ON PE.ENCOUNTER_NUM = TEMP_WBC.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_WBC.PATIENT_NUM 
        LEFT JOIN TEMP_TROPONIN_1 
            ON PE.ENCOUNTER_NUM = TEMP_TROPONIN_1.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_TROPONIN_1.PATIENT_NUM 
        LEFT JOIN TEMP_CPK_MB 
            ON PE.ENCOUNTER_NUM = TEMP_CPK_MB.ENCOUNTER_NUM 
            AND PE.PATIENT_NUM = TEMP_CPK_MB.PATIENT_NUM 
        JOIN TEMP_AGE_AT_ENCOUNTER AAE 
            ON PE.PATIENT_NUM = AAE.PATIENT_NUM 
            AND PE.ENCOUNTER_NUM = AAE.ENCOUNTER_NUM 
        LEFT JOIN TEMP_PATIENT_GENDER PG 
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            ON PE.PATIENT_NUM = PG.PATIENT_NUM 
        WHERE AAE.AGE_AT_ENC >= 18 
        ]'; 
     
    --DBMS_OUTPUT.PUT_LINE(sql_string); 
    execute immediate sql_string; 
         
             
--Actual Tabak score 
    table_name:='TABAK_SCORE'; 
    dbms_output.PUT_LINE('***Creating '||table_name||' table at ' || my_date); 
    drop_table(table_name); 
 
    sql_string := q'[  
        CREATE TABLE JGARDNER.]'||table_name||q'[ AS 
        SELECT --RS.PATIENT_NUM,  
            RS.ENCOUNTER_NUM, RS.DISCHARGE_DISPOSITION, 
            RS.DISCHARGE_STATUS, round(RS.LOS,2) LENGTH_OF_STAY, 
            trunc(RS.AGE_AT_ENC) AGE, RS.GENDER,  
            999 AS TABAK_TOTAL_SCORE, 
            CASE WHEN RS.ALBUMIN_NVAL_NUM IS NULL THEN 1 ELSE 0 END + 
                CASE WHEN RS.AST_NVAL_NUM IS NULL THEN 1 ELSE 0 END + 
                CASE WHEN RS.TOTAL_BILIRUBIN_NVAL_NUM IS NULL THEN 1 ELSE 0 
END + 
                CASE WHEN RS.CALCIUM_NVAL_NUM IS NULL THEN 1 ELSE 0 END + 
                CASE WHEN RS.CREATININE_NVAL_NUM IS NULL THEN 1 ELSE 0 END + 
                CASE WHEN RS.PRO_BNP_NVAL_NUM IS NULL THEN 1 ELSE 0 END + 
                CASE WHEN RS.BNP_NVAL_NUM IS NULL THEN 1 ELSE 0 END + 
                CASE WHEN RS.GLUCOSE_NVAL_NUM IS NULL THEN 1 ELSE 0 END + 
                CASE WHEN RS.POTASSIUM_NVAL_NUM IS NULL THEN 1 ELSE 0 END + 
                CASE WHEN RS.SODIUM_NVAL_NUM IS NULL THEN 1 ELSE 0 END + 
                CASE WHEN RS.ALKALINE_PHOS_NVAL_NUM IS NULL THEN 1 ELSE 0 END 
+ 
                CASE WHEN RS.BUN_NVAL_NUM IS NULL THEN 1 ELSE 0 END + 
                CASE WHEN RS.PH_ARTERIAL_NVAL_NUM IS NULL THEN 1 ELSE 0 END + 
                CASE WHEN RS.PO2_ARTERIAL_NVAL_NUM IS NULL THEN 1 ELSE 0 END + 
                CASE WHEN RS.PCO2_ARTERIAL_NVAL_NUM IS NULL THEN 1 ELSE 0 END 
+ 
                CASE WHEN RS.PTT_NVAL_NUM IS NULL THEN 1 ELSE 0 END + 
                CASE WHEN RS.PT_INR_NVAL_NUM IS NULL THEN 1 ELSE 0 END + 
                CASE WHEN RS.BANDS_NVAL_NUM IS NULL THEN 1 ELSE 0 END + 
                CASE WHEN RS.HB_NVAL_NUM IS NULL THEN 1 ELSE 0 END + 
                CASE WHEN RS.PLATELETS_NVAL_NUM IS NULL THEN 1 ELSE 0 END + 
                CASE WHEN RS.WBC_NVAL_NUM IS NULL THEN 1 ELSE 0 END + 
                CASE WHEN RS.TROP_CPK_NVAL_NUM IS NULL THEN 1 ELSE 0 END 
NumberOfNullFields, 
            CASE WHEN RS.AGE_AT_ENC BETWEEN 18 AND 29 THEN 0 
                WHEN RS.AGE_AT_ENC BETWEEN 30 AND 34.9 THEN 3 
                WHEN RS.AGE_AT_ENC BETWEEN 35 AND 39.9 THEN 10 
                WHEN RS.AGE_AT_ENC BETWEEN 40 AND 44.9 THEN 13 
                WHEN RS.AGE_AT_ENC BETWEEN 45 AND 49.9 THEN 17 
                WHEN RS.AGE_AT_ENC BETWEEN 50 AND 54.9 THEN 20 
                WHEN RS.AGE_AT_ENC BETWEEN 55 AND 59.9 THEN 23 
                WHEN RS.AGE_AT_ENC BETWEEN 60 AND 64.9 THEN 25 
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                WHEN RS.AGE_AT_ENC BETWEEN 65 AND 69.9 THEN 27 
                WHEN RS.AGE_AT_ENC BETWEEN 70 AND 74.9 THEN 30 
                WHEN RS.AGE_AT_ENC BETWEEN 75 AND 79.9 THEN 32 
                WHEN RS.AGE_AT_ENC BETWEEN 80 AND 84.9 THEN 35 
                WHEN RS.AGE_AT_ENC BETWEEN 85 AND 89.9 THEN 38 
                WHEN RS.AGE_AT_ENC > 89.9 THEN 42 
                ELSE 0 
                END AGE_SCORE, 
            CASE WHEN RS.GENDER = 'Male' THEN 2 
                WHEN RS.GENDER = 'Female' THEN 0 
                ELSE 0 
                END GENDER_SCORE, 
            CASE WHEN ALBUMIN_NVAL_NUM <= 2.4 THEN 14 
                WHEN ALBUMIN_NVAL_NUM BETWEEN 2.5 AND 2.7 THEN 7 
                WHEN ALBUMIN_NVAL_NUM BETWEEN 2.8 AND 3 THEN 4 
                WHEN ALBUMIN_NVAL_NUM BETWEEN 3.1 AND 3.3 THEN 1 
                WHEN ALBUMIN_NVAL_NUM > 3.3 THEN 0 
                ELSE 0 
                END AS ALBUMIN_SCORE, 
            RS.ALBUMIN_NVAL_NUM, 
            CASE WHEN AST_NVAL_NUM <= 30 THEN 0 
                WHEN AST_NVAL_NUM BETWEEN 31 AND 40 THEN 2 
                WHEN AST_NVAL_NUM BETWEEN 41 AND 60 THEN 4 
                WHEN AST_NVAL_NUM BETWEEN 61 AND 100 THEN 6 
                WHEN AST_NVAL_NUM > 100 THEN 9 
                ELSE 0 
                END AS AST_SCORE, 
            RS.AST_NVAL_NUM, 
            CASE WHEN TOTAL_BILIRUBIN_NVAL_NUM <= 1.4 THEN 0 
                WHEN TOTAL_BILIRUBIN_NVAL_NUM BETWEEN 1.5 AND 2 THEN 1 
                WHEN TOTAL_BILIRUBIN_NVAL_NUM > 2 THEN 4 
                ELSE 0 
                END AS TOTAL_BILIRUBIN_SCORE, 
            RS.TOTAL_BILIRUBIN_NVAL_NUM, 
            CASE WHEN CALCIUM_NVAL_NUM <= 7.9 THEN 4 
                WHEN CALCIUM_NVAL_NUM BETWEEN 8 AND 8.4 THEN 1 
                WHEN CALCIUM_NVAL_NUM BETWEEN 8.5 AND 10.1 THEN 0 
                WHEN CALCIUM_NVAL_NUM > 10.1 THEN 3 
                ELSE 0 
                END AS CALCIUM_SCORE, 
            RS.CALCIUM_NVAL_NUM, 
            CASE WHEN CREATININE_NVAL_NUM <=2 THEN 0 
                WHEN CREATININE_NVAL_NUM > 2 THEN 1 
                ELSE 0 
                END AS CREATININE_SCORE, 
            RS.CREATININE_NVAL_NUM, 
            CASE WHEN PRO_BNP_NVAL_NUM <= 8000 THEN 0 
                WHEN PRO_BNP_NVAL_NUM BETWEEN 8001 AND 18000 THEN 5 
                WHEN PRO_BNP_NVAL_NUM > 18000 THEN 10 
                ELSE 0 
                END AS PRO_BNP_SCORE, 
            RS.PRO_BNP_NVAL_NUM, 
            CASE WHEN BNP_NVAL_NUM <= 1200 THEN 0 
                WHEN BNP_NVAL_NUM BETWEEN 1201 AND 2400 THEN 2 
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                WHEN BNP_NVAL_NUM > 2400 THEN 4 
                ELSE 0 
                END AS BNP_SCORE, 
            RS.BNP_NVAL_NUM, 
            CASE WHEN GLUCOSE_NVAL_NUM <=70 THEN 7 
                WHEN GLUCOSE_NVAL_NUM BETWEEN 71 AND 135 THEN 0 
                WHEN GLUCOSE_NVAL_NUM BETWEEN 136 AND 165 THEN 2 
                WHEN GLUCOSE_NVAL_NUM > 165 THEN 5 
                ELSE 0 
                END AS GLUCOSE_SCORE, 
            RS.GLUCOSE_NVAL_NUM, 
            CASE WHEN POTASSIUM_NVAL_NUM <= 3.2 THEN 3 
                WHEN POTASSIUM_NVAL_NUM BETWEEN 3.3 AND 4.9 THEN 0 
                WHEN POTASSIUM_NVAL_NUM BETWEEN 5 AND 5.3 THEN 2 
                WHEN POTASSIUM_NVAL_NUM >5.3 THEN 3 
                ELSE 0 
                END AS POTASSIUM_SCORE, 
            RS.POTASSIUM_NVAL_NUM, 
            CASE WHEN SODIUM_NVAL_NUM <= 130    THEN 4 
                WHEN SODIUM_NVAL_NUM BETWEEN 131 AND 135 THEN 1 
                WHEN SODIUM_NVAL_NUM BETWEEN 136 AND 143 THEN 0 
                WHEN SODIUM_NVAL_NUM BETWEEN 144 AND 145 THEN 4 
                WHEN SODIUM_NVAL_NUM > 145 THEN 9 
                ELSE 0 
                END AS SODIUM_SCORE, 
            RS.SODIUM_NVAL_NUM, 
            CASE WHEN ALKALINE_PHOS_NVAL_NUM <= 115 THEN 0 
                WHEN ALKALINE_PHOS_NVAL_NUM BETWEEN 116 AND 220 THEN 2 
                WHEN ALKALINE_PHOS_NVAL_NUM BETWEEN 221 AND 630 THEN 5 
                WHEN ALKALINE_PHOS_NVAL_NUM >630 THEN 8 
                ELSE 0 
                END AS ALKALINE_PHOS_SCORE, 
            RS.ALKALINE_PHOS_NVAL_NUM, 
            CASE WHEN BUN_NVAL_NUM <= 25 THEN 0 
                WHEN BUN_NVAL_NUM BETWEEN 26 AND 30 THEN 4 
                WHEN BUN_NVAL_NUM BETWEEN 31 AND 40 THEN 6 
                WHEN BUN_NVAL_NUM BETWEEN 41 AND 55 THEN 8 
                WHEN BUN_NVAL_NUM >55 THEN 10 
                ELSE 0 
                END AS BUN_SCORE, 
            RS.BUN_NVAL_NUM, 
            CASE WHEN PH_ARTERIAL_NVAL_NUM <= 7.2 THEN 21 
                WHEN PH_ARTERIAL_NVAL_NUM BETWEEN 7.21 AND 7.3 THEN 13 
                WHEN PH_ARTERIAL_NVAL_NUM BETWEEN 7.31 AND 7.35 THEN 10 
                WHEN PH_ARTERIAL_NVAL_NUM BETWEEN 7.36 AND 7.48 THEN 0 
                WHEN PH_ARTERIAL_NVAL_NUM >7.48 THEN 8 
                ELSE 0 
                END AS PH_ARTERIAL_SCORE, 
            RS.PH_ARTERIAL_NVAL_NUM, 
            CASE WHEN PO2_ARTERIAL_NVAL_NUM <= 50 THEN 12 
                WHEN PO2_ARTERIAL_NVAL_NUM BETWEEN 50.1 AND 55 THEN 9 
                WHEN PO2_ARTERIAL_NVAL_NUM BETWEEN 55.1 AND 140 THEN 0 
                WHEN PO2_ARTERIAL_NVAL_NUM > 140 THEN 12 
                ELSE 0 
155 
 
                END AS PO2_ARTERIAL_SCORE, 
            RS.PO2_ARTERIAL_NVAL_NUM, 
            CASE WHEN PCO2_ARTERIAL_NVAL_NUM <=35 THEN 9 
                WHEN PCO2_ARTERIAL_NVAL_NUM BETWEEN 36 AND 50 THEN 0 
                WHEN PCO2_ARTERIAL_NVAL_NUM > 50 THEN 7 
                ELSE 0 
                END AS PCO2_ARTERIAL_SCORE, 
            RS.PCO2_ARTERIAL_NVAL_NUM, 
            CASE WHEN PTT_NVAL_NUM <= 22    THEN 3 
                WHEN PTT_NVAL_NUM BETWEEN 23 AND 45 THEN 0 
                WHEN PTT_NVAL_NUM BETWEEN 45.1 AND 55 THEN 3  
                WHEN PTT_NVAL_NUM > 55 THEN 4 
                ELSE 0 
                END AS PTT_SCORE, 
            RS.PTT_NVAL_NUM, 
            CASE WHEN PT_INR_NVAL_NUM <=1.1 THEN 0 
                WHEN PT_INR_NVAL_NUM BETWEEN 1.11 AND 1.4 THEN 4 
                WHEN PT_INR_NVAL_NUM BETWEEN 1.41 AND 2 THEN 7 
                WHEN PT_INR_NVAL_NUM BETWEEN 2.1 AND 5 THEN 5 
                WHEN PT_INR_NVAL_NUM > 5 THEN 8 
                ELSE 0 
                END AS PT_INR_SCORE, 
            RS.PT_INR_NVAL_NUM, 
            CASE WHEN BANDS_NVAL_NUM <=6 THEN 0 
                WHEN BANDS_NVAL_NUM BETWEEN 7 AND 13 THEN 6 
                WHEN BANDS_NVAL_NUM BETWEEN 14 AND 32 THEN 9 
                WHEN BANDS_NVAL_NUM > 32 THEN 12 
                ELSE 0  
                END AS BANDS_SCORE, 
            RS.BANDS_NVAL_NUM, 
            CASE WHEN HB_NVAL_NUM <=10 THEN 2 
                WHEN HB_NVAL_NUM BETWEEN 11 AND 18 THEN 0 
                WHEN HB_NVAL_NUM > 18 THEN 4 
                ELSE 0  
                END AS HB_SCORE, 
            RS.HB_NVAL_NUM, 
            CASE WHEN PLATELETS_NVAL_NUM <=115 THEN 10 
                WHEN PLATELETS_NVAL_NUM BETWEEN 115.1 AND 150 THEN 2 
                WHEN PLATELETS_NVAL_NUM BETWEEN 150.1 AND 420 THEN 0 
                WHEN PLATELETS_NVAL_NUM > 420 THEN 2 
                ELSE 0 
                END AS PLATELETS_SCORE, 
            RS.PLATELETS_NVAL_NUM, 
            CASE WHEN WBC_NVAL_NUM <=4.3 THEN 4 
                WHEN WBC_NVAL_NUM BETWEEN 4.4 AND 10.9 THEN 0 
                WHEN WBC_NVAL_NUM BETWEEN 11 AND 14.1 THEN 4 
                WHEN WBC_NVAL_NUM BETWEEN 14.2 AND 19.8 THEN 7  
                WHEN WBC_NVAL_NUM > 19.8 THEN 12 
                ELSE 0 
                END AS WBC_SCORE, 
            RS.WBC_NVAL_NUM, 
            CASE WHEN TROP_CPK_LAB_LABEL = 'TROPONIN_1'  
                    AND TROP_CPK_NVAL_NUM <= 0.04 THEN 0 
                WHEN TROP_CPK_LAB_LABEL = 'TROPONIN_1' 
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                    AND TROP_CPK_NVAL_NUM BETWEEN 0.05 AND 0.1 THEN 2 
                WHEN TROP_CPK_LAB_LABEL = 'TROPONIN_1' 
                    AND TROP_CPK_NVAL_NUM BETWEEN 0.11 AND 0.2 THEN 4 
                WHEN TROP_CPK_LAB_LABEL = 'TROPONIN_1' 
                    AND TROP_CPK_NVAL_NUM BETWEEN 0.21 AND 0.3 THEN 8 
                WHEN TROP_CPK_LAB_LABEL = 'TROPONIN_1' 
                    AND TROP_CPK_NVAL_NUM >0.3 THEN 13 
                WHEN TROP_CPK_LAB_LABEL = 'CPK_MB' 
                    AND TROP_CPK_NVAL_NUM <= 2 THEN 0 
                WHEN TROP_CPK_LAB_LABEL = 'CPK_MB' 
                    AND TROP_CPK_NVAL_NUM BETWEEN 3 AND 5 THEN 2 
                WHEN TROP_CPK_LAB_LABEL = 'CPK_MB' 
                    AND TROP_CPK_NVAL_NUM BETWEEN 6 AND 10 THEN 4 
                WHEN TROP_CPK_LAB_LABEL = 'CPK_MB' 
                    AND TROP_CPK_NVAL_NUM BETWEEN 11 AND 34 THEN 8 
                WHEN TROP_CPK_LAB_LABEL = 'CPK_MB' 
                    AND TROP_CPK_NVAL_NUM > 34 THEN 13 
                ELSE 0 
                END AS TROP_CPK_SCORE, 
            RS.TROP_CPK_NVAL_NUM, 
            RS.TROP_CPK_LAB_LABEL 
        FROM TEMP_TABAK_RAW_SCORE RS 
    ]'; 
     
    --DBMS_OUTPUT.PUT_LINE(sql_string); 
    execute immediate sql_string; 
    DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted.'); 
     
    sql_string:=q'[UPDATE JGARDNER.TABAK_SCORE 
        SET TABAK_TOTAL_SCORE = ALBUMIN_SCORE + 
        AST_SCORE + 
        TOTAL_BILIRUBIN_SCORE + 
        CALCIUM_SCORE + 
        CREATININE_SCORE + 
        PRO_BNP_SCORE + 
        BNP_SCORE + 
        GLUCOSE_SCORE + 
        POTASSIUM_SCORE + 
        SODIUM_SCORE + 
        ALKALINE_PHOS_SCORE + 
        BUN_SCORE + 
        PH_ARTERIAL_SCORE + 
        PO2_ARTERIAL_SCORE + 
        PCO2_ARTERIAL_SCORE + 
        PTT_SCORE + 
        PT_INR_SCORE + 
        BANDS_SCORE + 
        HB_SCORE + 
        PLATELETS_SCORE + 
        WBC_SCORE + 
        TROP_CPK_SCORE + 
        GENDER_SCORE + 




    ]'; 
     
    --DBMS_OUTPUT.PUT_LINE(sql_string); 
    execute immediate sql_string; 
     
     
     
--Add columns for binning with 1 = yes and 0 = no: 
table_name:='TABAK_SCORE_BINS'; 
    dbms_output.PUT_LINE('***Creating '||table_name||' table at ' || my_date); 
    drop_table(table_name); 
 
    sql_string := q'[  
        CREATE TABLE JGARDNER.]'||table_name||q'[ AS 
        SELECT TS.*, 
            CASE WHEN AGE BETWEEN 18 AND 29.9 THEN 1 ELSE 0 END AS AGE_LT_30, 
            CASE WHEN AGE BETWEEN 30 AND 34.9 THEN 1 ELSE 0 END AS AGE_30_34, 
            CASE WHEN AGE BETWEEN 35 AND 39.9 THEN 1 ELSE 0 END AS AGE_35_39, 
            CASE WHEN AGE BETWEEN 40 AND 44.9 THEN 1 ELSE 0 END AS AGE_40_44, 
            CASE WHEN AGE BETWEEN 45 AND 49.9 THEN 1 ELSE 0 END AS AGE_45_49, 
            CASE WHEN AGE BETWEEN 50 AND 54.9 THEN 1 ELSE 0 END AS AGE_50_54, 
            CASE WHEN AGE BETWEEN 55 AND 59.9 THEN 1 ELSE 0 END AS AGE_55_59, 
            CASE WHEN AGE BETWEEN 60 AND 64.9 THEN 1 ELSE 0 END AS AGE_60_64, 
            CASE WHEN AGE BETWEEN 65 AND 69.9 THEN 1 ELSE 0 END AS AGE_65_69, 
            CASE WHEN AGE BETWEEN 70 AND 74.9 THEN 1 ELSE 0 END AS AGE_70_74, 
            CASE WHEN AGE BETWEEN 75 AND 79.9 THEN 1 ELSE 0 END AS AGE_75_79, 
            CASE WHEN AGE BETWEEN 80 AND 84.9 THEN 1 ELSE 0 END AS AGE_80_84, 
            CASE WHEN AGE BETWEEN 85 AND 89.9 THEN 1 ELSE 0 END AS AGE_85_89, 
            CASE WHEN AGE > 89 THEN 1 ELSE 0 END AS AGE_GT_89, 
            CASE WHEN GENDER = 'Male' THEN 1 ELSE 0 END AS GENDER_M, 
            CASE WHEN GENDER = 'Female' THEN 1 ELSE 0 END AS GENDER_F, 
            CASE WHEN ALBUMIN_NVAL_NUM <= 2.4 THEN 1 ELSE 0 END AS 
ALBUMIN_LE_24, 
            CASE WHEN ALBUMIN_NVAL_NUM BETWEEN 2.5 AND 2.7 THEN 1 ELSE 0 END 
AS ALBUMIN_25_27, 
            CASE WHEN ALBUMIN_NVAL_NUM BETWEEN 2.8 AND 3 THEN 1 ELSE 0 END AS 
ALBUMIN_28_3, 
            CASE WHEN ALBUMIN_NVAL_NUM BETWEEN 3.1 AND 3.3 THEN 1 ELSE 0 END 
AS ALBUMIN_31_33, 
            CASE WHEN ALBUMIN_NVAL_NUM > 3.3 THEN 1 ELSE 0 END AS 
ALBUMIN_GT_33, 
            CASE WHEN AST_NVAL_NUM <= 30 THEN 1 ELSE 0 END AS AST_LE_30, 
            CASE WHEN AST_NVAL_NUM BETWEEN 31 AND 40 THEN 1 ELSE 0 END AS 
AST_31_40, 
            CASE WHEN AST_NVAL_NUM BETWEEN 41 AND 60 THEN 1 ELSE 0 END AS 
AST_41_60, 
            CASE WHEN AST_NVAL_NUM BETWEEN 61 AND 100 THEN 1 ELSE 0 END AS 
AST_61_100, 
            CASE WHEN AST_NVAL_NUM > 100 THEN 1 ELSE 0 END AS AST_GT_100, 
            CASE WHEN TOTAL_BILIRUBIN_NVAL_NUM <= 1.4 THEN 1 ELSE 0 END AS 
TOT_BIL_LE_14, 
            CASE WHEN TOTAL_BILIRUBIN_NVAL_NUM BETWEEN 1.5 AND 2 THEN 1 ELSE 0 
END AS TOT_BIL_15_2, 
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            CASE WHEN TOTAL_BILIRUBIN_NVAL_NUM > 2 THEN 1 ELSE 0 END AS 
TOT_BIL_GT_2, 
            CASE WHEN CALCIUM_NVAL_NUM <= 7.9 THEN 1 ELSE 0 END AS 
CALCIUM_LE_79, 
            CASE WHEN CALCIUM_NVAL_NUM BETWEEN 8 AND 8.4 THEN 1 ELSE 0 END AS 
CALCIUM_8_84, 
            CASE WHEN CALCIUM_NVAL_NUM BETWEEN 8.5 AND 10.1 THEN 1 ELSE 0 END 
AS CALCIUM_85_101, 
            CASE WHEN CALCIUM_NVAL_NUM > 10.1 THEN 1 ELSE 0 END AS 
CALCIUM_GT_101, 
            CASE WHEN CREATININE_NVAL_NUM <=2 THEN 1 ELSE 0 END AS 
CREATININE_LE_2, 
            CASE WHEN CREATININE_NVAL_NUM > 2 THEN 1 ELSE 0 END AS 
CREATININE_GT_2, 
            CASE WHEN PRO_BNP_NVAL_NUM <= 8000 THEN 1 ELSE 0 END AS 
PRO_BNP_LE_8000, 
            CASE WHEN PRO_BNP_NVAL_NUM BETWEEN 8001 AND 18000 THEN 1 ELSE 0 
END AS PRO_BNP_8_18, 
            CASE WHEN PRO_BNP_NVAL_NUM > 18000 THEN 1 ELSE 0 END AS 
PRO_BNP_GT_18, 
            CASE WHEN BNP_NVAL_NUM <= 1200 THEN 1 ELSE 0 END AS BNP_LE12, 
            CASE WHEN BNP_NVAL_NUM BETWEEN 1201 AND 2400 THEN 1 ELSE 0 END AS 
BNP_12_24, 
            CASE WHEN BNP_NVAL_NUM > 2400 THEN 1 ELSE 0 END AS BNP_GT24, 
            CASE WHEN GLUCOSE_NVAL_NUM <=70 THEN 1 ELSE 0 END AS 
GLUCOSE_LE_70, 
            CASE WHEN GLUCOSE_NVAL_NUM BETWEEN 71 AND 135 THEN 1 ELSE 0 END AS 
GLUCOSE_71_135, 
            CASE WHEN GLUCOSE_NVAL_NUM BETWEEN 136 AND 165 THEN 1 ELSE 0 END 
AS GLUCOSE_136_165, 
            CASE WHEN GLUCOSE_NVAL_NUM > 165 THEN 1 ELSE 0 END AS 
GLUCOSE_GT_165, 
            CASE WHEN POTASSIUM_NVAL_NUM <= 3.2 THEN 1 ELSE 0 END AS 
POTASSIUM_LE_32, 
            CASE WHEN POTASSIUM_NVAL_NUM BETWEEN 3.3 AND 4.9 THEN 1 ELSE 0 END 
AS POTASSIUM_33_49, 
            CASE WHEN POTASSIUM_NVAL_NUM BETWEEN 5 AND 5.3 THEN 1 ELSE 0 END 
AS POTASSIUM_5_53, 
            CASE WHEN POTASSIUM_NVAL_NUM >5.3 THEN 1 ELSE 0 END AS 
POTASSIUM_GT_53, 
            CASE WHEN SODIUM_NVAL_NUM <= 130 THEN 1 ELSE 0 END AS 
SODIUM_LE_130, 
            CASE WHEN SODIUM_NVAL_NUM BETWEEN 131 AND 135 THEN 1 ELSE 0 END AS 
SODIUM_131_135, 
            CASE WHEN SODIUM_NVAL_NUM BETWEEN 136 AND 143 THEN 1 ELSE 0 END AS 
SODIUM_136_143, 
            CASE WHEN SODIUM_NVAL_NUM BETWEEN 144 AND 145 THEN 1 ELSE 0 END AS 
SODIUM_144_145, 
            CASE WHEN SODIUM_NVAL_NUM > 145 THEN 1 ELSE 0 END AS 
SODIUM_GT_145, 
            CASE WHEN ALKALINE_PHOS_NVAL_NUM <= 115 THEN 1 ELSE 0 END AS 
ALKALINE_PHOS_LE_115, 
            CASE WHEN ALKALINE_PHOS_NVAL_NUM BETWEEN 116 AND 220 THEN 1 ELSE 0 
END AS ALKALINE_PHOS_116_220, 
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            CASE WHEN ALKALINE_PHOS_NVAL_NUM BETWEEN 221 AND 630 THEN 1 ELSE 0 
END AS ALKALINE_PHOS_221_630, 
            CASE WHEN ALKALINE_PHOS_NVAL_NUM >630 THEN 1 ELSE 0 END AS 
ALKALINE_PHOS_GT_630, 
            CASE WHEN BUN_NVAL_NUM <= 25 THEN 1 ELSE 0 END AS BUN_LE_25, 
            CASE WHEN BUN_NVAL_NUM BETWEEN 26 AND 30 THEN 1 ELSE 0 END AS 
BUN_26_30, 
            CASE WHEN BUN_NVAL_NUM BETWEEN 31 AND 40 THEN 1 ELSE 0 END AS 
BUN_31_40, 
            CASE WHEN BUN_NVAL_NUM BETWEEN 41 AND 55 THEN 1 ELSE 0 END AS 
BUN_41_55, 
            CASE WHEN BUN_NVAL_NUM >55 THEN 1 ELSE 0 END AS BUN_GT_55, 
            CASE WHEN PH_ARTERIAL_NVAL_NUM <= 7.2 THEN 1 ELSE 0 END AS 
PH_ARTERIAL_LE_72, 
            CASE WHEN PH_ARTERIAL_NVAL_NUM BETWEEN 7.21 AND 7.3 THEN 1 ELSE 0 
END AS PH_ARTERIAL_721_73, 
            CASE WHEN PH_ARTERIAL_NVAL_NUM BETWEEN 7.31 AND 7.35 THEN 1 ELSE 0 
END AS PH_ARTERIAL_731_735, 
            CASE WHEN PH_ARTERIAL_NVAL_NUM BETWEEN 7.36 AND 7.48 THEN 1 ELSE 0 
END AS PH_ARTERIAL_736_748, 
            CASE WHEN PH_ARTERIAL_NVAL_NUM >7.48 THEN 1 ELSE 0 END AS 
PH_ARTERIAL_GT_748, 
            CASE WHEN PO2_ARTERIAL_NVAL_NUM <= 50 THEN 1 ELSE 0 END AS 
PO2_ARTERIAL_LE_50, 
            CASE WHEN PO2_ARTERIAL_NVAL_NUM BETWEEN 50.1 AND 55 THEN 1 ELSE 0 
END AS PO2_ARTERIAL_501_55, 
            CASE WHEN PO2_ARTERIAL_NVAL_NUM BETWEEN 55.1 AND 140 THEN 1 ELSE 0 
END AS PO2_ARTERIAL_551_140, 
            CASE WHEN PO2_ARTERIAL_NVAL_NUM > 140 THEN 1 ELSE 0 END AS 
PO2_ARTERIAL_GT_140, 
            CASE WHEN PCO2_ARTERIAL_NVAL_NUM <=35 THEN 1 ELSE 0 END AS 
PCO2_ARTERIAL_LE_35, 
            CASE WHEN PCO2_ARTERIAL_NVAL_NUM BETWEEN 36 AND 50 THEN 1 ELSE 0 
END AS PCO2_ARTERIAL_36_50, 
            CASE WHEN PCO2_ARTERIAL_NVAL_NUM > 50 THEN 1 ELSE 0 END AS 
PCO2_ARTERIAL_GT_50, 
            CASE WHEN PTT_NVAL_NUM <= 22 THEN 1 ELSE 0 END AS PTT_LE_22, 
            CASE WHEN PTT_NVAL_NUM BETWEEN 23 AND 45 THEN 1 ELSE 0 END AS 
PTT_23_45, 
            CASE WHEN PTT_NVAL_NUM BETWEEN 45.1 AND 55 THEN 1  ELSE 0 END AS 
PTT_451_55, 
            CASE WHEN PTT_NVAL_NUM > 55 THEN 1 ELSE 0 END AS PTT_GT_55, 
            CASE WHEN PT_INR_NVAL_NUM <=1.1 THEN 1 ELSE 0 END AS PT_INR_LE_11, 
            CASE WHEN PT_INR_NVAL_NUM BETWEEN 1.11 AND 1.4 THEN 1 ELSE 0 END 
AS PT_INR_111_14, 
            CASE WHEN PT_INR_NVAL_NUM BETWEEN 1.41 AND 2 THEN 1 ELSE 0 END AS 
PT_INR_141_2, 
            CASE WHEN PT_INR_NVAL_NUM BETWEEN 2.1 AND 5 THEN 1 ELSE 0 END AS 
PT_INR_21_5, 
            CASE WHEN PT_INR_NVAL_NUM > 5 THEN 1 ELSE 0 END AS PT_INR_GT_5, 
            CASE WHEN BANDS_NVAL_NUM <=6 THEN 1 ELSE 0 END AS BANDS_LE_6, 




            CASE WHEN BANDS_NVAL_NUM BETWEEN 14 AND 32 THEN 1 ELSE 0 END AS 
BANDS_14_32, 
            CASE WHEN BANDS_NVAL_NUM > 32 THEN 1 ELSE 0 END AS BANDS_GT_32, 
            CASE WHEN HB_NVAL_NUM <=10 THEN 1 ELSE 0 END AS HB_LE_10, 
            CASE WHEN HB_NVAL_NUM BETWEEN 11 AND 18 THEN 1 ELSE 0 END AS 
HB_11_18, 
            CASE WHEN HB_NVAL_NUM > 18 THEN 1 ELSE 0 END AS HB_GT_18, 
            CASE WHEN PLATELETS_NVAL_NUM <=115 THEN 1 ELSE 0 END AS 
PLATELETS_LE_115, 
            CASE WHEN PLATELETS_NVAL_NUM BETWEEN 115.1 AND 150 THEN 1 ELSE 0 
END AS PLATELETS_115_150, 
            CASE WHEN PLATELETS_NVAL_NUM BETWEEN 150.1 AND 420 THEN 1 ELSE 0 
END AS PLATELETS_150_420, 
            CASE WHEN PLATELETS_NVAL_NUM > 420 THEN 1 ELSE 0 END AS 
PLATELETS_GT_420, 
            CASE WHEN WBC_NVAL_NUM <=4.3 THEN 1 ELSE 0 END AS WBC_LE_43, 
            CASE WHEN WBC_NVAL_NUM BETWEEN 4.4 AND 10.9 THEN 1 ELSE 0 END AS 
WBC_44_109, 
            CASE WHEN WBC_NVAL_NUM BETWEEN 11 AND 14.1 THEN 1 ELSE 0 END AS 
WBC_11_141, 
            CASE WHEN WBC_NVAL_NUM BETWEEN 14.2 AND 19.8 THEN 1 ELSE 0 END AS 
WBC_142_198, 
            CASE WHEN WBC_NVAL_NUM > 19.8 THEN 1 ELSE 0 END AS WBC_GT_198, 
            CASE WHEN (TROP_CPK_LAB_LABEL = 'TROPONIN_1'  
                        AND TROP_CPK_NVAL_NUM <= 0.04) 
                    OR 
                        (TROP_CPK_LAB_LABEL = 'CPK_MB' 
                        AND TROP_CPK_NVAL_NUM <= 2) 
                    THEN 1 ELSE 0  
                    END AS TROP_CPK_0, 
            CASE WHEN (TROP_CPK_LAB_LABEL = 'TROPONIN_1' 
                        AND TROP_CPK_NVAL_NUM BETWEEN 0.05 AND 0.1) 
                    OR  
                        (TROP_CPK_LAB_LABEL = 'CPK_MB' 
                        AND TROP_CPK_NVAL_NUM BETWEEN 3 AND 5) 
                    THEN 1 ELSE 0 
                    END AS TROP_CPK_2, 
            CASE WHEN (TROP_CPK_LAB_LABEL = 'TROPONIN_1' 
                        AND TROP_CPK_NVAL_NUM BETWEEN 0.11 AND 0.2) 
                    OR 
                        (TROP_CPK_LAB_LABEL = 'CPK_MB' 
                        AND TROP_CPK_NVAL_NUM BETWEEN 6 AND 10) 
                    THEN 1 ELSE 0 
                    END AS TROP_CPK_4, 
            CASE WHEN (TROP_CPK_LAB_LABEL = 'TROPONIN_1' 
                        AND TROP_CPK_NVAL_NUM BETWEEN 0.21 AND 0.3) 
                    OR 
                        (TROP_CPK_LAB_LABEL = 'CPK_MB' 
                        AND TROP_CPK_NVAL_NUM BETWEEN 11 AND 34) 
                    THEN 1 ELSE 0 
                    END AS TROP_CPK_8, 
            CASE WHEN (TROP_CPK_LAB_LABEL = 'TROPONIN_1' 
                        AND TROP_CPK_NVAL_NUM >0.3) 
                    OR 
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                        (TROP_CPK_LAB_LABEL = 'CPK_MB' 
                        AND TROP_CPK_NVAL_NUM > 34) 
                    THEN 1 ELSE 0 
                    END AS TROP_CPK_13 
    FROM JGARDNER.TABAK_SCORE TS 
    ]'; 
     
    --DBMS_OUTPUT.PUT_LINE(sql_string); 
    execute immediate sql_string; 









APPENDIX D – SQL SCRIPTS TO IDENTIFY PREGNANT 
POPULATION AND ASSOCIATED VARIABLES 
CREATE OR REPLACE PROCEDURE "JGARDNER"."PREG_FACT_TABLE_PROC_DEID" 
 
AS 
--nightherondata.visit_dimension_2 is date shifted 
--heronloader.visit_dimension is NOT date shifted 
--nightherondata.patient_dimension is NOT date shifted 
--heronloader.patient_dimension is NOT date shifted 
 
    my_date date; 
    rec_count int; 
    i int; 
    sql_string varchar2(32767); 
    table_name varchar2(100); 
    temp_table varchar2(100); 
    window_start_date date; 
    window_end_date date; 
 
    BEGIN 
 
    DBMS_OUTPUT.put_line('Start of PREG_FACT_TABLE_PROC_DEID'); 
    window_start_date:= to_date('2015/11/01', 'yyyy/mm/dd'); 
    window_end_date:= to_date('2016/12/31', 'yyyy/mm/dd'); 
 
    DBMS_OUTPUT.put_line('window_start_date = '|| window_start_date); 
    DBMS_OUTPUT.put_line('window_end_date = '|| window_end_date); 
    --DBMS_OUTPUT.put_line('window_start_date - 280 = '|| (window_start_date - 
270)); 
     
    table_name:='JGARDNER.PREGNANCY_PROJECT_FACT_TABLE'; 
    select sysdate into my_date from dual; 
    dbms_output.put_line('Creating '||table_name||' table at ' || my_date); 
    drop_table(table_name); 
 
 
    --Create table of PREGNANCY_PROJECT_FACT_TABLE: 
    temp_table:='JGARDNER.PREGNANCY_PROJECT_FACT_TABLE'; 
    drop_table(temp_table); 
    sql_string := q'[ 
CREATE TABLE ]'||temp_table||q'# AS 
WITH 
    VARIABLES(VARIABLE_CD, TAG) AS 
 
--1. SUPERVISION OF PREGNANCY 
        (select concept_cd VARIABLE_CD, 'SUPERVISION OF PREGNANCY' TAG 
            from BlueHeronData.ITCP_DIAGNOSIS  
            where C_FULLNAME = '\UNMCDIAG\ICD10CM\(Z00-Z99) Fact~rmj9\(Z30-
Z39) Pers~awcc\(Z33) Pregnant state\' 
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        UNION 
        select concept_cd VARIABLE_CD, 'SUPERVISION OF PREGNANCY' TAG 
            from BlueHeronData.ITCP_DIAGNOSIS  
            where C_FULLNAME = '\UNMCDIAG\ICD10CM\(Z00-Z99) Fact~rmj9\(Z30-
Z39) Pers~awcc\(Z34) Encounte~f8zh\' 
             
--2. COMPLICATIONS OF DELIVERY 
        UNION  
        select concept_cd VARIABLE_CD, 'COMPLICATIONS OF DELIVERY' TAG 
            from BlueHeronData.ITCP_DIAGNOSIS    
            where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) Preg~a433\(O60-
O77) Comp~zbt1\'   
        union 
        select concept_cd VARIABLE_CD, 'COMPLICATIONS OF DELIVERY' TAG 
            from BlueHeronData.ITCP_DIAGNOSIS    
            where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) Preg~a433\(O80-
O82) Enco~1n2b\'   
        union 
        select concept_cd VARIABLE_CD, 'COMPLICATIONS OF DELIVERY' TAG 
            from BlueHeronData.ITCP_DIAGNOSIS    
            where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) Preg~a433\(O85-
O92) Comp~cvwo\' 
             
--3. DISORDERS DURING PREGNANCY 
        union 
        select concept_cd VARIABLE_CD, 'DISORDERS DURING PREGNANCY' TAG 
            from BlueHeronData.ITCP_DIAGNOSIS    
            where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) Preg~a433\(O09-
O09) Supe~n4q2\'   
        union  
        select concept_cd VARIABLE_CD, 'DISORDERS DURING PREGNANCY' TAG 
            from BlueHeronData.ITCP_DIAGNOSIS    
            where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) Preg~a433\(O10-
O16) Edem~7xf2\'   
        union  
        select concept_cd VARIABLE_CD, 'DISORDERS DURING PREGNANCY' TAG 
            from BlueHeronData.ITCP_DIAGNOSIS    
            where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) Preg~a433\(O20-
O29) Othe~2ok2\'   
        union  
        select concept_cd VARIABLE_CD, 'DISORDERS DURING PREGNANCY' TAG 
            from BlueHeronData.ITCP_DIAGNOSIS    
            where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) Preg~a433\(O94-
O9A) Othe~id4e\(O98) Maternal~73qv\'   
        union  
        select concept_cd VARIABLE_CD, 'DISORDERS DURING PREGNANCY' TAG 
            from BlueHeronData.ITCP_DIAGNOSIS    
            where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) Preg~a433\(O94-
O9A) Othe~id4e\(O99) Other ma~dyic\'  
 
--4.  'PREGNANCY COMPLICATIONS' 
        union 
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        select concept_cd VARIABLE_CD, 'PREGNANCY COMPLICATIONS' TAG from  
BlueHeronData.ITCP_DIAGNOSIS   where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) 
Preg~a433\(O30-O48) Mate~b9yp\(O31) Complica~dv5r\'   
        union  
        select concept_cd VARIABLE_CD, 'PREGNANCY COMPLICATIONS' TAG from  
BlueHeronData.ITCP_DIAGNOSIS   where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) 
Preg~a433\(O30-O48) Mate~b9yp\(O32) Maternal~2pdg\'   
        union  
        select concept_cd VARIABLE_CD, 'PREGNANCY COMPLICATIONS' TAG from  
BlueHeronData.ITCP_DIAGNOSIS   where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) 
Preg~a433\(O30-O48) Mate~b9yp\(O33) Maternal~17i3\'   
        union  
        select concept_cd VARIABLE_CD, 'PREGNANCY COMPLICATIONS' TAG from  
BlueHeronData.ITCP_DIAGNOSIS   where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) 
Preg~a433\(O30-O48) Mate~b9yp\(O34) Maternal~3tra\'   
        union  
        select concept_cd VARIABLE_CD, 'PREGNANCY COMPLICATIONS' TAG from  
BlueHeronData.ITCP_DIAGNOSIS   where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) 
Preg~a433\(O30-O48) Mate~b9yp\(O35) Maternal~zs1x\'   
        union  
        select concept_cd VARIABLE_CD, 'PREGNANCY COMPLICATIONS' TAG from  
BlueHeronData.ITCP_DIAGNOSIS   where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) 
Preg~a433\(O30-O48) Mate~b9yp\(O36) Maternal~kssm\'   
        union  
        select concept_cd, 'PREGNANCY COMPLICATIONS' TAG from  
BlueHeronData.ITCP_DIAGNOSIS   where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) 
Preg~a433\(O30-O48) Mate~b9yp\(O40) Polyhydramnios\'   
        union  
        select concept_cd VARIABLE_CD, 'PREGNANCY COMPLICATIONS' TAG from  
BlueHeronData.ITCP_DIAGNOSIS   where C_FULLNAME = '\UNMCDIAG\ICD10CM\(O00-O9A) 
Preg~a433\(O30-O48) Mate~b9yp\(O41) Other di~8hg3\' 
         
--5.  'OBSTETRIC ULTRASOUND' 
        union 
        select CONCEPT_CD VARIABLE_CD, 'OBSTETRIC ULTRASOUND' TAG from  
BlueHeronData.CONCEPT_DIMENSION   where CONCEPT_PATH LIKE 
'\UNMC\Procedures\cpt?_codes\70000-79999\76500-76999\76801-76857\76801-
76828\%' ESCAPE '?' 
 
--6.  'ABO AND RH GROUP' 
        union 
        select concept_cd VARIABLE_CD, 'ABO AND RH GROUP' TAG  
            from BlueHeronData.concept_dimension    
            where concept_path LIKE '\UNMC\Laboratory Results\Blood and body 
fluids\Blood typing and transfusion\882-1\%' 
            or concept_cd in ('LOINC:882-1','LOINC:884-7','LOINC:77397-
8','LOINC:972-0', 
                    'LOINC:34961-3','LOINC:978-7','LOINC:10331-7','LOINC:1305-
2') 
 
--7.  'HCG IN SERUM EIA' 
        union 
        select concept_cd VARIABLE_CD, 'HCG IN SERUM EIA' TAG  
            from BlueHeronData.concept_dimension    
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            where concept_path LIKE '\HH\LP29693-6\LP7786-9\20415-6\%' 
            or concept_cd in ('LOINC:20415-6','LOINC:80384-1','LOINC:80385-8') 
            group by concept_cd, 'HCG IN SERUM EIA' 
 
--8.  'HCG IN URINE' 
        union 
        select concept_cd VARIABLE_CD, 'HCG IN URINE' TAG  
            from  BlueHeronData.concept_dimension    
            where concept_path LIKE '\HH\LP29693-6\LP7786-9\2106-3\%' 
            or concept_cd in ('LOINC:2112-1','LOINC:2106-3','LOINC:2113-
9','LOINC:2107-1','LOINC:2114-7', 
                    'LOINC:25372-4') 
            group by concept_cd, 'HCG IN URINE' 
         
--9.  'HCG IN SERUM_PLASMA' 
        union 
        select concept_cd VARIABLE_CD, 'HCG IN SERUM_PLASMA' TAG  
            from BlueHeronData.concept_dimension   
            where concept_path LIKE '\HH\LP29693-6\LP7786-9\2118-8\%' 
            or concept_cd in ('LOINC:19080-1','LOINC:19180-9','LOINC:2115-
4','LOINC:2110-5','LOINC:2111-3', 
                    'LOINC:2118-8','LOINC:2119-6','LOINC:21198-
7','LOINC:20994-0','LOINC:25373-2', 
                    'LOINC:34670-0','LOINC:45194-8','LOINC:55869-
2','LOINC:56497-1') 
            group by concept_cd, 'HCG IN SERUM_PLASMA' 
 
--10. 'DISORDER OF PREGNANCY' 
        union 
        select concept_cd VARIABLE_CD, 'DISORDER OF PREGNANCY' TAG from  
BlueHeronData.ITCP_DIAGNOSIS   where C_FULLNAME = 
'\UNMCDIAG\SNOMEDCT\404684003\250171008\248982007\118185001\77386006\' 
 
--11. 'PATIENT CURRENTLY PREGNANT' 
        union 
        select concept_cd VARIABLE_CD, 'PATIENT CURRENTLY PREGNANT' TAG from  
BlueHeronData.ITCP_DIAGNOSIS   where C_FULLNAME = 
'\UNMCDIAG\SNOMEDCT\404684003\250171008\248982007\118185001\77386006\' 
 
--12. 'MULTIPLE PREGNANCY' 
        union 
        select concept_cd VARIABLE_CD, 'MULTIPLE PREGNANCY' TAG from  




--13. 'VISIT OBSTETRIC CLINIC' 
        union 
        select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\10\10601054\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  




        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\10\10601030\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\10\10601051\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\10\10801042\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\10\10601028\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\10\10604005\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\10\10701043\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\10\10701044\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\10\10601052\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\10\10601053\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\10\10801019\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\10\10801009\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\10\10801018\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\10\10601035\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\10\10701045\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\10\10601072\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\10\10801034\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\10\10601034\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  




        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\10\10801015\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\10\10601031\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\20\20101054\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\20\20101073\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\20\20101030\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\20\20104007\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\20\20101051\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\20\20103003\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\20\20101028\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\20\20104005\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\20\20101052\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\20\20101055\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\20\20101053\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\20\20501019\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\20\20501009\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\20\20501018\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\20\20101035\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  




        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\20\20501034\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\20\20101034\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\20\20501017\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\20\20501015\%' 
        UNION select concept_cd VARIABLE_CD, 'VISIT OBSTETRIC CLINIC' TAG from  
BlueHeronData.concept_dimension   where concept_path like 
'\i2b2\Encounters\Service Areas\20\20101031\%' 
 
--14. 'UTERUS FUNDAL HEIGHT' 
        union 
        select concept_cd VARIABLE_CD, 'UTERUS FUNDAL HEIGHT' TAG  
            from BlueHeronData.concept_dimension    
            where concept_path LIKE '\HH\LP29694-4\LP29717-3\LP7830-5\11881-
0\%' 
     
--15. 'FETAL HEART RATE' 
        union 
        select concept_cd VARIABLE_CD, 'FETAL HEART RATE' TAG  
            from  BlueHeronData.concept_dimension    
            where concept_path LIKE '\HH\LP29694-4\LP29711-6\LP7800-8\55283-
6\%' 
 
--16. 'FETAL MOVEMENT' 
        union 
        select concept_cd VARIABLE_CD, 'FETAL MOVEMENT' TAG  
            from BlueHeronData.concept_dimension    
            where concept_path LIKE '\HH\LP29694-4\LP29711-6\LP7800-8\57088-
7\%' 
    ), 
 
    PROVIDERS(PROVIDER_ID, PROVIDER_NAME, PROVIDER_PATH) AS 
    (SELECT PROVIDER_ID, NAME_CHAR, PROVIDER_PATH 
        FROM BLUEHERONDATA.PROVIDER_DIMENSION PD 
        WHERE REGEXP_LIKE(PD.NAME_CHAR, '*[^ 0123456789 ]')), 
     
    PATIENTS_WITHIN_50_MILES(PATIENT_NUM) AS 
    (SELECT DISTINCT PATIENT_NUM 
        FROM BLUEHERONDATA.OBSERVATION_FACT 
        WHERE CONCEPT_CD IN ('DEM|GEO|UNMC:50mi', 
            'DEM|GEO|UNMC:10mi', 
            'DEM|GEO|UNMC:15mi', 
            'DEM|GEO|UNMC:20mi', 
            'DEM|GEO|UNMC:5mi') 
        ) 
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SELECT ENCOUNTER_NUM,  
        O.PATIENT_NUM,  
        O.CONCEPT_CD,  
        --PROVIDER_ID, 
        P.PROVIDER_NAME, 
        P.PROVIDER_PATH, 
        O.START_DATE,  
        O.MODIFIER_CD,  
        O.INSTANCE_NUM,  
        O.VALTYPE_CD,  
        O.TVAL_CHAR,  
        O.NVAL_NUM,  
        O.VALUEFLAG_CD,  
        O.QUANTITY_NUM,  
        O.UNITS_CD,  
        O.END_DATE,  
        --LOCATION_CD, 
        LD.NAME_CHAR AS ENC_LOCATION, 
        O.UPLOAD_ID, 
        V.VARIABLE_CD, 
        V.TAG, 
        P50.PATIENT_NUM AS MILES 
        FROM BLUEHERONDATA.OBSERVATION_FACT O 
        LEFT JOIN BLUEHERONDATA.LOCATION_DIMENSION LD 
            ON O.LOCATION_CD = LD.LOCATION_CD 
        LEFT JOIN PROVIDERS P 
            ON O.PROVIDER_ID = P.PROVIDER_ID 
        JOIN VARIABLES V 
            ON O.CONCEPT_CD = V.VARIABLE_CD 
        LEFT JOIN PATIENTS_WITHIN_50_MILES P50 
            ON O.PATIENT_NUM = P50.PATIENT_NUM 
        #'; 
 
    --dbms_output.put_line(sql_string); 
    execute immediate sql_string; 
    DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table); 
 
 
--PREG_FACT_TABLE_PROC_DEID UPDATE POSITIVE HCG URINE: 
    sql_string := q'[  
    UPDATE ]'||temp_table||q'[ 
        SET TAG = 'HCG IN URINE - POS' 
        WHERE   TAG = 'HCG IN URINE' 
                AND modifier_cd = '@'   
                AND valtype_cd = 'T'  




+')   
        ]'; 
 
    --dbms_output.put_line(sql_string); 
    execute immediate sql_string; 
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    DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table); 
 
--PREG_FACT_TABLE_PROC_DEID UPDATE NEGATIVE HCG URINE: 
    sql_string := q'[  
    UPDATE ]'||temp_table||q'[ 
        SET TAG = 'HCG IN URINE - NEG/UNK' 
        WHERE   TAG = 'HCG IN URINE' 
                AND modifier_cd = '@'   
                AND valtype_cd = 'T' 









TIVE','neg x 1','ng','NG','ngative','nrgative','Normal','No Specimen 
Received','NO SPECIMEN RECEIVED, SEE SERUM PREG REPORT.','Not Done','See 
text','See Text','SEE TEXT','unsure','weak posit','WRONG ORDER','PARTIAL 




        ]'; 
 
    --dbms_output.put_line(sql_string); 
    execute immediate sql_string; 
    DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table); 
         
 
 
--PREG_FACT_TABLE_PROC_DEID UPDATE POSITIVE HCG URINE: 
    sql_string := q'[  
    UPDATE ]'||temp_table||q'[ 
        SET TAG = 'HCG IN URINE - POS' 
        WHERE   TAG = 'HCG IN URINE' 
                AND modifier_cd = '@'   
                AND valtype_cd = 'N'  
                AND NVAL_NUM > 5 
        ]'; 
 
    --dbms_output.put_line(sql_string); 
    execute immediate sql_string; 
    DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table); 
 
--PREG_FACT_TABLE_PROC_DEID UPDATE NEGATIVE HCG URINE: 
    sql_string := q'[  
    UPDATE ]'||temp_table||q'[ 
        SET TAG = 'HCG IN URINE - NEG/UNK' 
        WHERE   TAG = 'HCG IN URINE' 
                AND modifier_cd = '@'   
                AND valtype_cd = 'N' 
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                AND NVAL_NUM <= 5 
        ]'; 
 
    --dbms_output.put_line(sql_string); 
    execute immediate sql_string; 
    DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table); 
         
 
--PREG_FACT_TABLE_PROC_DEID UPDATE HCG IN SERUM_PLASMA - POSTIVE: 
    sql_string := q'[  
    UPDATE ]'||temp_table||q'[ 
        SET TAG = 'HCG IN SERUM/PLASMA -POS' 
        WHERE   TAG = 'HCG IN SERUM_PLASMA' 
                AND modifier_cd = '@'   
                AND valtype_cd = 'T'  
                AND tval_char IN ('pos','Positive','POSITIVE') 
        ]'; 
 
    --dbms_output.put_line(sql_string); 
    execute immediate sql_string; 
    DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table); 
 
     
--PREG_FACT_TABLE_PROC_DEID UPDATE HCG IN SERUM_PLASMA - NEGATIVE/UNKNOWN: 
    sql_string := q'[  
    UPDATE ]'||temp_table||q'[ 
        SET TAG = 'HCG IN SERUM/PLASMA -NEG/U' 
        WHERE   TAG = 'HCG IN SERUM_PLASMA' 
                AND modifier_cd = '@'   
                AND valtype_cd = 'T' 
                AND TVAL_CHAR IN ('neg','negative','Negative','<SEE 
TEXT>','E', 
                    'Equicical, suggest repeating.','Incorrect 
Order','PENDING', 
                    'See note','See Text','SEE TEXT', 'NEGATIVE') 
        ]'; 
 
    --dbms_output.put_line(sql_string); 
    execute immediate sql_string; 
    DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table); 
 
     
--PREG_FACT_TABLE_PROC_DEID UPDATE HCG IN SERUM_PLASMA - POSTIVE: 
    sql_string := q'[  
    UPDATE ]'||temp_table||q'[ 
        SET TAG = 'HCG IN SERUM/PLASMA -POS' 
        WHERE   TAG = 'HCG IN SERUM_PLASMA' 
                AND modifier_cd = '@'   
                AND valtype_cd = 'N'  
                AND NVAL_NUM > 5 
        ]'; 
 
    --dbms_output.put_line(sql_string); 
    execute immediate sql_string; 
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    DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table); 
 
--PREG_FACT_TABLE_PROC_DEID UPDATE HCG IN SERUM_PLASMA - NEGATIVE/UNKNOWN: 
    sql_string := q'[  
    UPDATE ]'||temp_table||q'[ 
        SET TAG = 'HCG IN SERUM/PLASMA -NEG/U' 
        WHERE   TAG = 'HCG IN SERUM_PLASMA' 
                AND modifier_cd = '@'   
                AND valtype_cd = 'N' 
                AND NVAL_NUM <= 5 
        ]'; 
 
    --dbms_output.put_line(sql_string); 
    execute immediate sql_string; 
    DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table); 
         
 
         
--PREG_FACT_TABLE_PROC_DEID UPDATE FETAL HEART RATE - POSITIVE: 
    sql_string := q'[  
    UPDATE ]'||temp_table||q'# 
        SET TAG = 'FETAL HEART RATE - POS' 
        WHERE   TAG = 'FETAL HEART RATE' 
                AND modifier_cd = '@'   
                AND valtype_cd = 'T' 
                    AND (upper(TVAL_CHAR) IN ('PRESENT', 'POS', 'PRESENT ', 
'PRSENT', 'PRES', 'PRESENT/PRESEMT','PRESE', 
                            'PRESETN', 'PRESEMT', 'PRESENT ON US', 'PRESNT', 
'PRESENT ON ULTRASOUND', 'PRESNET', 
                            'PREENT', 'PRESEENT', 'PRESESNT', 'PRESENET', 
'PRESENTS', 'PRESET') 
                    OR TVAL_CHAR LIKE '%+%' 
                    OR UPPER(TVAL_CHAR) LIKE '%POS%' 
                    OR REGEXP_LIKE(TVAL_CHAR, '*[1-9]')) 
 
        #'; 
    --dbms_output.put_line(sql_string); 
    execute immediate sql_string; 
    DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table); 
 
 
--PREG_FACT_TABLE_PROC_DEID UPDATE FETAL HEART RATE - NEGATIVE: 
    sql_string := q'[  
    UPDATE ]'||temp_table||q'# 
        SET TAG = 'FETAL HEART RATE - N/U' 
        WHERE   TAG = 'FETAL HEART RATE' 
                AND modifier_cd = '@'   
                AND valtype_cd = 'T' 
                    AND upper(TVAL_CHAR) IN ('ABSENT', 'NEG', 'NOT 
HEARD','NONE', 'NEGATIVE', 'NO', 'NOT SEEN', 
                            'NOT PRESENT') 
                     
        #'; 
    --dbms_output.put_line(sql_string); 
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    execute immediate sql_string; 
    DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table); 
 
     
--PREG_FACT_TABLE_PROC_DEID UPDATE FETAL HEART RATE - POSITIVE: 
    sql_string := q'[  
    UPDATE ]'||temp_table||q'[ 
        SET TAG = 'FETAL HEART RATE - POS' 
        WHERE   TAG = 'FETAL HEART RATE' 
                AND modifier_cd = '@'   
                AND VALTYPE_CD = 'N' 
                AND NVAL_NUM > 0 
        ]'; 
    --dbms_output.put_line(sql_string); 
    execute immediate sql_string; 
    DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table); 
 
     
--PREG_FACT_TABLE_PROC_DEID UPDATE FETAL HEART RATE - NEGATIVE/UNKNOWN: 
    sql_string := q'[  
    UPDATE ]'||temp_table||q'[ 
        SET TAG = 'FETAL HEART RATE - N/U' 
        WHERE   TAG = 'FETAL HEART RATE' 
                AND modifier_cd = '@'   
                AND VALTYPE_CD = 'N' 
                AND NVAL_NUM = 0 
        ]'; 
    --dbms_output.put_line(sql_string); 
    execute immediate sql_string; 
    DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table); 
 
     
--PREG_FACT_TABLE_PROC_DEID UPDATE FETAL MOVEMENT - POSITIVE: 
    sql_string := q'[  
    UPDATE ]'||temp_table||q'[ 
        SET TAG = 'FETAL MOVEMENT - POS' 
        WHERE   TAG = 'FETAL MOVEMENT' 
                AND modifier_cd = '@'   
                AND VALTYPE_CD = 'T' 
                AND TVAL_CHAR IN ('Increased','Present') 
        ]'; 
    --'Absent','Decreased' are tval_char not included in this logic. Tag from 
earlier in procedure remains unchanged. 
    --dbms_output.put_line(sql_string); 
    execute immediate sql_string; 
    DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table); 
     
     
--PREG_FACT_TABLE_PROC_DEID UPDATE HCG IN SERUM EIA  POSITIVE: 
    sql_string := q'[  
    UPDATE ]'||temp_table||q'[ 
        SET TAG = 'HCG IN SERUM EIA - POS' 
        WHERE   TAG = 'HCG IN SERUM EIA' 
                AND modifier_cd = '@'   
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                AND VALTYPE_CD = 'N' 
                AND NVAL_NUM > 5 
        ]'; 
    --dbms_output.put_line(sql_string); 
    execute immediate sql_string; 
    DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table); 
     
     
--PREG_FACT_TABLE_PROC_DEID UPDATE HCG IN SERUM EIA  NEGATIVE: 
    sql_string := q'[  
    UPDATE ]'||temp_table||q'[ 
        SET TAG = 'HCG IN SERUM EIA - N/U' 
        WHERE   TAG = 'HCG IN SERUM EIA' 
                AND modifier_cd = '@'   
                AND VALTYPE_CD = 'N' 
                AND NVAL_NUM <= 5 
        ]'; 
    --dbms_output.put_line(sql_string); 
    execute immediate sql_string; 
    DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table); 
     
     
--Create PREG_HEALTH_MAIN 
    temp_table:='JGARDNER.PREG_HEALTH_MAIN'; 
    drop_table(temp_table); 
    sql_string := q'[ 
    CREATE TABLE ]'||temp_table||q'# AS 
    WITH 
    PROVIDERS(PROVIDER_ID, PROVIDER_NAME, PROVIDER_PATH) AS 
    (SELECT PROVIDER_ID, NAME_CHAR, PROVIDER_PATH 
        FROM BLUEHERONDATA.PROVIDER_DIMENSION PD 
        WHERE REGEXP_LIKE(PD.NAME_CHAR, '*[^ 0123456789 ]')) 
 
    SELECT O.ENCOUNTER_NUM,  
            O.PATIENT_NUM,  
            O.CONCEPT_CD,  
            P.PROVIDER_NAME, 
            P.PROVIDER_PATH, 
            VD.START_DATE,  
            O.MODIFIER_CD,  
            O.INSTANCE_NUM,  
            O.VALTYPE_CD,  
            O.TVAL_CHAR,  
            O.NVAL_NUM,  
            VD.END_DATE,  
            LD.NAME_CHAR AS ENC_LOCATION 
        FROM BLUEHERONDATA.OBSERVATION_FACT O 
        JOIN JGARDNER.PREGNANCY_PROJECT_FACT_TABLE P 
            ON O.PATIENT_NUM = P.PATIENT_NUM 
        LEFT JOIN BLUEHERONDATA.LOCATION_DIMENSION LD 
            ON O.LOCATION_CD = LD.LOCATION_CD 
        LEFT JOIN PROVIDERS P 
            ON O.PROVIDER_ID = P.PROVIDER_ID 
        JOIN BLUEHERONDATA.VISIT_DIMENSION VD 
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            ON O.ENCOUNTER_NUM = VD.ENCOUNTER_NUM 
        WHERE O.CONCEPT_CD IN 
('CPT4:99381','CPT4:99382','CPT4:99383','CPT4:99384','CPT4:99385','CPT4:99386'
, 
                
'CPT4:99387','CPT4:99391','CPT4:99392','CPT4:99393','CPT4:99394','CPT4:99395', 
                'CPT4:99396','CPT4:99397') 
        AND VD.ENC_TYPE IN ('AV', 'IP', 'EI', 'ED', 'IS') 
        GROUP BY O.ENCOUNTER_NUM,  
            O.PATIENT_NUM,  
            O.CONCEPT_CD,  
            P.PROVIDER_NAME, 
            P.PROVIDER_PATH, 
            VD.START_DATE,  
            O.MODIFIER_CD,  
            O.INSTANCE_NUM,  
            O.VALTYPE_CD,  
            O.TVAL_CHAR,  
            O.NVAL_NUM,  
            VD.END_DATE,  
            LD.NAME_CHAR 
    #'; 
 
-- DBMS_OUTPUT.PUT_LINE(sql_string); 
execute immediate sql_string; 
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||table_name||'.'); 
commit; 
     
     
     
     
/*               
drop temporary tables: 
    temp_table:='JGARDNER.PREGNANCY_PROJECT_PATIENTS'; 
        drop_table(temp_table); 
    temp_table:='JGARDNER.PREGNANCY_PROJECT_RACE'; 
        drop_table(temp_table); 
    temp_table:='JGARDNER.PREGNANCY_PROJECT_RESIDENCE'; 
        drop_table(temp_table); 
    temp_table:='JGARDNER.PREGNANCY_PROJECT_DEMOGRAPHICS'; 








CREATE OR REPLACE PROCEDURE "JGARDNER"."PREG_FACT_TABLE_PROC" 
 
AS 
--nightherondata.visit_dimension_2 is date shifted 
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--heronloader.visit_dimension is NOT date shifted 
--nightherondata.patient_dimension is NOT date shifted 
--heronloader.patient_dimension is NOT date shifted 
 
    my_date date; 
    rec_count int; 
    i int; 
    sql_string varchar2(32767); 
    table_name varchar2(100); 
    temp_table varchar2(100); 
    window_start_date date; 
    window_end_date date; 
 
    BEGIN 
 
    DBMS_OUTPUT.put_line('Start of PREG_FACT_TABLE_PROC'); 
    window_start_date:= to_date('2015/11/01', 'yyyy/mm/dd'); 
    window_end_date:= to_date('2016/12/31', 'yyyy/mm/dd'); 
 
    DBMS_OUTPUT.put_line('window_start_date = '|| window_start_date); 
    DBMS_OUTPUT.put_line('window_end_date = '|| window_end_date); 
    --DBMS_OUTPUT.put_line('window_start_date - 280 = '|| (window_start_date - 
270)); 
     
    table_name:='JGARDNER.PREGNANCY_PROJECT_FACT_TABLE'; 
    select sysdate into my_date from dual; 
    dbms_output.put_line('Creating '||table_name||' table at ' || my_date); 
    drop_table(table_name); 
 
 
    --Create table of PREG_FACT_TABLE: 
    temp_table:='JGARDNER.PREG_FACT_TABLE'; 
    drop_table(temp_table); 
    sql_string := q'[ 
    CREATE TABLE ]'||temp_table||q'[ AS 
    SELECT ENCOUNTER_NUM, 
            PATIENT_NUM, 
            CONCEPT_CD, 
            PROVIDER_NAME, 
            PROVIDER_PATH, 
            START_DATE, 
            MODIFIER_CD, 
            INSTANCE_NUM, 
            VALTYPE_CD, 
            TVAL_CHAR, 
            NVAL_NUM, 
            VALUEFLAG_CD, 
            QUANTITY_NUM, 
            UNITS_CD, 
            END_DATE, 
            ENC_LOCATION, 
            UPLOAD_ID, 
            VARIABLE_CD, 
            TAG, 
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            MILES 
        FROM JGARDNER.PREGNANCY_PROJECT_FACT_TABLE@DEID 
        ]'; 
 
    --dbms_output.put_line(sql_string); 
    execute immediate sql_string; 




--Limit facts to date range +/- 90 days 
    temp_table:='JGARDNER.PREG_FACT_TABLE_DATES'; 
    drop_table(temp_table); 
    sql_string := q'[ 
    CREATE TABLE ]'||temp_table||q'[ AS 
        SELECT PM.PATIENT_IDE,  
                PFT.ENCOUNTER_NUM, 
                PFT.PATIENT_NUM, 
                PFT.CONCEPT_CD, 
                PFT.PROVIDER_NAME, 
                PFT.PROVIDER_PATH, 
                (PFT.START_DATE - PD.DATE_SHIFT) START_DATE, 
                PFT.MODIFIER_CD, 
                PFT.INSTANCE_NUM, 
                PFT.VALTYPE_CD, 
                PFT.TVAL_CHAR, 
                PFT.NVAL_NUM, 
                PFT.VALUEFLAG_CD, 
                PFT.QUANTITY_NUM, 
                PFT.UNITS_CD, 
                (PFT.END_DATE - PD.DATE_SHIFT) END_DATE, 
                PFT.ENC_LOCATION, 
                PFT.UPLOAD_ID, 
                PFT.VARIABLE_CD, 
                PFT.TAG, 
                PFT.MILES 
        FROM JGARDNER.PREG_FACT_TABLE PFT 
        JOIN NIGHTHERONDATA.PATIENT_DIMENSION PD 
            ON PFT.PATIENT_NUM = PD.PATIENT_NUM 
        JOIN NIGHTHERONDATA.PATIENT_MAPPING PM 
            ON PFT.PATIENT_NUM = PM.PATIENT_NUM 
        WHERE (PFT.START_DATE - PD.DATE_SHIFT)  
            BETWEEN 
                (TO_DATE(']' ||window_start_date|| q'[','dd-MON-yy') - 90) 
                AND (TO_DATE(']' ||window_end_date|| q'[','dd-MON-yy') + 90) 
        ]'; 
 
    --dbms_output.put_line(sql_string); 
    execute immediate sql_string; 
    DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table); 
     
     
--PREGNANCY_PROJECT_FACT_TABLE_PATIENTS: 
    temp_table:='JGARDNER.PREG_FACT_TABLE_PATIENTS'; 
178 
 
    drop_table(temp_table); 
    sql_string := q'[ 
    CREATE TABLE ]'||temp_table||q'[ AS 
        SELECT  COALESCE(P.PAT_MRN_ID, P2.PAT_MRN_ID) MRN,  
                PPD.PATIENT_IDE ELIGIBLE_PATIENT_IDE,  
                PPD.PATIENT_NUM ELIGIBLE_PATIENT_NUM,  
                CASE  
                    WHEN PPF.PAT_ID IS NOT NULL THEN 'IDENTIFIED' 
                    ELSE NULL 
                    END AS EPISODE_DATA,  
                PPD.AGE,  
                PPD.RACE,  
                PPD.RESIDENCE, 
                PPF.PREG_START_DATE,  
                PPF.PREG_END_DATE,  
                PPF.PREG_LENGTH,  
                PPF.PREG_OUTCOME,  
                PPF.GESTATIONAL_AGE, 
                PPF.PREG_EPISODE_ID PREGNANCY_EPISODE_ID, 
                PPF.DEL_EPISODE_ID DELIVERY_EPISODE_ID, 
                EM.ENCOUNTER_IDE, 
                PFTD.* 
        FROM JGARDNER.PREG_FACT_TABLE_DATES PFTD 
        FULL JOIN JGARDNER.PREGNANCY_PROJECT_DEMOGRAPHICS PPD 
            ON PFTD.PATIENT_NUM = PPD.PATIENT_NUM 
        FULL JOIN JGARDNER.PREGNANCY_PROJECT_FINAL_FILTER PPF 
            ON PFTD.PATIENT_IDE = PPF.PAT_ID 
        LEFT JOIN NIGHTHERONDATA.ENCOUNTER_MAPPING EM 
            ON PFTD.ENCOUNTER_NUM = EM.ENCOUNTER_NUM 
        LEFT JOIN PATIENT@VCLARITY P 
            ON PFTD.PATIENT_IDE = P.PAT_ID 
        LEFT JOIN PATIENT@VCLARITY P2 
            ON PPD.PATIENT_IDE = P2.PAT_ID 
        ]'; 
 
    --dbms_output.put_line(sql_string); 
    execute immediate sql_string; 
    DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table); 
 
/*Certain elements have been redacted from this procedure as they contain 
proprietary content. Further details available via request to author and 
demonstration of authorization to view Clarity content. 
*/ 
   
--PREG_FACT_TABLE_ENROLL: 
--Limit to patients seeking consistent care at UNMC 
    temp_table:='JGARDNER.PREG_FACT_TABLE_ENROLL'; 
    drop_table(temp_table); 
    sql_string := q'[ 
    CREATE TABLE ]'||temp_table||q'[ AS 
    SELECT ENCOUNTER_NUM,  
            PATIENT_NUM,  
            CONCEPT_CD,  
            PROVIDER_NAME, 
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            PROVIDER_PATH, 
            START_DATE,  
            MODIFIER_CD,  
            INSTANCE_NUM,  
            VALTYPE_CD,  
            TVAL_CHAR,  
            NVAL_NUM,  
            END_DATE,  
            ENC_LOCATION     
        FROM JGARDNER.PREG_HEALTH_MAIN@DEID 
    ]'; 
 
    --dbms_output.put_line(sql_string); 
    execute immediate sql_string; 
    DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table); 
 
--PREG_FACT_TABLE_ENROLL_DATES: 
--Limit to patients seen 2x in 2015-2016 OR have health maintenance visit in 
this range 
    temp_table:='JGARDNER.PREG_FACT_TABLE_ENROLL_DATES'; 
    drop_table(temp_table); 
    sql_string := q'[ 
    CREATE TABLE ]'||temp_table||q'[ AS 
        SELECT PM.PATIENT_IDE,  
                PFT.ENCOUNTER_NUM, 
                PFT.PATIENT_NUM, 
                PFT.CONCEPT_CD, 
                PFT.PROVIDER_NAME, 
                PFT.PROVIDER_PATH, 
                (PFT.START_DATE - PD.DATE_SHIFT) START_DATE, 
                PFT.MODIFIER_CD, 
                PFT.INSTANCE_NUM, 
                PFT.VALTYPE_CD, 
                PFT.TVAL_CHAR, 
                PFT.NVAL_NUM, 
                (PFT.END_DATE - PD.DATE_SHIFT) END_DATE, 
                PFT.ENC_LOCATION 
        FROM JGARDNER.PREG_FACT_TABLE_ENROLL PFT 
        JOIN NIGHTHERONDATA.PATIENT_DIMENSION PD 
            ON PFT.PATIENT_NUM = PD.PATIENT_NUM 
        JOIN NIGHTHERONDATA.PATIENT_MAPPING PM 
            ON PFT.PATIENT_NUM = PM.PATIENT_NUM 
        WHERE (PFT.START_DATE - PD.DATE_SHIFT)  
            BETWEEN 
                TO_DATE('2015/01/01', 'yyyy/mm/dd') 
                AND TO_DATE(']' ||window_end_date|| q'[','dd-MON-yy') 
        ]'; 
 
    --dbms_output.put_line(sql_string); 
    execute immediate sql_string; 
    DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||temp_table); 
     




    temp_table:='JGARDNER.PREG_ENROLLED_PATIENT_TABLE'; 
    drop_table(temp_table); 
    sql_string := q'[ 
    CREATE TABLE ]'||temp_table||q'[ AS 
 
WITH 
  PATIENTS_SEEN_2X_IN_WINDOW(PATIENT_NUM, FIRST_ADMIT_DATE, LAST_ADMIT_DATE) 
AS 
    (SELECT 
       VD.PATIENT_NUM, 
       MIN(VD.ADMIT_DATE) AS FIRST_ADMIT_DATE,  
       MAX(VD.ADMIT_DATE) AS LAST_ADMIT_DATE 
     FROM 
       NIGHTHERONDATA.VISIT_DIMENSION_2 VD 
       JOIN NIGHTHERONDATA.ENCOUNTER_MAPPING EM 
         ON VD.ENCOUNTER_NUM = EM.ENCOUNTER_NUM 
       JOIN NIGHTHERONDATA.PATIENT_MAPPING PM 
         ON VD.PATIENT_NUM = PM.PATIENT_NUM 
       JOIN NIGHTHERONDATA.PATIENT_DIMENSION PD 
         ON VD.PATIENT_NUM = PD.PATIENT_NUM 
       JOIN JGARDNER.PREG_FACT_TABLE_PATIENTS_D PFTD 
         ON PM.PATIENT_IDE = PFTD.ELIGIBLE_PATIENT_IDE 
     WHERE 
       VD.ADMIT_DATE BETWEEN 
            TO_DATE('2015/01/01', 'yyyy/mm/dd') 
            AND TO_DATE('2016/12/31', 'yyyy/mm/dd') 
       AND VD.ENC_TYPE IN ('AV', 'IP', 'EI', 'ED', 'IS') 
     GROUP BY 
       VD.PATIENT_NUM 
     HAVING 
       MAX(VD.ADMIT_DATE) - MIN(VD.ADMIT_DATE) > 30), 
 
  PATIENTS_HEALTH_MAINTENANCE(PATIENT_NUM, FIRST_ADMIT_DATE, LAST_ADMIT_DATE) 
AS 
    (SELECT 
       P.PATIENT_NUM, 
       CASE WHEN MAX(P.START_DATE) - MIN(P.START_DATE) < 365  
            THEN MAX(P.START_DATE) -365 
            ELSE MIN(P.START_DATE) END 
         AS FIRST_ADMIT_DATE,  
       MAX(P.START_DATE) AS LAST_ADMIT_DATE 
     FROM 
       JGARDNER.PREG_FACT_TABLE_ENROLL_DATES P 
       JOIN NIGHTHERONDATA.VISIT_DIMENSION_2 VD 
        ON P.PATIENT_NUM = VD.PATIENT_NUM 
     WHERE 
       P.START_DATE BETWEEN 
            TO_DATE('2015/01/01', 'yyyy/mm/dd') 
            AND TO_DATE('2016/12/31', 'yyyy/mm/dd') 
       AND VD.ENC_TYPE IN ('AV', 'IP', 'EI', 'ED', 'IS') 





            
'CPT4:99387','CPT4:99391','CPT4:99392','CPT4:99393','CPT4:99394','CPT4:99395', 
            'CPT4:99396','CPT4:99397') 
     GROUP BY 
       P.PATIENT_NUM), 
 
  ALL_ENROLLED_PATIENTS(PATIENT_NUM, FIRST_ADMIT_DATE, LAST_ADMIT_DATE) AS 
    (SELECT 
       COALESCE(A.PATIENT_NUM, B.PATIENT_NUM), 
       CASE WHEN A.FIRST_ADMIT_DATE IS NOT NULL 
              AND B.FIRST_ADMIT_DATE IS NOT NULL THEN 
              LEAST(A.FIRST_ADMIT_DATE, B.FIRST_ADMIT_DATE) 
            ELSE COALESCE(A.FIRST_ADMIT_DATE, B.FIRST_ADMIT_DATE) 
            END 
          AS FIRST_ADMIT_DATE, 
        CASE WHEN A.LAST_ADMIT_DATE IS NOT NULL 
               AND B.LAST_ADMIT_DATE IS NOT NULL THEN  
               GREATEST(A.LAST_ADMIT_DATE, B.LAST_ADMIT_DATE) 
             ELSE COALESCE(A.LAST_ADMIT_DATE, B.LAST_ADMIT_DATE) 
             END 
          AS LAST_ADMIT_DATE 
      FROM 
        PATIENTS_SEEN_2X_IN_WINDOW A 
        FULL OUTER JOIN PATIENTS_HEALTH_MAINTENANCE B 
          ON A.PATIENT_NUM = B.PATIENT_NUM) 
 
    SELECT 
      PATIENT_NUM, 
      FIRST_ADMIT_DATE AS ENR_START_DATE, 
      LAST_ADMIT_DATE AS ENR_END_DATE 
    FROM 





execute immediate sql_string; 
DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into '||table_name||'.'); 
commit;  
     
     
--Create PREG_FACT_TABLE_PATIENTS_E 
    temp_table:='JGARDNER.PREG_FACT_TABLE_PATIENTS_E'; 
    drop_table(temp_table); 
    sql_string := q'[ 
    CREATE TABLE ]'||temp_table||q'[ AS 
    SELECT A.*, B.PATIENT_NUM PATIENT_NUM_ENROLL, B.ENR_START_DATE, 
B.ENR_END_DATE 
    FROM JGARDNER.PREG_FACT_TABLE_PATIENTS_D A 
    LEFT JOIN JGARDNER.PREG_ENROLLED_PATIENT_TABLE B 
        ON A.PATIENT_NUM = B.PATIENT_NUM 
    ]'; 
 
    -- DBMS_OUTPUT.PUT_LINE(sql_string); 
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    execute immediate sql_string; 
    DBMS_OUTPUT.PUT_LINE(SQL%ROWCOUNT || ' rows inserted into 
'||table_name||'.'); 
    commit;      
/*       
             
drop temporary tables: 
    temp_table:='JGARDNER.PREG_PATIENTS'; 
        drop_table(temp_table); 
    temp_table:='JGARDNER.PREGNANCY_PROJECT_RACE'; 
        drop_table(temp_table); 
    temp_table:='JGARDNER.PREGNANCY_PROJECT_RESIDENCE'; 
        drop_table(temp_table); 
    temp_table:='JGARDNER.PREGNANCY_PROJECT_DEMOGRAPHICS'; 
        drop_table(temp_table); 
 
*/ 
 
commit; 
 
END; 
 
 
 
 
 
 
